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Introduction  
About 10,000 years ago, people 
discovered that if they settled in one place 
for long enough they could sow and then 
harvest crops of cereals like wheat instead 
that hunting animals and gathering wild 
berries and fruits. The discovery in the 
Neolithic age of ways to produce and store 
food was the greatest revolution 
humankind ever experienced. To our 
current knowledge, the origin of farming 
practices was located in the ‘Fertile 
Crescent’, the wide belt of Southeast Asia 
including Iran, Turkey Israel/Palestine, 
Syria, Lebanon and Iraq (1). This extends 
from the Mediterranean Coast on its 
western extreme to the great Tigris–
Euphrates plain eastward (2,3). Cultivation 
of wheat and barley, first exploited and 
intensively developed in the Levant and 
western Zagros (Iran), slowly spread 
westward across northern Europe to reach 
Britain by Circa 4000 b.c. (1,4). 
Not surprisingly, the major living and 
dietary changes caused by the agriculture 
revolution led to the appearance of ‘new’ 
diseases, such as coeliac disease (CD).  
This is an autoimmune disorder which 
affects genetically predisposed individuals 
upon the ingestion of gluten and is now 
recognized as a common disorder among 
Middle Eastern. Gluten is the major protein 
fraction in the cereals wheat, rye and 
barley. CD was already known in the most 
ancient times (5). 
 Genetic, immunological and 
environmental factors are involved in the 
pathogenesis of the celiac disease. Despite 
advances in investigations techniques, 
celiac disease remains a challenging 
problem that often eludes diagnosis and 
receives sub-optimal attention (6). There 
are overwhelming reports and descriptions 
on celiac associated disorders but the 
severity and prevalence of such an 
involvement have not been systematically 
evaluated. Inflammation may lead to the 
malabsorption of several important 
nutrients. Malabsorption and nutritional 
deficiency are therefore causing a range of 
other disorders commonly associated with 
CD (table 1, 2).  
Much has been learned about the 
immunology of CD in recent years, and 
there is overwhelming evidence that the 
immune response to gluten is central to the 
pathogenesis. This aspect provides 
evidence for association with some 
autoimmune disorders. Although there is a 
clear genetic association between CD, 
Dermatitis herpetiformis (DH) and 
Diabetes Mellitus Type I (DM), we are 
uncertain about a number of other 
disorders claiming an association with CD. 
The question is how far these conditions 
are in reality related to CD and what the 
underlying patho-mechanism for these 
associations is (7). What are the clinical 
implications? What is the management and 
what would be the role of gluten free diet 
(GFD) in treating these conditions?  
 
Table 1. Complications and disorders, which 
are the results of nutritional deficiency 
following to malabsorption syndrome 
Anemia, Folate & Iron 
Deficiency 
Osteomalacia, 
Osteoporosis  
Failure to Thrive 
(children) 
Low Bone Mass 
Infertility  and 
Impotency  
Vitamin K Deficiency  
Neuropathies Malignancy 
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Clinical spectrum of Coeliac 
Disease 
There are plenty reports dividing CD in 
a range of subgroups in the current 
literature, but the most simple and 
comprehensive classification would be 
classical and atypical (8). Using the world's 
silent, latent and potentials are overlapping 
and confusing the readers (9). Now you 
may ask this question: why some celiac 
patients present with typical and with 
atypical signs and symptoms: limited 
knowledge (still we cannot explain, there 
must be other factors involved beyond our 
understanding), constitutional other 
factors, other environmental factors (drugs, 
infection, etc.). 
Thirty years ago our understanding 
about CD was limited to the classical 
presentation and the prevalence of this 
form of gluten sensitivity (GS) was still 
low. By development of serological tests 
and advances in immuno-genetic, we also 
have been able to diagnose those atypical 
cases under the water line. The atypical 
forms comprise a range of various forms of 
this condition including those with typical 
histology with minimal symptoms, those 
with minimal or normal mucosal changes 
(microenteropathy) with positive or 
negative serology. Finally, those cases with 
typical mucosal changes and symptoms but 
non-responsive to GFD are known as 
refractory celiac disease. 
A team of 16 physicians from seven 
countries designed a multidisciplinary 
task force during a meeting in Oslo and 
phone conferences (10). They suggest 
that different definitions for CD-related 
terms such as asymptomatic, atypical, 
classical, latent, non-classical, overt, 
paediatric classical, potential, refractory, 
silent, subclinical, symptomatic, typical, 
CD serology, CD autoimmunity, 
genetically at risk of CD, dermatitis 
herpetiformis, gluten, gluten ataxia, 
gluten intolerance, gluten sensitivity and 
gliadin-specific antibodies should be 
consensus on the use of terms related to 
coeliac disease and gluten. They finally 
concluded that classical CD should 
define as 'CD presenting with signs and 
symptoms of malabsorption including 
diarrhoea, steatorrhoea, weight loss or 
growth failure.' 'Gluten-related disorders' 
is the suggested umbrella term for all 
diseases triggered by gluten and the term 
gluten intolerance should not to be used. 
 
Table 2. A list of diseases/disorders reported as 
associated with celiac disease 
Primary Biliary 
Cirrhosis 
Short Stature, Delayed 
Puberty 
Recurrent Pericarditis Sarcoidosis 
Thrombocytosis 
(Hyposplenism) 
Schizophrenia / 
Mental Problems 
Systemic 
LupusErythematosus 
Small-Intestinal 
Adenocarcinomas 
Scleroderma Chronic Fatigue 
Syndrome 
Thrombocytopenic 
Purpura (ITP) 
Spontaneous Abortion 
and Fetal Growth 
Retardation 
Thyrotoxicosis Vasculitis 
Peripheral Neuropathy Gastroparesis 
IBD Farmeris Lung 
Head Aches 
(Migraine) 
Myasthenia Gravis 
Follicular Keratosis Polyneuropathy 
Autoimmune Hepatitis Cystic Fibrosis 
Dyspepsia Fibromyalgia 
Fibrosing Alveolitis Pulmonary 
Hemosiderosis 
 
Sapone et al. state that, besides celiac 
disease and wheat allergy, there are cases of 
gluten reactions in which neither allergic nor 
autoimmune mechanisms can be identified 
(11). These are generally defined as non-
celiac gluten sensitivity (GS). Some 
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individuals who experience distress when 
eating gluten-containing products and show 
improvement when following a GFD may 
have GS instead of CD. 
GS is a condition distinct from CD and is 
not accompanied by the concurrence of anti-
tTG autoantibodies or other autoimmune 
comorbidities. The small intestine of GS 
patients is usually normal. 
 
Epidemiology of celiac 
disease in the world and Iran 
It is very likely that many associated 
disorders represent as a simple coincident 
rather than a real association. However, 
there are clearly many disorders in 
different way related to gluten sensitivity.  
The theories behind this coexistence 
first of all bring to our attention that a good 
part of these associated disorders might be 
simple overlaps and/or coincidences as 
coeliac disease is quite a common and 
easily can overlap with these disorders 
(10). On the other hand the immunogenesis 
leading to CD is stimulated by an 
exogenous antigen with a different 
pathway compared to many of the 
associated disorders. 
Many studies have shown that the total 
prevalence of coeliac disease throughout 
the world has increased significantly over 
the last three decades and despite 
previously belief, comparison of studies in 
European and Middle Eastern countries has 
shown that CD is common in both areas, 
with an almost similar prevalence (10-21). 
This discovery can be attributed to the 
judicious use of serological screening tests 
which measure anti-gliadin antibodies 
(AGA) and anti-endomysial (EMA), and 
more recently anti-transglutaminase (anti-
tTG) which has permitted the diagnosis of 
many subclinical CD cases that otherwise 
would not have been recognized (9, 22). 
Nowadays, the map of CD prevalence 
in different areas of the world is much 
more detailed than in the past. For 
instance, Finland has one of the highest 
recorded rates, with recent estimates 
suggesting a prevalence of 2%, a near 
doubling of historical values (23).  The 
prevalence of CD amongst different 
populations worldwide is varied and the 
actual prevalence of CD has been shown to 
be more frequent than in the past. 
However, there is limited data about the 
prevalence of CD in Middle Eastern 
countries. Recent studies of serum markers 
in blood donors have shown a prevalence 
of 1:250 in Sweden, 1:524 in Denmark, 
1:333 in Holland, 1:157 in Israel, 1:250 in 
the USA, 1.5:100 in the Syria and 1:681 in 
Brasília. On the other hand most of the 
asymptomatic patients are still 
undiagnosed or misdiagnosed. A large UK 
population-based study (24) has suggested 
that more than 90% of coeliac disease in 
asymptomatic children remains 
undiagnosed. 
Until the past decade CD was 
considered uncommon in Iran. Following 
the application of simple serological tests 
for diagnosis of CD in Western countries, 
some studies have been published on the 
prevalence and the importance of CD in 
Iran and showed that this prevalence 
ranges from 0.5% among schizophrenia 
patients (25) to 12% in patients with 
irritable bowel syndrome (IBS) (26). For 
instance, the prevalence of CD in low risk 
subjects was reported even higher than that 
of Western countries (1 out of 166 healthy 
Iranian blood donors) (27). Recent 
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screening studies performed on the general 
population and at-risk groups in different 
geographical areas in Iran have shown that 
the prevalence of CD is similar to that in 
Western countries.  
In studies on apparently healthy blood 
donors in Northern (Sari and Gorgan) and 
Southeastern Iran (Kerman) have shown an 
overall prevalence of 1:91 to 1:120 for 
these cities (28). On the other study 1440 
healthy individuals were screened in Shiraz 
and the result of this study showed that the 
prevalence of CD in this region was less 
than 0.5% which was much lower than 
reports from other areas of the country 
(29). The different prevalence between the 
northern versus the southern areas in Iran 
might be because of different genetic 
background of population in these regions 
(30). Although the prevalence of CD in 
some areas in Iran like Shiraz is very low, 
but other studies suggest a prevalence of 
1% in the remaining areas of Iran which is 
similar to the frequency of this disorder in 
Western European countries (27, 30-32).  
 
Genetic Associations 
Coeliac disease is a polygenic disorder 
and HLA is the single most important 
genetic factor in this condition (33). The 
sharing of a similar HLA haplotypes may 
partly explain the strong association 
between DM, Dawn Syndrome, IgA-
Deficiency, DH and CD. Evidence that 
there is a strong inherited predisposition to 
coeliac disease susceptibility comes from 
twin studies and studies of prevalence in 
relatives of affected individuals (34). There 
is, however, no discernable Mendelian 
inheritance pattern in families, and risk 
falls more rapidly in distant relatives than 
would be expected in a disease caused by a 
single gene defect. Exons of both CD28 
and CTLA4 have been sequenced in large 
numbers of coeliac patients, and no 
evidence for mutations specific to coeliac 
disease has been found. Large scale studies 
in type I diabetes and autoimmune thyroid 
disease have recently clarified the 
haplotypic structure of the CD28-CTLA4-
ICOS region, and a variant 6 kB 30 of the 
CTLA4 transcription start site (CT60) 
demonstrates the strongest autoimmune 
disease associations of over 100 variants 
studied from the region (35).  
The finding that diseases such as type I 
diabetes, coeliac disease and multiple 
sclerosis are HLA-DQ associated is not 
easily explained by a simple hypothesis of 
DQ-restricted, autoreactive T cells, 
considering the generally marginal role of 
DQ in restricting responses. Thus, both 
HLA-DR and -DQ polymorphism exists 
for hTg in autoimmune thyroiditis.  
We know that more than 30% of 
general population are HLADQ2/8 positive 
(36). Unfortunately there is no enough 
evidence to show whether this group are 
more prone to develop autoimmune 
disorders compared with those who have 
no HLA-DQ2/DQ8. As described for other 
populations (33, 35), the most frequent 
haplotype in Iranian CD patients was 
HLA-DQ2.5 (69.5%) and this frequency is 
very similar to that in European CD 
populations.  
 
Aim of this thesis 
This thesis consists of 5 parts. 
Introduction and outline of the thesis are 
presented in part I. The aim of part II was 
to present the epidemiological data 
regarding the celiac disease in Iran in 
different population and this part including 
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8 chapters. The aim of part III is describing 
the correlation between associated 
disorders and celiac disease and also this 
part including 6 chapters regarding this 
association. The aim of part VI was 
presented the data regarding the effect of 
gluten free diet in CD and this part include 
3 chapters. Part V consists of Discussion, 
Summery, Acknowledgement and a brief 
CV. 
 
PART I INTRODUCTION AND 
OUTLINE OF THE THESIS  
 
PART II EPIDEMIOLOGY  
Chapter II.1 consists of the review 
article which summarizes the 
epidemiological data on CD in Middle East 
and highlights different clinical 
presentations and management of CD in 
Iran.  
Prevalence of CD in patients with GI 
symptoms is reported and the 
differentiation of typical manifestations 
from the atypical forms of CD was 
discussed in Chapter II.2. 
In Chapter II.3 we assessed the 
association between celiac disease and 
severe chronic depression and 
schizophrenia. 
Chapter II.4 This is a multicenter 
study (European and middle eastern) in 
which the current practice in particular the 
number of biopsies taken by different 
center have been investigated and 
determined the incremental diagnostic 
yield of adherence to the recommended 
number of specimens. 
The distribution of HLA-DQ2 and -
DQ8 alleles in Iranian CD patients 
compared to healthy controls were 
explored and studied in Chapter II.5. 
Chapter II.6; The result of this multi-
center study indicated that upper 
abdominal disorders such as abdominal 
pain and dyspepsia were the most common 
primary complaints in European patients, 
while for Iranian patients, diarrhea and 
bloating were considered the classic 
presentations of CD. 
Chapter II.7: Atypical forms of CD 
have increased considerably and the 
presence of dyspepsia as a unique 
symptom has been frequently attributed to 
CD. In classical CD with prominent 
malabsorptive features, dyspepsia may be 
one of the symptoms. It has been reported 
that the frequency of CD in people with 
dyspeptic complaints is 1.1-3%, which is 
two to nine times higher than in the general 
population. In the present study we 
described the prevalence of celiac disease 
in dyspeptic patients and compare the 
value of serology with histology in 
diagnosing CD.  
Chapter II.8; In this Chapter, we have 
studied body mass index in celiac patients 
diagnosed in a population-based study, 
using a well-matched case-control analysis 
in order to obtain updated information 
regarding the underweight in celiac 
patients. 
 
PART III ASSOCIATED 
DISORDERS  
Chapter III.1 consist the review 
article. In this review we provide 
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information regarding liver disorders that 
may be seen in association with celiac 
disease and the effect of treatment of CD 
on these disorders.  
In Chapter III.2 we estimated the 
prevalence of undiagnosed CD and the co-
existence of Toxoplasma gondii infection 
in a population of pregnant women and 
pregnancy outcome. 
In Chapter III.3 we assessed the 
prevalence, the related symptoms, and the 
endoscopic and histological feature of 
gastritis described in a simplified 
classification and celiac disease correlation 
in patients with Helicobacter pylori (Hp) 
was investigated. 
We have evaluated the correlation of 
gluten related auto-antibodies in infertile 
couples and assessed in which proportion 
celiac disease is responsible for 
unexplained fertility disorders between 
men and women in Chapter III.4. 
The prevalence of Rotavirus and CD 
serology among Iranian adults with non-
specific gastrointestinal (GI) symptoms 
were shown in Chapter III.5. 
Chapter III.6 was assessed the relation 
between clinical and demographic factors 
in coeliac patient, using logit and probit 
analysis. 
 
PART IV GLUTEN FREE DIET  
Chapter IV.1 consists of a review 
article on non-coeliac gluten sensitivity, 
and suggesting a simplified terminology 
called subclinical instead of silent and 
potential/latent. 
Chapter IV.2: In this study the effects 
of a gluten free diet on 
hypertransaminasemia in patients with 
newly diagnosed celiac disease were 
studied. 
Chapter IV.3: The aim of this study 
was to investigate the relation between CD 
and unexplained DUB in celiac women. 
 
PART V: 
DISCUSSION, SUMMARY, 
ACKNOWLEDGEMENT, and a 
BRIEF CV.  
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ABSTRACT 
 
In the past, celiac disease (CD) was believed to be a chronic enteropathy, almost exclusively 
affecting people of European origin. Celiac disease is the permanent intolerance to dietary 
gluten, the major protein component of wheat. The availability of new, simple, very sensitive 
and specific serological tests (AGA, AEM and tTGA) has shown that CD is as common in 
Middle Eastern countries as in Europe, Australia and New Zealand where the major dietary 
staple is wheat. A high prevalence of CD has been found in Iran, in both general population and 
at-risk groups, i.e. patients with type 1 diabetes or irritable bowel syndrome (IBS).  
In developing countries, serological testing in at risk groups is necessary for early identification 
of celiac patients. Clinical studies show that presentation with non-specific symptoms or a lack 
of symptoms is as common in the Middle East as in Europe. Wheat is a major component of the 
Iranian diet and exposure to wheat proteins induces some degree of immune tolerance, leading 
to milder symptoms that may be misdiagnosed with other GI disorders. The implementation of 
GFD is a major challenge for both patients and clinicians in Iran, especially since commercial 
gluten-free products are not available in this area.  
Keywords: Celiac disease; Epidemiology; Iran. 
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Introduction  
In the last few years, considerable 
changes in the epidemiology of celiac 
disease (CD) have been observed. A 
marked increase in CD prevalence and 
incidence has been reported, which can be 
at least partially explained by both the 
development of more sensitive serological 
tests and a high degree of disease 
suspicion.1, 2 Although screening programs 
may discover some of the asymptomatic 
CD cases, if a clinical diagnostic approach 
is taken as well, a high proportion of under 
diagnosed patients may be detected.3 
CD is the result of both environmental 
(gluten) and genetic factors (HLA and non-
HLA genes). Distribution of these two 
components can probably be used to 
predict at risk areas of the world for gluten 
intolerance.4 In this respect, the world 
geographical distribution of CD seems to 
have followed the spread of wheat 
consumption and migratory flows of 
mankind. Cultivation of wheat and barley, 
first exploited and intensively developed in 
Levant and western Zagros (Iran), slowly 
spread westward across northern Europe to 
reach Britain by circa 4000 B.C.5, 6 The 
aim of this review is to investigate the 
epidemiology, different clinical 
presentations and management of CD in 
Iran. 
Epidemiology of CD in the 
World 
The age of presentation and prevalence 
of CD appears to have changed 
dramatically over the last 30-40 years.7 
Until a few years ago, gluten intolerance 
was thought to be a disorder almost 
exclusively affecting Europeans or people of 
European origin and they described typical 
features of celiac patients. Also until a decade 
ago, CD was considered to be very rare in 
Middle Eastern countries. A comparison of 
studies in European and Middle Eastern 
countries has shown that CD is common in 
both areas, with an almost similar prevalence 
(Table 1).8-17 This discovery can be attributed 
to the judicious use of serological screening 
tests which measure anti-gliadin antibodies 
(AGA) and anti-endomysial (EMA), and more 
recently anti-transglutaminase (anti-tTG) 
which has permitted the diagnosis of many 
silent and subclinical CD cases that otherwise 
would not have been recognized. 18, 19 
Table 1. Prevalence of CD in Europe compared 
to Middle East population based on serological 
screenings.8-17, 50, 58 
Europe Prevalence Asia Prevalence 
Italy 1:106 Iran 1:166 
Czech 1:218 Israel 1: 157 
Norway 1:262 Syria 1.5:100 
Portugal 1:134 Turkey 1:87 
Sweden 1:190 Anatolian 
adults 
1:100 
Netherlands 1:198 Kuwait 
(Chronic 
diarrhea ) 
1:18 
United 
Kingdom 
1:100 Saudi Arabia 
(Type1 
diabetes) 
12:100 
Switzerland 1:132 Japan 1:20,000 
Spain 1:118 India 1:500-2000 
 
Nowadays, the map of CD prevalence 
in different areas of the world is much 
more detailed than in the past. However, 
there is limited data about the prevalence 
of CD in Middle Eastern countries. The 
prevalence of CD amongst different 
populations worldwide is varied and the 
 Celiac disease, Epidemiology, Genetic and Clinical Behavior in Iran 
24  Epidemiology of Celiac Disease in Iran: A Review
actual prevalence of CD has been shown to 
be more frequent than in the past. For 
instance, recent studies of serum markers 
in blood donors have shown a prevalence 
of 1:250 in Sweden, 1:524 in Denmark, 
1:333 in Holland, 1:157 in Israel, 1:250 in 
the USA and 1:681 in Brasília.20-24 
Epidemiology of CD in Iran 
Until the past decade CD was 
considered uncommon in Iran; but 
following the application of simple 
serological tests for diagnosis of CD in 
Western countries, only few studies have 
been published on the prevalence and the 
importance of CD in Iran. This prevalence 
varies in different fields and ranges from 
0.5% among schizophrenia patients 25 to 
12% in patients with irritable bowel 
syndrome (IBS) in some areas of Iran.26 
For instance, the prevalence of CD in low 
risk subjects was reported even higher than 
that of Western countries (1 out of 166 
healthy Iranian blood donors).27  Recent 
screening studies performed by means of 
simple, sensitive and specific tests (AGA, 
AEM and AtTG) on the general population 
and at-risk groups in different geographical 
areas in Iran with a large consumption of 
wheat have shown that the prevalence of 
gluten sensitivity is similar to that in 
Western countries. However, there might 
be a different prevalence of CD between 
the northern versus the southern areas in 
Iran.28    
The first study on CD ran from 
November 1998 through February 1999 in 
2000 healthy blood donors in Tehran. Total 
serum AGA was measured and analyzed in 
all donors by an ELISA test and those with 
positive results were tested for EMA. All 
donors who had a positive serology for 
both AGA and EMA underwent small 
intestinal biopsies. 
Of 2000 healthy blood donors, 49 were 
positive for IgA AGA (38 males, 11 
females) and 12 were EMA positive. 
Gluten sensitive enteropathy was found in 
all subjects who had positive serology as 
follows:  Marsh I (3), Marsh II (4) and 
Marsh IIIa (5) lesions. The results of this 
study showed that the prevalence of CD in 
this group was 1/166 and these results were 
similar to that of Western countries.27 
In a study on apparently healthy blood 
donors in Northern Iran (Sari), CD was 
detected in 13 out of 1438 individuals. 
Small bowel biopsy histologies were 
consistent with Marsh 0 (1), Marsh I (8), 
Marsh II (2) and Marsh IIIa (2). At the 
same time, out of 1361 blood samples 
collected from apparently healthy blood 
donors in Southeastern Iran (Kerman), 16 
were serologically CD positive. The 
histology of the small bowel biopsies was 
consistent with Marsh 0 (1), Marsh I (8), 
Marsh II (2) and Marsh IIIa (2) which 
represented an overall prevalence of 1:120 
and 1:91 for these two cities, 
respectively.29 
Saberi-Firouzi et al. also screened 1440 
healthy individuals for EMA and tTG 
antibodies in Shiraz, Iran. Only 7 were 
positive for tTG antibody, of these 2 were 
also EMA positive. Five subjects with 
positive serologies agreed to undergo 
upper GI endoscopies. Small bowel 
intestinal abnormalities that included 
Marsh I-IIIc were noted in all patients with 
positive tTGA assays. The prevalence of 
CD in this study was less than 0.5% which 
was much lower than reports from other 
areas of the country.30 
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A seroprevalence study of 2547 healthy 
blood donors in Golestan Province showed 
28 (1.1%) tTG positive cases 31.This study 
had the same results as a study by Akbari 
et al.29   
A case control study by Shahbazkhani 
et al. was undertaken at a university clinic 
in Tehran to determine the frequency of 
CD among patients diagnosed with IBS 
and consisted of 105 cases in each arm. 
Twelve IBS cases and no controls were 
diagnosed with CD. The result of this 
evaluation showed a prevalence of CD 
greater than 11% among IBS patients.27 On 
the other hand, Emami et al. did not find 
any cases of CD based on serum IgA t-TG 
in a much larger sample size of IBS 
patients in Isfahan.28 
Two different studies evaluated the 
prevalence of CD in iron deficiency anemia 
(IDA) patients in Iran. In a study by Nikpour 
and Hosseini, 126 patients with IDA 
underwent D2 biopsies during endoscopy. 
The average Hb level was 8.8 mg/dl. 
Serology was evaluated (AGA and EMA) for 
those who had a positive histopathology for 
CD. The researchers found that duodenal 
biopsies revealed histological features of CD 
in 8 (6.3%) patients according to modified 
Marsh criteria (6 Marsh IIIA; 2 Marsh IIIC). 
Six (75%) had positive serology for CD (2 
positive EMA; 3 positive AGA; 1 positive 
for both).  
In another study by Zamani et al., 206 
patients were found to have IDA of 
obscure origin. Serology tests showed 31 
positive tests (tTG and/or EMA). Thirty 
cases (14.6%) had abnormal duodenal 
histology of which 16 had Marsh III, 12 had 
Marsh II, and 2 had Marsh I lesions. After 4 
to 6 months of gluten-free diet (GFD), the 
mean hemoglobin concentration of the 
patients rose from 8 g/dl to 13 g/dl. Both 
studies showed a high prevalence of CD in 
IDA of obscure origin and the efficacy of a 
GFD in patients who have mild to severe 
villous atrophy was demonstrated.32, 33 
Behcet’s disease (BD) is a chronic, 
relapsing inflammatory disease 
characterized by recurrent oral and genital 
aphthus lesions whose presentation is 
similar to CD. Based on a possible 
association, the sera of 288 patients with BD 
were screened with EMA and tTG 
antibodies for CD and D2 biopsies were 
taken from seropositive subjects.34 Fourteen 
patients had positive tTG (2 positive EMA) 
but only 4 had histology compatible with 
CD (1, Marsh III; 3, Marsh I). The patients 
with CD were placed on a GFD to evaluate 
its efficacy on the improvement of their 
lesions. All 4 cases responded to the GFD. 
Although there seems to be a high 
percentage of false positive tTG results in 
BD, CD is approximately twice as 
common as seen in the general population. 
A variety of neurological disorders such 
as epilepsy, ataxia and neuropathy have 
been reported in association with CD. 
Emami et al. studied 108 consecutive 
idiopathic epileptic patients.35 The diagnosis 
of CD was determined by tTG antibodies 
and small intestinal biopsy. Histopathologic 
changes were interpreted according to the 
modified Marsh classification criteria.36 The 
results of this study showed that 4 out of 
108 (3.7%) epileptic patients were positive 
for IgA anti t-TG while the known 
prevalence of CD in the study area was 
0.6%. The intestinal biopsy showed Marsh 
I lesions in all cases. The prevalence of CD 
is increased among patients with epilepsy 
of unknown etiology, justifying evaluation 
for CD in any patient with idiopathic 
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epilepsy even in the absence of digestive 
symptoms. 
To assess the prevalence, related 
symptoms, endoscopic and histologic 
gastric features of CD in patients with 
Helicobacter pylori (HP), Rostami Nejad 
et al. investigated 450 dyspeptic patients 
by routine D2 biopsies.37 HP was positive 
in 411 (91.3%) cases. Duodenal histology 
was normal in 385 (85.6%) patients, and 
positive in 28 (6.2%) who had Marsh I-IIIc 
lesions. In those with positive histology, 23 
(82.1%) were also HP positive and 31 had 
positive CD serology. Serological analysis 
indicated that 12 out of 31 (38.7%) positive 
patients had abnormal histology (Marsh I -
IIIc). The prevalence of CD in this group 
of patients was 2.6% and this finding 
indicated a false positive histology or low 
sensitivity of tTG in HP infection. 
Celiac disease is a common chronic 
intestinal disease frequently associated 
with dyspeptic symptoms. It fulfils many 
of the disease criteria required for a 
screening program. From November 2007 
to October 2008, 407 patients who 
underwent endoscopy for dyspeptic 
symptoms were studied. 38 _The results of 
this study showed that 10 out of 33 tTGA 
positive patients had abnormal histology 
(Marsh I-IIIc). In this study around 2.5% 
had small bowel mucosal abnormalities 
and positive CD serology. This may 
support routine serological screening for 
CD in dyspeptic patients. 
We are probably far from an ideal 
screening serologic tool which relies on the 
antibody test as the sole method of 
screening for CD since the overall 
sensitivity and specificity of the IgA anti-
tTG antibody has been determined to be 
38% and 98%, respectively, in one Iranian 
study. The positive and negative predictive 
values for the anti-tTG antibodies were 
57% and 96%, respectively. The sensitivity 
was 80% in patients with Marsh IIIC, 
which contrasts other reports that suggest a 
diagnostic accuracy of over 90% for anti-
tTG antibody. Therefore serologic 
screening could result in many missed 
diagnoses, particularly in patients with 
lesser degrees of mucosal abnormalities.39  
Rostami Nejad et al. evaluated 496 
pregnant women for CD by serology. 
Thirteen (2.6%) cases had a positive 
serology for tTGA; 2 had low birth weight 
babies and 2 had a previous history of 
miscarriage. 40 This study showed a high 
incidence of unfavorable outcomes in 
pregnancy associated with positive 
serology for CD. 
Different studies show that CD is the 
most common cause of chronic non-bloody 
diarrhea in adults and children in Iran, 
ranging from 6.5-19%.41,42 Thus routine 
testing for CD is necessary in all patients who 
present with chronic non-bloody diarrhea.  
Another study in 827 pregnant women 
showed 3.26% positive tTGA43 which is 
much higher than the general population. 
Since we expect a lower pregnancy rate in 
CD cases, further evaluation is needed with 
other well designed studies. 
EMA antibody was positive in 6 (2.4%) 
of 250 consecutive type I diabetes mellitus 
cases.  D2 histology was compatible with 
Marsh I (2), Marsh II (3) and Marsh IIIb 
(1).44 In another study by Fallahi et al., 96 
children with type 1 diabetes mellitus were 
tested for tTG antibody.45 Six (6.25%) 
were seropositive, and histopathological 
changes were compatible with CD in 
intestinal biopsies for all (5, Marsh IIIa; 1, 
Marsh IIIb). The results of both studies 
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show that the prevalence of CD in Iranian 
patients with type I diabetes mellitus is 
relatively high, justifying screening for CD 
in all patients with type I diabetes mellitus 
regardless of the presence or absence of 
symptoms. Patients should be screened at 
the onset of diabetes mellitus diagnosis and 
at regular intervals during follow up. 
A total of 670 cases with non-specific 
GI symptoms were tested for serum IgA 
levels and tTG antibodies. Positive IgA 
tTG and IgG tTG were found in 22 cases 
as well as in 3 out of 8 IgA-deficient 
individuals. The prevalence of CD 
antibodies in serologically screened 
samples, excluding IgA-deficient cases, was 
3.3% and 3.7% when IgA-deficient cases 
with positive tTG-IgG were included. This 
study indicated a high prevalence of CD 
antibodies among patients with non specific 
GI symptoms (3.7%). More awareness 
regarding the atypical presentation of CD 
could be the key step in identifying 
asymptomatic patients.46   
Short stature is one of the most common 
causes of referrals to pediatric 
endocrinologists and is a well-known 
feature of pediatric CD.47 Hashemi et al. 
studied 104 idiopathic short stature children 
(49 male, 55 female). All patients were 
investigated by serology and D2 
histopathology. IgA tTG antibodies and IgA 
AGA were positive in 36 and 35 cases, 
respectively. Histological abnormalities 
compatible with CD were seen in 31 IgA 
tTG antibody positive and 28 IgA AGA 
positive subjects (26.9% (28 were positive 
for both anti-tTG and anti-AGA)).48 This 
figure is very high and needs confirmation 
with other well designed studies.  
High wheat consumption has been a 
major component of the Iranian diet for 
thousands of years49 and the presence of 
about 57.6% frequency of HLA DQ2 and 
DQ8 in the general population suggest that 
the high percentage of our community could 
be susceptible to different presentations of 
CD.50 There seems to be a lower prevalence 
of CD in Isfahan and Shiraz.28, 30, 39 
The current wheat consumption per 
capita per year in Iran and other Middle 
Eastern countries is shown in Table 2. As 
this table shows, Iranians rank as one of 
the top wheat-consuming populations in 
the Asia–Pacific region with a per capita 
consumption of up to 150 kg/year.51, 52 
Conclusion 
Celiac disease was presumed to be rare in 
Iran because of lowered awareness and a 
low index of suspicion. However new 
epidemiological data show that CD is a 
common disorder in Middle Eastern 
countries, particularly Iran. Table 3 shows 
the current primary list of CD frequency in 
Iran 53-58. This suggests a need for a more 
uniformly designed evaluation of CD for 
the entire country and a mapping of HLA 
DQ in the same areas along with a gluten 
consumption assessment, since a variable 
frequency of CD in different parts of Iran 
may exist as is the case for India.59 
Although the prevalence of CD in some 
areas in Iran such as Shiraz Province is 
very low, a summary of the reviewed 
studies suggest a prevalence of 1% in the 
remaining areas of Iran which is similar to 
the frequency of this disorder in Western 
European countries.27, 29, 60, 61  
Since commercial gluten-free products 
are not readily available and significantly 
more expensive than their gluten-
containing products in this area,      
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therefore the main concern is the 
implementation of a GFD for Iranian 
patients. 
Table 2. Wheat consumption (kg) per person per 
year (kg/year) for countries in the Asia–Pacific 
region.19, 27, 51, 58 
> 150  75-150 25-74 < 25 
Iran China India Thailand 
Turkey Saudi Arabia Nepal Singapore 
Kazakhstan Oman Malaysia Indonesia 
TurkmenistanYemen North 
Korea 
Myanmar 
Iraq Afghanistan Japan Bangladesh 
Syria Pakistan Philippines Malaysia 
Jordan Mongolia Sir Lanka  
Uzbekistan South Korea Taiwan  
Tajikistan  Cambodia  
Kyrgyzstan  Laos  
Table 3. Prevalence of celiac disease among at 
risk groups in Iran (serological screenings) 
Disease groups  Prevalence Ref 
Normal population 0.6 27 
Chronic diarrhea (Children) 6.5-20 41,42 
Inflammatory bowel diseases 7.8 53 
Autoimmune hepatitis 3.6-10 54 
Chronic psychiatric disorders 1.5 25 
Irritable bowel syndrome 1-11.4 26 
Short stature 4-33.6 48 
Type 1 diabetes mellitus 2.4 44 
Epilepsy 2.7 35 
Dyspepsia 2.5 47 
Infertility 1.5 55 
Patients with non-specific GI 
symptoms 
3.3 46 
Mental retardation 1 56 
Recurrent aphthous stomatitis 2.84 57 
Behcet's 1.32 34 
Iron deficiency anemia of 
unknown origin 
14.6 58 
 
This information will be useful to 
dietitians and gastroenterologists who 
counsel celiac patients, and to celiac 
advocacy groups for seeking financial 
support from the government.  
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ABSTRACT 
 
Objectives: Atypical presentation is the most prevalent form of coeliac disease (CD) 
and mostly clinically indistinguishable from other gastrointestinal (GI) disorders. The 
first objective of this study was to determine the prevalence of CD in patients with GI 
symptoms and the second objective was to characterize the typical manifestations of 
the atypical forms of CD.  
Methods: This was a cross sectional study comprising 5,176 individuals by random 
sampling of self-referred people from the Tehran province, during the years 2006-2007 
in a primary care setting. From 5,176 individuals, 670 with GI symptoms were selected 
for coeliac serology including total immunoglobulin A (IgA) and anti-tissue 
transglutaminase (tTG) antibodies. Those with IgA deficiency were tested with IgG 
tTG.  
Results: This study shows that 13% (670/5176) of self-referred patients to a general 
practice suffer from GI symptoms. Dyspepsia was the most common symptom in 25 
seropositive cases similar to the rest of the study group. A positive anti-tTG test was 
found in 22 from 670 investigated subjects (17 women, 5 men) (95% CI: 1.70-4.30) 
and 8/670 were IgA deficient. A positive IgG tTG was detected in 3/8 IgA deficient 
individuals. The prevalence of CD antibodies in serologically screened samples 
excluding IgA-deficient was 3.3% and 3.7% when including those IgA-deficient with 
positive tTG-IgG.  
Conclusions: Non-specific GI symptoms seem to be the typical presentation of 
atypical CD. This study indicated that there is a high prevalence of CD antibodies 
among patients with GI symptoms (3.7%). More awareness regarding the atypical 
presentation of CD could be the key step in identifying asymptomatic patients. 
Keywords: Prevalence, Coeliac disease, Anti-tissue Transglutaminase, Dyspepsia, 
Atypical presentation, Serology. 
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Introduction  
Better awareness of “non-classical” 
coeliac disease (CD) and improved screening 
tests suggest that the prevalence of CD is 
underestimated in developed and developing 
countries [1-3]. The availability of 
serological tests for the diagnosis of CD 
during the last two decades, and a better 
knowledge of this disease, have permitted the 
identification of atypical CD [1, 4-8]. The 
symptoms of CD vary so widely among 
patients that there is no such thing as a 
“typical coeliac” as the individuals are 
affected differently. There is no correlation 
between the mode of presentation and the 
degree of mucosal damages [9]. There have 
been more than 200 signs and symptoms 
reported in association with gluten 
sensitivity, yet there are cases with this 
disorder which may have no symptoms at all 
[10, 11]. Terminologies such as latent, silent, 
potential and atypical are confusing and there 
is a need for a better definition to cover the 
spectrum of gluten sensitivity. 
Increasing evidence of the adverse 
consequences relating to delays in 
diagnosis and easier screening assays such 
as tTG [12, 13] justifies the routine 
screening of high risk cases [14-20]. Some 
preliminary reports have shown the 
efficacy of a case-finding strategy in both 
adult and pediatric populations [21-23]. 
This approach relies on an active role 
being played by primary care physicians in 
selecting individuals to be tested for CD. 
The aim of this study was to explore the 
etiology of GI disorders in a large cohort of 
symptomatic patients and to identify the 
typical gastrointestinal (GI) pattern of 
atypical CD. The atypical extra-intestinal 
symptoms have not been considered in this 
study. 
Patients and Methods 
Patients 
This was a cross sectional study which 
involved 5,176 individuals randomly 
sampled from the population of the Tehran 
province, Iran during the period October 
2006 – November 2007. Six hundred and 
seventy individuals with GI symptoms in 
their questionnaire were identified in a 
primary care setting and extensively 
investigated for a common GI pathology. 
From a total of 670 GI patients included in 
this study, 427 subjects were women 
(63.73%) and 243 subjects were men 
(36.27%) with a mean age of 41.61 and SD 
16.55 years.The study was approved by the 
Institutional Medical Ethics Committees of 
Research Center for Gastroenterology and 
Liver Disease, Shaheed Beheshti 
University, M.C. and all participants 
signed a written informed consent. 
Methods 
The optical density readings on 
enzyme-linked immunosorbent assay 
(ELISA) of 670 patients with GI symptoms 
received for tissue transglutaminase (tTG) 
antibody testing for CD were compared 
with their total IgA concentrations. Those 
with IgA deficiency were tested with IgG 
tTG. All serological investigations were 
performed without knowledge of the 
patient status. Human antitissue 
transglutaminase (tTG) antibody and 
Immunoglobulin A were measured. 
Determinations of IgA tTGA antibody 
were carried out using a commercially 
available kit (AESKULISA tTG, 
Germany) and an enzyme-linked 
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immunosorbent assay (ELISA) method. 
According to the manufacturer’s 
instructions, when a value higher than 15.0 
U/ml was recorded, the result was 
considered.  
Total serum IgA values were measured 
by an immunoturbidometric assay (Pars 
Azmoon, Iran) and serum levels below 70 
U/L were considered indicative of IgA 
deficiency. Immunoglobulin G (IgG) tTGG 
values were further obtained in individuals 
with IgA deficiency by an ELISA method, 
and using the commercially available kit 
(AESKULISA tTGG, Germany). 
Statistical analysis 
Descriptive statistics, the chi-square 
test and conditional logistic regression 
were carried out using SAS software in 
order to find significant associated factors. 
 
Table II. Etiology of gastrointestinal symptoms 
in 290/670 GI patients positive 
Etiology Cases 
affected 
Percentage 
Blastocystis hominis  30/670 4.47 
Giardia lamblia  41/670 6.11 
Iodomoeba butchelii 13/670 1.94 
Entamoeba Histolytica/ 
Entamoeba Dispar complex 
11/670 1.64 
Cryptosporidium parvum 3/670 0.44 
Chilomastix mesenelli 13/670 1.94 
Ascaris lumbricoides 2/670 0.3 
Enterobius vermicularis 2/670 0.3 
Rotavirus  150/670 22.38 
tTG positive 25/670 3.7 
Results 
Around 670/5176 (13%) of cases who 
attended primary care for various reasons 
had GI symptoms (Figs. 1, 2). We found an 
etiology for 290/670 symptomatic cases 
who participated in this screening. A 
positive serology for coeliac disease was 
detected in 25/290 (Table I) and another 
265/290 cases had an infectious etiology 
(Table II).  
Table I. Clinical and laboratory features of tTG positive patients
Subjects Gender  
Male/female
Age (yrs) tTGA tTGA level Total IgA tTGG Level Gastrointestinal symptoms 
Case 1 F 64 +ve 15.22 normal ----- Constipation, heartburn 
Case 2 F 14 +ve 19.97 normal ----- Heartburn 
Case 3 M 51 +ve 26.93 normal ----- Heartburn, abdominal pain 
Case 4 F 37 +ve 25.56 normal ----- Heartburn 
Case 5 F 69 +ve 24.4 normal ----- Abdominal pain, constipation, 
bloating, weight loss 
Case 6 F 63 +ve 17.44 normal ----- Heartburn, abdominal pain, bloating 
Case 7 F 22 +ve 102.7 normal ----- Heartburn 
Case 8 M 81 +ve 22.59 normal ----- Abdominal pain, weight loss 
Case 9 F 42 +ve 49.68 normal ----- Abdominal pain, constipation, bloating 
Case 10 F 21 +ve 286 normal ----- Abdominal pain, bloating 
Case 11 F 14 +ve 23.23 normal ----- Diarrhea 
Case 12 M 45 +ve 20.49 normal ----- Weight loss 
Case 13 F 46 +ve 20.93 normal ----- Abdominal pain, bloating 
Case 14 F 21 +ve 16.56 normal ----- Abdominal pain, constipation 
Case 15 M 68 +ve 17.61 normal ----- Heartburn 
Case 16 F 24 +ve 83.51 normal ----- Heartburn, bloating, weight loss 
Case 17 F 44 +ve 294.6 normal ----- Constipation, bloating, weight loss 
Case 18 F 41 +ve 15.50 normal ----- Diarrhea, 
Case 19 M 64 +ve 16.73 normal ----- Abdominal pain, constipation 
Case 20 F 43 +ve 21.99 normal ----- Heartburn, bloating 
Case 21 F 33 +ve 17.79 normal ----- Bloating 
Case 22 F 29 +ve 37.80 normal ----- Heartburn 
Case 23 M 23 -ve 0.07 deficient 80.25 Constipation 
Case 24 M 71 -ve 3.25 deficient 37.85 Abdominal pain 
Case 25 M 20 -ve 4.22 deficient 15.07 Abdominal pain 
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For 56.7% (380/670) symptomatic 
cases no organic etiology was found. 
293/380 (77.3%) had functional symptoms 
like constipation, diarrhea and dyspepsia. 
A number of 43/380 cases (11.3%) 
fulfilled the Rome III criteria for Irritable 
bowel syndrome. The remaining 44/380 
had only self-limited short term symptoms 
and responded to short term symptomatic 
treatment (Table III). 
Table III. Functional bowel symptoms (n=380) 
                                       Conditions Number 
(%) 
Functional bowel 
symptoms 
IBS 43 
(11.3) 
Non-IBS Heartburn 147 
(38.68) 
Abdominal 
pain 
145 
(38.15) 
Diarrhea 12 
(3.15) 
Constipation  94 
(24.73) 
 Short term 44 
(11.57) 
 
Figure 1. The frequency of gastrointestinal 
symptoms in 670 patients (percent)  
Figure 2. Flowchart or the study design. FBD 
functional bowel disorder, IBS irrritable bowel 
syndrome 
The most prevalent symptoms in these 670 
cases were dyspepsia (208/670), bloating 
(190/670), abdominal pain (185/670), 
constipation (139/670), weight loss 
(44/670), nausea (36/670), diarrhea 
(23/670) and reflux (23/670) (Fig.1). 
Constipation, heartburn, and bloating were 
significantly more prevalent in females 
compared to the male patients (Table IV). 
Abdominal pain, heartburn, bloating and 
constipation were the most common 
symptoms found in tTG positive cases and 
diarrhea was found only in 2/25 cases (Table 
I). However, these symptoms were not 
specific for CD as the rest of the study group 
presented with similar symptoms. 
A positive tTGA test was found in 22 out of 
670 investigated subjects (17 women, 5 men) 
(95% CI: 1.70- 4.30) and 8/670 were IgA 
deficient. tTGG was positive in 3/8 IgA 
deficient. The most tTG positive patients 
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ranged between 15- 45 years (14 patients) 
(Figs.3, 4). 
 
 Figure 3. Histogram of age (with normal 
curve) for patients with gastrointestinal 
symptoms 
A multivariate logistic regression was 
performed to assess the relationship between 
GI symptoms and CD. Only weight loss 
(OR=3.45, 95% CI: 1.15-10.30) and 
constipation (OR=0.33, 95% CI: 0.13-0.82) 
appear to be correlated significantly with CD. 
 
Table IV. The type and frequency of symptoms 
in all cases, actual number and (%) 
Symptoms Females Males Total 
Abdominal 
pain 
142 
(21.19) 
43 
(6.41) 
185 
(27.61) 
Constipation 110 
(16.41) 
29 
(4.32) 
139 
(20.74) 
Diarrhea 13 (1.94) 10 
(1.49) 
23 (3.43) 
Bloating 144 
(21.49) 
46 
(6.86) 
190 
(28.35) 
Heartburn 144 
(21.49) 
64(9.55) 208 
(31.04) 
Nausea 23 (3.43) 3 (0.44) 26 (3.88) 
Weight loss 23 (3.43) 21 
(3.13) 
44 (6.56) 
Dysphagia 18 (2.68) 6 (89) 24 (3.58) 
Fecal 
incontinence  
1 (0.14) 1 (0.14) 2 (0.29) 
 
 
Figure 4. Histogram of age (with normal curve) 
for CD patients 
Discussion 
Coeliac disease is the major 
diagnosable food related disorder and often 
it is diagnosed late presenting with milder 
and more atypical symptoms [24]. 
Serologic screening studies suggest that it 
occurs in about 1-2.5% of the population 
around the world [25, 26]. However, 
serology does not detect a subgroup of 
atypical patients with milder mucosal 
abnormalities [27-30]. Our study included 
screening of patients with non-specific GI 
symptoms running a greater risk of CD, 
e.g., some of the subjects with dyspepsia 
and changing of bowel habits etc. 
Classically, the condition presented with 
malabsorption and failure to thrive in 
infancy, but this picture has now been 
overtaken by the much more common 
presentation in adults, usually with non-
specific symptoms such as dyspepsia, 
disturbance in bowel habits or with 
symptoms outside the small bowel [31-39]. 
In this study, weight loss and constipation 
appeared to be correlated significantly with 
CD and dyspepsia was the most common 
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symptom in the whole study group (Fig. 1). 
This shows that a considerable number of 
coeliac patients do not have demonstrable 
clinical or functional characteristics of the 
disease [7, 40]. However, this atypical 
presentation especially with constipation 
has received considerably less attention 
than typical forms of disease such as 
diarrhea and malabsorption in clinical 
practice (Table V). 
It was suggested several decades ago 
that symptomatology might be related to 
the extent to which the small intestine is 
structurally involved. In other cases, 
symptoms arise only when the 
compensating hypertrophied lower small 
bowel is defunctioned through other 
factors, such as an inter-current bowel 
infection. However, Murray et al and 
others clearly identified that the symptoms 
are not only predominately atypical but 
also they do not seem to be related solely 
to the degree of mucosal changes [41-43]. 
Similarly, the sensitivity of antibodies is 
not influenced by clinical presentation as it 
does not differ between patients with 
typical or atypical disease [44]. 
Interestingly, early CD has been shown 
to have gluten-dependent GI symptoms 
even at the microscopic stage of the 
mucosal lesion such as Marsh 0 or Marsh I 
[45-47]. The main issue is not the degree 
of mucosal changes, but the consistency of 
mucosal abnormalities with gluten 
sensitivity [48-51]. There are gluten-
sensitised lymphocytes in the mucosa and 
this is what gluten sensitivity means, 
irrespective of the degrees of mucosal 
damage [46, 47, 49, 52]. Unfortunately, 
there are no facilities to look routinely for 
the subtle mucosal changes even in the 
most modern centers. In contrast to the 
current guidelines restrictions, we believe 
that symptomatic gluten sensitive cases 
with any degree of mucosal abnormalities 
Table V. Typical presentation of atypical CD compared to classical CD 
Investigations Classical CD Atypical CD outside small bowel Atypical GI like this study 
 Abdominal pain 
Chronic diarrhea 
Vomiting 
Weight loss 
Foul smelling stool 
Fatigue 
Failure to thrive or 
short stature 
Delayed puberty 
Osteoporosis 
Anaemia 
Obesity 
Dyspepsia 
Constipation 
Depression and anxiety 
 
 
Abdominal pain 
Dyspepsia 
Constipation 
Biochemistry 
and 
haemathology 
Iron deficiency 
Anaemia 
Low serum protein 
levels 
Low serum calcium 
levels 
Macrocytic anaemia, 
Vitamin B12 deficiency, 
Abnormal liver function tests 
Serology Positive serology, 
tTGA, EMA 
Negative or +ve serology, IgA 
deficient, or only positive in small 
bowel mucosa or in stool samples 
 
Histology Macroscopic lesion 
(Marsh IIIa-IIIc) 
Microscopic and macroscopic lesions 
Marsh 0-IIIc affecting atypical site of 
small bowel: bulb or terminal ileum 
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would potentially benefit from a gluten 
free diet. 
In this study, 380/670 presented 
functional and nonspecific bowel 
disorders. The symptomatology in this 
group was very similar to that of those with 
an organic etiology (Table VI). It is 
possible that there might be some 
unidentified gluten sensitive cases in this 
group which we have been unable to detect 
due to the lack of routine effective facilities 
[53]. Similar published analyses have shown 
that testing for CD in other symptomatic 
patients such as patients with suspected IBS 
is likely to be cost-effective even at a low CD 
prevalence (3–8%) [54-56]. Similar 
prevalence found in patients with dyspepsia 
and other atypical symptoms in this study 
would justify screening for gluten sensitivity 
in most patients with GI symptoms. Although 
a negative result of antibody screening does 
not exclude the CD diagnosis, a positive 
result of EMA/tTGA is associated with 
important histological changes. Therefore, 
with the limitations of serology [28, 29, 57] 
in detecting CD, one can assume that the 
prevalence of undiagnosed CD among 
patients with GI symptoms is even higher 
than the number of cases detected in this 
study.  
 
Table VI. Gastrointestinal symptoms in 380 
patients with functional symptoms and 290 with 
an organic GI disorder 
Symptoms with functional 
symptoms 
with an organic 
etiology 
Bloating 110 (28.9%) 80 (27.6%) 
Heartburn 115 (30.30%) 93 (32.1%) 
Nausea 16 (4.2%) 10 (3.4%) 
Weight loss 30 (7.90%) 14 (4.8%) 
Dyspepsia  18 (4.7%) 6 (2.1%) 
Incontinence  1 (0.26%) 1 (0.3%) 
Abdominal 
pain 
102 (26.8%) 83 (28.6%) 
Constipation  85 (22.3%) 54 (18.6%) 
Diarrhea 11 (2.9%) 12 (4.1%) 
One way to optimize the efficacy of 
screening would be by using the strategy 
suggested by Rashtak and Murray [5, 58]. 
They suggest using HLA typing as a high-
sensitivity rule-out test when there is a 
high suspicion of CD and to use serologic 
testing a high-specificity rule-in test when 
the probability is low [5]. This strategy 
might be helpful in encouraging health 
professionals to use serology because the 
index of suspicion is generally low for 
atypical presentation. On the other hand, 
relying on serology alone might result in 
overlooking those patients with negative 
serology even when the suspicion is low 
[28-30, 57, 59]. Perhaps performing HLA 
typing in seronegatives would give some 
more degree of reassurance in ruling it out 
as suggested by Hadithi et al [58]. Finally, 
it is time to forget the classical GI 
presentation and focus on non-specific 
specificities of the CD spectrum when the 
health-related life quality of coeliac 
patients with atypical presentation is 
impaired. Implementing a new diagnostic 
strategy with a high index of suspicion 
based on recent evidence on atypical forms 
of CD would be the key step in identifying 
patients without symptoms. 
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ABSTRACT 
 
Aim: The aim of this study was to determine the prevalence of celiac disease in Iranian 
patients suffering from chronic depression or schizophrenia.  
Background: Psychiatric disorders are common in untreated celiac disease.  
Patients and methods: Two hundred Iranian inpatient men with in chronic phase of 
depressive disorders or schizophrenia, and 200 age-matched healthy male subjects 
were screened for celiac disease by anti-tissue transglutaminase IgA antibodies. The 
mean age of the study patients was 37 years. 
Results: One (1%) schizophrenic and two (2%) depressive patients were positive for 
anti-tissue transglutaminase IgA antibodies; duodenal biopsy was not possible in these 
subjects. In the control group one (0.5%) individual was positive for anti-tissue 
transglutaminase IgA antibodies, but had normal duodenal histology. The difference 
between patients and controls was not statistically significant. 
Conclusion: The frequency of celiac disease serology in schizophrenic and depressive 
inpatients was not significantly higher than that in the general population. We would 
therefore not advocate systematic serologic screening in these patients, but alertness to 
celiac disease should be kept in mind. 
Keywords: Celiac disease, Depression, Schizophrenia, Serologic screening, 
Tissue transglutaminase antibodies. 
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Introduction  
Celiac disease is an under diagnosed 
condition in which gluten ingestion in 
genetically susceptible individuals 
results in small-bowel mucosal 
inflammation and villous atrophy. Most 
patients are asymptomatic or suffer from 
mild symptoms only, (1) and many 
present with extraintestinal 
manifestations such as neurologic 
disorders (2). The anti-tissue 
transglutaminase antibody (tTGA) test is 
a sensitive and specific tool in disclosing 
celiac disease with overt villous atrophy 
(3). With a specificity of approximately 
95%, false positive tests are uncommon, 
and tTGA may appear in serum at an 
early stage in the disease, in other words 
before the clinical manifestations and 
even before the development of villous 
atrophy (4). Psychiatric disorders are 
also common in untreated celiac disease, 
especially depressive symptoms (5-8). 
Hallert & Derefeldt reported that nine 
out of 42 studied subjects had attended a 
psychiatric clinic because of neurotic 
problems and most of them are involved 
with depressive disorders (7).  
Celiac disease was considered 
relatively uncommon in Iran, until 
recently an estimated population 
prevalence of 1:166 was reported (9). 
Greater awareness of its varying 
presentation and the availability of new 
serologic tests have shown celiac disease 
to be relatively common (10). These 
observations prompted us now to assess 
the association between celiac disease 
and severe chronic depression and 
schizophrenia.  
Patients and Methods 
This cross-sectional study was carried 
out in 2006-2007. By random sampling, 
200 inpatient men comprising 100 with 
chronic depression and 100 with 
schizophrenia (mean age 37 years, range 
18-68 years) were enrolled in Razi 
Hospital, Tabriz, Iran. Chronic depression 
was defined according to DSM-IV criteria, 
11 diagnosed and treated by semi-
structural clinical interview by two 
psychiatric experts. The duration of the 
diseases was more than two years, and the 
diseases were unbearable without 
antipsychotic drugs. Patients with 
schizophrenia suffered from different types 
of the disease such as paranoid, phrenetic 
or undistinguished. Two hundred healthy 
males were selected as controls, matched 
for age and birthplace (mean age 32, range 
4-77 years).  
A written informed consent was 
obtained from patients (or from next of kin 
if necessary) and the study was approved 
by the Institutional Ethics Committees of 
the Research center for gastroenterology 
and liver disease, Tabriz Medical 
University. Blood samples were collected 
and the sera stored at −20°C until analysis. 
IgA class TTGA antibody was measured 
by enzyme-linked immunosorbent assay 
using a commercially available kit (Eu-tTG 
IgA, Eurospital, Trieste, Italy). A titer of > 
7 U/mL was considered positive as 
recommended by the manufacturer. Serum 
IgA was measured in each subject. 
Statistical analysis 
A frequency of 0.6% celiac disease has 
been reported in Iran. 9 Assuming this 
frequency in 200 controls and a tenfold 
frequency in psychiatric patients (6%, as 
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has been reported in many autoimmune 
conditions) the statistical power of 0.80 at 
a significance level of 0.05 would then be 
achieved. Percentages were compared by 
rates and proportion; 95% confidence 
intervals (CI) were reported. 
Results 
None of the 200 patients had a history 
of chronic diarrhea and all were taking 
antipsychiatric drugs (antipsychotic such as 
risperidone, haloperidol or perphenazine 
and anticholinegic for schizophrenic 
patients, and fluoxetine and tricyclic 
antidepressants for depressive patients). 
Three patients with chronic psychiatric 
disorders were TTGA positive, in which 
one (age 52 years) with schizophrenia and 
two (both 30 years of age) with chronic 
depression. Of these three patients, two 
refused duodenal biopsy and one died 
during the study period. In the control 
group, one (age 25 years) out of 200 
individuals was positive, but duodenal 
histology proved normal. The prevalence 
of positive celiac disease serology in 
patients with chronic psychiatric disorders 
was thus slightly but not significantly 
higher than in controls; 1.5%, (95% CI: 
0.38-4.03) and 0.5 % (95% CI 0.00025-
2.44), respectively (P=0.0623).  
 
Table 1. Clinical and laboratory features of 
male patients with schizophrenia and depression 
 Schizophrenia
(n=100) 
Depression 
(n=100) 
Healthy 
controls 
(n=200) 
Age (yrs) 37±11* 37±8 32±14 
tTGA+† 1 2 1 
Constipation 12% ١٢% --- 
Heartburn 7% 10% --- 
* Mean± standard deviation; † tTGA: IgA-class anti-
tissue transglutaminase antibody 
Clinical features and laboratory findings 
among the patients with schizophrenia and 
depression are shown in table 1. Five in the 
study group and none in the control group had 
selective IgA deficiency.  
Discussion 
In our reports, the frequency of positive 
celiac disease serology in Iranian inpatients 
suffering from depression or schizophrenia 
was 1.5%. By comparison, Pynnönen et al. 
have shown the prevalence of celiac 
disease in patients with depression to be 
0.7% (5). The same authors have reported 
that in adolescent celiac disease patients 
the frequency of depression and disruptive 
behavioral disorders was higher than in 
controls, 31% and 7%, respectively (6). 
The present observations support 
earlier findings that celiac disease is not 
increased in patients with schizophrenia. 
Eaton et al. (12) studied 7754 
schizophrenia patients in Denmark and 
found a frequency of untreated celiac 
disease of 0.05%. In UK, West et al. 
showed that in subjects with celiac disease 
the prevalence of schizophrenia was 
0.25%, the adjusted odds ratios showing no 
association between the two conditions 
(celiac disease vs. controls 0.76, 95% CI: 
0.41-1.4) (13). 
By contrast, a study in the UK revealed 
that patients with celiac disease developed 
schizophrenia 3 times more frequently than 
non-celiac controls (14). Some studies 
have suggested that schizophrenia and 
celiac disease may be associated with 
similar or adjacent genes (15,16). It has 
indeed been reported that genetic 
susceptibility in schizophrenia lies in 
human leukocyte antigen (HLA) DQ, 
similarly to autoimmune disorders such as 
celiac disease (17). By contrast, a recent 
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study showed no such HLA association in 
schizophrenia (18).  
In a case report, the symptoms of 
schizophrenia were improved in a celiac 
patient aged 33 years after the introduction of 
gluten free diet (19). Here we had no 
opportunity to investigate the effect of 
gluten-free diet, since two patients refused 
and one died during the study. 
In this present study, the frequency of 
positive celiac disease serology in patients 
with chronic depressive (1%) and 
schizophrenia (0.5%) was in fact similar to 
that found in healthy blood donors in Iran 
(0.6%) (9). In the latter study, the 
frequency of celiac disease in males (1.8%) 
was higher than in females (0.5%), 
although usually 60%-70% of celiac 
disease patients are female. We could not 
investigate females with psychiatric 
disorders, which may be considered as a 
limitation to the current study. On the other 
hand, all our patients were inpatients, 
indicating that they suffered from severe 
manifestations of chronic psychiatric 
disorders. Patients with selective IgA 
deficiency remain negative by tTGA IgA 
class screening, and we had no opportunity 
to test our 5 such subjects by IgG class 
tTGA. In blood donors positive IgG class 
tTGA was found in 9.8% (20). There may 
thus be additional celiac case in our study 
group, but we consider that this would not 
change our conclusions. 
To conclude, mass screening for celiac 
disease in patients with depression or 
schizophrenia is not advocated. Despite 
this, alertness to celiac disease should be 
high, since early diagnosis and treatment 
by gluten-free diet may ameliorate the 
symptoms and quality of life of these 
patients.  
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ABSTRACT 
 
Background and Study aim: The traditional diagnosis of celiac disease (CD) requires 
a small bowel biopsy to identify the characteristic mucosal changes. The current 
biopsy practice among endoscopists for CD is in most part unknown. The aim of this 
study was to compare the different diagnostic policies in various centers in their 
current practice. To measure the number of specimens submitted during duodenal 
biopsy among patients in Italy, Iran, Lithuania, Romania and the UK, and to determine 
the incremental diagnostic yield of adherence to the recommended number of 
specimens.  
Patients and Methods:  A total of 931 patients who underwent duodenal biopsy for 
CD were recruited retrospectively at nine centers in European and Middle Eastern 
countries. Small-bowel biopsies were obtained from the duodenal bulb and the second 
part of the duodenum. The histopathological appearances were described according to 
the modified Marsh classification.  
Results: The most frequent degree of mucosal changes amongst Iranian subjects was 
Marsh IIIa whereas in the rest of the study population was Marsh IIIc. The most 
common number of biopsy specimens for Romanian subjects was 1 (52%) followed by 
2 for Iranian (56%), 3 for Lithuanian (66.7%) and British patients (65%) and 4 for 
Italian patients (48.3%). The main presenting symptom was anaemia (18.7%) followed 
by malabsorption (10.5%), diarrhoea (9.3%) and dyspepsia (8.2%).  
Conclusions: Despite the evidence based recommendations, this assessment revealed a 
poor compliance with major guidelines on diagnosis of CD. We emphasize that taking 
adequate number of duodenal biopsies is mandatory and essential for an accurate 
diagnosis or its exclusion of CD. 
Keywords: Celiac disease, pitfall, biopsy specimen, multicenter. 
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Introduction  
Celiac disease (CD) is an auto-
immune disorder generated in genetically 
susceptible subjects via the ingestion of 
gluten containing grains such as wheat, 
rye and barley. The immune response to 
these grains leads to progressive damage 
in the small intestine and to the 
production of serum antibodies directed 
against tTGA (1-4). 
Despite the availability of specific and 
sensitive serological tests diagnosis of 
atypical forms of CD could be very 
challenging (5). Intestinal biopsy is still 
considered a useful diagnostic tool for 
detection of CD in different stages (6). 
Histology also permits to evaluate the 
response to gluten-free diet, should there 
be any doubt about the diagnosis. 
The sensitivity of the serological tests 
available does not correlate with the 
degree of mucosal abnormalities and 
according to many studies a negative 
serological test does not exclude the 
diagnosis of CD (7). The mucosal lesions 
in CD can be patchy, and if the sampling 
is insufficient, the risk of missing the 
diagnosis increases (8, 9). Low degrees of 
mucosal abnormalities like microscopic 
enteritis in small intestinal specimens are 
not specific for CD, but a combination of 
clinical, serological and genetic 
evaluation may help to confirm the 
diagnosis (10). If possible, it would be 
more desirable to avoid endoscopy 
completely. We might argue that 
endoscopy may be unnecessary in the 
small sub group of patients who have 
classic symptoms and positive serology, 
but we still find that taking a biopsy 
appears essential in the majority of cases 
(11). A multicentre endoscopy database 
study found that most patients undergoing 
upper GI Endoscopy for indications such 
as anaemia, iron deficiency, and weight 
loss had no duodenal biopsy taken during 
the procedures (12). Smith et al. 2004 
found that only one third of the patients 
with duodenal biopsies were actually 
diagnosed with CD; thus, pre-Endoscopy 
testing for CD is not specific (13). 
Moreover, a normal endoscopic 
appearance lacks sufficient sensitivity to 
exclude CD (14). 
As mucosal abnormalities in CD are 
patchy and the orientation of biopsies are 
variable, multiple biopsies (4-6 biopsies) 
from the duodenal bulb and descending 
duodenum are usually recommended as 
indicated by most studies as the standard 
method for CD evaluation (10, 15-17). 
Study results by Pais and co-workers 
showed that 2 biopsies confirmed CD in 
90 % of patients, while 4 biopsies 
established a diagnosis in 100% of cases 
(10). By using a large, international, 
pathology database we assessed the 
adherence to these proposed guidelines.  
To address diagnostic yield of biopsies 
versus ecologic fallacy versus 
clinicopathologic correlation, we 
investigated the proportion of patients 
diagnosed with CD. We also investigated 
procedure-related factors associated with 
the submission of biopsy specimens and 
compared the different diagnostic criteria 
in various centers in Italy, Iran, Lithuania, 
Romania and the UK. This study 
elucidates how a guideline is exercised in 
clinical practice, both in terms of 
adherence to the recommendation as well 
as the incremental yield of adherence.  
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Patients and Methods 
In this retrospective multicentre study, 
data were collected in the period May 
2009-May 2011 from Iran (Tehran), 
Romania (Bucharest), Lithuania (Vilnius), 
the United Kingdom (Birmingham) and 6 
different areas in Italy, including Brescia, 
Bologna, Desio, Messina, Perugia and 
Empoli. For each center, at least 100 CD 
patients with endoscopic procedures and 
small bowel biopsies were included.  
During the same period, the number of 
biopsy sample taken from each center and 
their clinical data were compared. For each 
specimen, the following information was 
available: sex and age of the patient, 
location and sample provider, summary of 
the clinical history, serology/genetic and 
histopathological findings.  
GI symptoms such as abdominal pain, 
diarrhoea, constipation, nausea and 
vomiting, weight loss and flatulence as 
well as additional signs and symptoms 
such as iron deficiency anaemia, 
osteoporosis, hypertransaminasemia, and 
other related abnormalities were recorded. 
To determine the number of duodenal 
biopsy specimens for each biopsy set, we 
used a free-text search of the pathologist’s 
description of each sample. When present, 
specimens from the duodenal bulb were 
included in the total number of specimens 
submitted. In each lab, biopsies were 
interpreted by expert gastrointestinal 
pathologists (blinded to the clinical data). 
In Bucharest the patients suspected for CD 
are usually referred directly for the 
gastroenteroscopy because of lack of 
funding for serological tests and HLA-
typing. The duodenal specimens in 
Bucharest were oriented using Endokit and 
the biopsies in some departments in Italy 
(Brescia, Desio and Messina) were 
oriented on acetate cellulose filters. 
Histopathological findings were evaluated 
in accordance with the original modified 
Marsh classification (1). 
All centers used the cutoff of: >25 
intraepithelial lymphocytes per 100 
enterocytes for (Marsh I), increased 
intraepithelial lymphocytes accompanied 
by crypt hyperplasia (Marsh II), partial 
(Marsh 3A), subtotal (Marsh 3B) and total 
villous atrophy (Marsh 3C) as described in 
original classification (1). The final 
diagnosis of CD was considered when 
patients with abnormal mucosal findings 
were serologically positive for tTGA 
and/or EMA. Centers with the lowest and 
highest number of biopsy specimens were 
analysed separately and also compared in 
order to investigate causes for those 
differences. According to the follow up 
reports to ordering HLA typing, the genetic 
data available were incomplete and HLA DQ 
typing was carried out only in some centers. 
Statistical analysis 
We used the chi-square test to assess the 
association between adherence to the 
recommendation of submitting ≥ 4 
specimens and the proportion of patients with 
pathological findings consistent with CD. 
The results with a p-value <0.05 were 
considered statistically significant. Because 
our data set did not contain information 
regarding HLA typing for all cases and 
clinical follow-ups, we defined a priority that 
results with either blunted villi (Marsh 3A) or 
flat villi (Marsh 3B/C) were meeting the 
pathological definition of CD. For assessing 
the relationship between ordinal categories 
such as the number of specimens and the 
pathologic diagnosis of CD, we used the 
Fisher’s Exact Test for trend. 
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Results 
Overall, 658 women and 273 men (mean 
age at diagnosis 35.4±17.25 years, median 
age 36 years, age range 1–72 years) with a 
diagnosis of CD were included. Around 
70.7% of patients were women, and the mean 
(± standard deviation [SD]) age was 36.6-
16.4 years. Lithuanian patients were the 
oldest, with a mean age of 43.7± 18.6 yrs, 
and Iranian patients the youngest (30±13.6 
yrs). In all participating countries females 
were predominant. Sixty nine patients were 
excluded based on their incomplete data 
collection. 
Marsh I and II lesions were noted in 152 
individuals (16.3%), Marsh 3A was found in 
108 (19.3%), Marsh 3B was found in 178 
(19.1%) and Marsh 3C in 233 study subjects 
(25.2%) (Fig 1). When a pathological 
diagnosis of CD was defined as that of 
blunted or flat villi (Marsh 3A/B/C), a total of 
519 individuals (55.7%) were categorized as 
having CD. In 18 individuals (1.9%) Marsh 0 
was recorded (table 1).  Regarding the 
number of biopsy specimens taken per CD 
case, we found that 1 biopsy specimen had 
led to a diagnosis in 63 (6.7%) cases (11 
specimens were Marsh I and II and the rest 
was higher), 2 in 212 (22.7%) cases (96 
specimens were Marsh II or lower), 3 in 306 
(32.9%) cases (153 were Marsh II or lower), 
4 in 299 (32.1%) cases (81 specimens were 
Marsh II or lower) and ≥ 5 in 51 (5.5%) 
cases (9 specimens were Marsh II or lower) 
(Fig 2). The average number of biopsy 
specimens per patient was 3 (Fig 3).  
The most common number of biopsy 
specimens taken from Romanian subjects 
was 1 (52%) followed by 2 from Iranian 
patients (56%), 3 from Lithuanian (66.7%) 
and British patients (65%) and 4 from Italian 
patients (48.3%). Villous atrophy (partial, 
subtotal or total) was the predominant 
histologic lesion in all studied countries 
(Fig 1).  
 
Table 1.  Frequency of different degrees 
mucosal abnormalities correlated to the number 
biopsies.    
 
No. of 
Biopsy 
Modified Marsh classification 
Marsh 
0 
Marsh 
I 
Marsh 
II 
Marsh 
3A 
Marsh 
3B 
Marsh 
3C 
1 0 10 1 15 15 22 
2 1 72 23 37 32 47 
3 15 92 36 32 27 104 
4 2 35 44 67 94 57 
≥5 0 5 4 5 10 27 
 
 
Fig 1. The percent of mucosal changes in this 
study group according to modified Marsh 
classification 
 
The most frequent degree of villous 
atrophy for Iranian subjects was 3A and for 
the rest of the study population 3C (Table 
2). According to the histological variability 
illustrated above, a statistical correlation 
was found between type and distribution of 
the histological lesions and the number of 
biopsy specimens (P= 0.0001). Four or 
more duodenal biopsies had been taken for 
58.7% of the Italian, 37% of the British, 
7% of the Romanian and 5% of the Iranian 
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studied subjects. None of the Lithuanian 
patients had 4 or more duodenal biopsies.  
Routine immune-histochemical 
evaluation of T lymphocytes with CD3 and 
CD8 antibodies was used only in Iran and 
one center in Italy (Brescia). Serological 
data for anti-EMA was available in only 
32.3% Iranian and Italian patients while 
serology results for anti-tTG IgA and anti 
gliadine IgA were available only in 39.3% 
and 6.3% of the Iranian, Italian and 
Lithuanian, respectively. 
  
Table 2. Frequency of different degrees of 
mucosal abnormalities based on modified 
Marsh classification in different countries per 
100 cases.   
 
HLA typing was not performed for 
Lithuanian subjects. If performed, there 
was no access to genetic results of the 
HLA DQ typing in this country. HLA 
typing was performed for very few selected 
cases in Romania. HLA-typing for Italian 
(72/602) and Iranian subjects (52/100) 
showed that, HLA DQ2 is the predominant 
genotype in both countries. 
 
 
Fig 2. Number of specimens submitted and the 
probability of the diagnosis of celiac disease 
 
The clinical data available to 
pathologists also varied by region and the 
variability of this data show that, the main 
presenting symptoms of the majority of 
cases were anaemia (18.7%) malabsorption 
(10.5%), diarrhoea (9.3%) and dyspepsia 
(8.2%) (Fig 4).  
 
 
Fig 3. Histogram of number of specimens of 
small bowel biopsies among investigated 
patients (n=913) 
 
There is a statistically significant 
correlation between these symptoms and 
abnormality in histology. As showed in fig 
4 anemia and diarrhea is more correlated 
with Marsh 3c, malabsorbtion with Marsh 
Country No of 
Biopsy 
Modified Marsh 
Classification 
Total 
 
Iran 
 
 
 0 1 2 3A 3B 3C  
2 1 13 10 12 9 11 56 
3 1 6 7 13 4 8 39 
4 0 0 2 2 0 1 5 
 
Italy 
 
1 0 7 0 3 0 1 11 
2 0 25 2 21 17 16 81 
3 14 34 16 18 22 68 172 
4 2 34 42 64 93 56 291 
≥5 0 5 4 4 8 26 29 
Lithuania 
 
2 0 32 10 0 0 1 43 
3 0 51 12 0 0 23 86 
 
 
Romania 
 
 
1 0 3 1 12 15 21 52 
2 0 2 1 4 6 19 32 
3 0 1 1 1 1 5 9 
4 0 1 0 1 1 0 3 
≥5 0 0 0 1 2 1 2 
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1 and dyspepsia with Marsh 3b.  Table 3 
shows most of the clinical symptoms for 
the countries investigated. 90 percent of 
the Lithuanian study subjects were affected 
by malabsorption. The most frequent 
symptom in Italian patients was dyspepsia 
(14.6%) (Probably related to high 
carbohydrate diet) followed by anaemia 
(14.2%) and diarrhoea (8.8%). For Iranian 
subjects predominant symptoms were 
anaemia (55%), diarrhoea (32%) and 
osteopenia (25%). Romanian subjects 
predominantly complained of diarrhoea 
(8%), abdominal pain (6%) and weight loss 
(5%). Statistically significant differences 
were observed when comparing the 
reported clinical symptoms in different 
countries.  
In spite of the histological variability 
illustrated in this study, a statistical 
correlation was found between type and 
distribution of the histological 
abnormalities and some of the clinical 
symptoms such as abdominal pain, 
diarrhoea, low B12/Acid folic, 
malabsorption, IgA deficiency, dyspepsia, 
asthenia and failure to thrive (P ≥ 0.05).  
Table 4 shows the significant association 
between some of the clinical symptoms 
and the number of specimens submitted, 
with increased adherence to submitting ≥4 
specimens and decreased adherence to 
submitting >4 specimens regarding a 
number of indications for patients 
undergoing endoscopy.  
Among the 931 study subjects, 419 
(45%) displayed typical presentation, 430 
(46.2%) atypical presentation, and 64 (6.9 
%) had no or only minor GI symptoms. A 
statistically significant correlation was 
found between abnormal histology and 
abdominal pain, dyspepsia and failure to 
thrive for Italian patients and between 
abnormal histology and anaemia for 
Lithuanian patients (P≤ 0.5). 
 
 Fig 4. Compare the rate of anemia, diarrhea, 
dyspepsia and malabsorption in cases with 
abnormal histology (Marsh 0-II and Marsh 
IIIabc).  
Discussion 
Even though noninvasive antibody 
testing is an excellent screening tool for 
CD, endoscopic evaluation via duodenal 
biopsy in suspected patients remain crucial 
in the diagnosis of clinical atypical CD. 
The number of diagnosed patients has 
increased; this may be due to a greater 
proportion of outpatients being 
investigated for relatively minor 
symptoms, especially elderly people who 
visit their physicians more often (18).  
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 In this analysis of an international 
pathology database of duodenal biopsies, 
37.6% of patients had ≥4 specimens 
submitted upon upper endoscopy. 
Adherence to the proposed standard 
remained low even for patients with typical 
CD, with fewer than 40% of such patients 
having ≥4 specimens submitted (1, 15, 18, 
19).  
 As biopsy handling and experience of 
pathologists in different sites including 
duodenal bulb (17) can vary, it is suggested 
to take multiple biopsies from different 
duodenal sites in all cases where CD is 
suspected in order to minimize the risk of 
misdiagnosis (10). Biopsy specimens taken 
from the descending duodenum as well as 
jejunal specimens produce good results. 
However, contrary to common teaching 
and practice, duodenal bulb biopsy 
specimens appear adequate, and possibly 
should be taken as well (15, 17).  
A duodenal biopsy should have a 
reasonable size, should be well orientated 
and adequately stained and should be 
thoroughly examined by an experienced GI 
pathologist (20). General pathologists are 
not aware of the variety of pathological 
changes seen in CD. Therefore, it appears 
of utmost importance in CD diagnosis that 
Table 3. Clinical symptoms in different countries 
Clinical symptoms Country (n) Total n (%) P value 
 Italy Iran Lithuania Romania   
Abdominal pain 18 3 0 6 27 (2.9)  
Diarrhea 44 32 0 8 87 (9.3) < 0.05 
Anemia 71 55 37 0 174 (18.7) < 0.05 
Constipation 19 8 0 1 28 (3) < 0.05 
Family CD 49 1 0 0 56 (6) < 0.05 
Dermatitis herpetiformis 10 3 0 0 16 (1.7)  
IBS 10 0 0 0 10 (1.1)  
Osteoporosis  11 2 0 0 14 (1.5)  
Osteopenia 5 25 0 0 30 (3.2) < 0.05 
Malabsorption 6 0 90 2 98 (10.5) < 0.05 
Hypertransaminasemia 14 4 0 0 18 (1.9) < 0.05 
Thyroiditis 27 1 0 0 29 (3.1) < 0.05 
Autoimmune gastritis 2 0 0 0 2 (0.2)  
Weight loss 7 5 0 5 19 (2) < 0.05 
Aphthous 13 3 0 0 16 (1.7)  
Lymphoma  0 0 1 1 (0.1)  
Diabet 6 0 0 0 6 (0.6)  
Food allergy 1 4 2 0 7 (0.8)  
IgA deficiency 4 0 0 0 4 (0.4)  
Neurology symptoms 2 21 0 0 23 (2.5) < 0.05 
Menstrual abnormality 0 14 0 0 14 (1.5) < 0.05 
Bloating 2 11 0 0 13 (1.4) < 0.05 
Asthenia 9 0 0 2 11 (1.2)  
Failure to thrive 12 7 0 0 19 (2) < 0.05 
Low B12/Acid folic 8 0 0 0 8 (0.9)  
Dyspepsia 73 3 0 0 76 (8.2) < 0.05 
Gastritis 10 7 0 0 18 (1.9) < 0.05 
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all biopsies should be reviewed by an 
expert GI pathologist. 
Villanacci et al. suggested that even a 
single biopsy taken from anywhere along 
the duodenum could theoretically lead to 
the diagnosis of CD if the specimen would 
have the quality and assessed according to 
the standards (20). More often, an impaired 
clinical state including the improvement of 
typical symptoms may be sufficient to 
provide a convincing clinical diagnosis. 
Having said this, some additional biopsies 
for complete diagnosis may be needed 
(21). 
In a recent review, Yantiss & Odze 
2009 referred to the “optimal method of 
obtaining biopsies in patients with celiac 
disease” as “controversial” (22). It may be 
stressed at this point that the proposed 
guideline entirely derives from the 
observation that the histopathologic 
abnormalities of CD are patchy, and can be 
missed if an insufficient quantity of 
specimens is submitted. The 
recommendation is supported by a single-
centre retrospective study of 93 patients 
with CD, which found that 4 specimens led 
to a positive diagnosis in 100% of patients, 
whereas 2 specimens were diagnostic in 
only 90% of patients (10). The authors 
concluded that at least 4 duodenal biopsy 
specimens should be taken to rule out CD. 
A second study, investigating 56 patients 
with known CD, found that 3 biopsy 
specimens were sufficient as long as 1 
specimen was obtained from the duodenal 
bulb; however, 5 biopsy specimens were 
necessary to recognize the most severe 
extent of villous atrophy. These studies are 
limited by small sample size and single-
center settings (23). Evans et al. recently 
solve these problems. They investigated 
overall 461 patients including 126 newly 
diagnosed CD, 85 established CD, and 250 
controls. Their study suggests that the 
optimal strategy for diagnosing celiac 
disease in both suspected patients with 
positive serology and those with 
established CD could only achieve 100 % 
sensitivity by always incorporating a 
duodenal bulb biopsy (17). 
In this study, taking 1-2 biopsy 
specimens led to the confirmation of 
diagnosis in 29.5% of cases, while more 
than 3 biopsy specimens led to the 
diagnosis in 70.5%. We found a statistical 
correlation (P≤0.05) between the number 
of biopsies and histologic abnormalities. 
The variation in the number of biopsy 
samples in this study may be associated 
with endoscopists practice in each region. 
Endoscopists in Romania, Iran and 
Lithuania are more likely to perform less 
and fewer numbers of biopsies compared 
to endoscopists in Italy where CD is more 
common. 
Because villous atrophy in CD is 
patchy and the orientation of the specimens 
is variable, 4 to 6 random biopsy 
specimens including at least one from the 
duodenal bulb are recommended in order 
to maximize the sensitivity and achieve a 
correct diagnosis of CD (10, 15, 17, 20). 
This may suggest that if additional biopsy 
specimens in our study had been taken 
from subjects CD may have been 
confirmed in more cases (10). 
The incremental yield varied with 
indication and was greatest when the 
symptom was anaemia (18.7%). However, 
submitting ≥4 specimens also increased the 
diagnostic yield of CD even when the 
indication was dyspepsia (8.2%). Lecleire 
et al. suggest that endoscopic markers of 
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villous atrophy are not useful for the 
detection of celiac disease in patients with 
dyspeptic symptoms (24).  
Retrospective analysis of pathology 
tissue databases produced high-quality 
analyses of GI epidemiology and quality 
measures (25, 26). In our study, conducted 
in a similar manner, we had some 
limitations. For instance, we did not have 
access to socioeconomic or racial data to 
determine whether these individual patient 
characteristics were associated with the 
submission of the recommended number of 
specimens. We also had no access to key 
variables that influence the likelihood of 
CD, such as data regarding family history 
of CD. We are looking at patients with 
confirmed diagnosis for most of the 
locations. We did not describe a yield of 
biopsies because the total number of 
patients biopsied for suspected CD was not 
included. Therefore, the false negative rate 
was not assessed. Moreover, information 
regarding the type of sedation used during 
the procedure and the degree of sedation, 
which may have impacted the ability to 
obtain ≥4 specimens, was not available. 
The degrees to which endoscopists adhere 
to such recommendations in clinical 
practice and the diagnostic yield of 
adherence to this standard have not been 
studied. 
Since many of our CD patients did not 
have complete results of serology and 
clinical findings, we were not able to 
analyze the correlation between serology 
results and clinical findings regarding the 
degree of villous atrophy. Also, since the 
study was retrospective and many patients 
did not have uniform information 
regarding the degree of adherence to the 
diet in their medical record, we were not 
able to assess the correlation between 
seronegativity after treatment and the 
degree of compliance to the GFD (25). For 
example in Bucharest, for the majority of 
the patients that are suspected to have CD, 
endoscopy is performed prior to 
serological and genetic investigation; after 
the histological diagnosis of a picture 
compatible with CD, patients tend to have 
serological tests and, rarely, genetic 
testing. As methodological approach to the 
diagnosis of CD in this region may be 
attributed to high costs involved with 
genetic testing for DQ2/DQ8 (more than 
minimum salary/month), HLA typing is 
rarely performed. A similar situation is 
present in Iran and Lithuania; because 
HLA typing is expensive and access to 
laboratories that can perform genetic 
testing is limited, HLA typing is rarely 
carried out, and if performed, then it will 
be only in specific cases. This may 
represent the main obstacle for clinicians 
working without the facility for HLA-
typing. However, the situation is not better 
in UK, as HLA typing is not popular 
between clinician again due to high cost 
and National Health Service strict cost 
saving policies. 
Another obstacle for correct diagnosis 
in all investigated geographical locations 
may be that clinicians generally do not 
share clinical data or serology results of 
patients with pathologists. Most 
pathologists ignore the subtle histological 
changes like microscopic enteritis27 in 
absence of such clinical data.  
In our opinion this practice indicates 
the different levels of approach involved 
with the correct histological diagnosis of 
CD in different centers. Pathologists in 
general should know the subtle 
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manifestations and presentations of the 
disease. The evidence suggests that sharing 
the clinical data with pathologists might be 
essential toward a correct diagnosis as the 
pathologist is able to detect the majority of 
CD patients (26). 
Our results indicate that we should 
implement the biopsy guidelines with ≥4 
biopsy specimens into clinical practice 
including or with additional samples from 
bulb.17 In our multicentre study only the 
minority of patients with upper GI 
endoscopy and duodenal biopsy had ≥4 
specimens. In the light of the beneficial 
effect on the histological diagnosis of CD 
(28), in particular in atypical cases increased 
adherence to biopsy guidelines is warranted. 
In typical cases, as suggested by ESPGAN, 
the endoscopy and biopsy obviously might 
be avoided. However, the majority of celiac 
patients present with atypical manifestation 
where endoscopy and the correct sampling 
approach are paramount in diagnostic 
pathway (5).  
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ABSTRACT 
 
Background: Celiac disease (CD) susceptibility has been strongly associated with 
HLA-DQ2 and -DQ8. No data are available on the distribution of these HLA alleles in 
Iranian CD patients, so our objective in this study was to assess the distribution of 
these alleles in Iranian CD patients and compare them to healthy Iranian controls.  
Methodology: To predict the HLA-DQA1 and -DQB1 genes, we used the six 
previously reported HLA-tagging SNPs to determine HLA genotypes in 59 patients 
with CD and in 151 healthy individuals from Iran. To test the transferability of the 
method, 50 cases and controls were also typed using a commercial kit that identifies 
individual carriers of DQ2, DQ8 and DQ7 alleles. 
Results: The results of the transferability test showed that the sensitivity and the 
specificity for DQ2 and DQ7 was 100% and 97%, respectively, and for DQ8 it was 
86.4%. We observed that 96.6% of CD cases (n=57) and 57.6% of controls (n=87) 
were carriers of HLA-DQ2 and/or HLA-DQ8 heterodimers, either in the homozygous 
or heterozygous state. The HLA-DQ pattern of these 57 CD patients was: heterozygous 
DQ2.2 (n=14), and homozygous DQ2.2 (n=1), heterozygous DQ2.5 (n=33) and 
homozygous DQ2.5 (n=8), heterozygous DQ8 (n=13) and homozygous DQ8 (n=2). 
Twenty patients and controls were compound DQ2/DQ8 heterozygous. Two patients 
were negative for both DQ2 and DQ8 (3.4%).  
Conclusion: We observed that the frequency of DQ2 was higher in CD patients than 
controls. The prevalence of DQ8 in our CD population was higher than that reported in 
other populations. Our results underline the primary importance of HLA-DQ alleles in 
the Iranian population’s susceptibility to CD. 
Keywords: HLA typing, validation, celiac disease, Iran. 
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Introduction  
Celiac disease (CD) is characterized 
by malabsorption of nutrients in the 
small intestine after ingestion of wheat 
gluten or related proteins from rye and 
barley. The disease is characterized by 
villous atrophy of the small intestinal 
mucosa. With adherence to a strict 
gluten-free diet, most CD patients show 
prompt clinical and histological 
improvement, with relapse of the 
symptoms if gluten is re-introduced [1-
3].  
Many studies reflect the importance of 
genetic factors in the pathogenesis of CD 
[3]. The HLA-DQ2 heterodimer, which is 
coded by alleles DQA1*05 and DQB1*02, 
is present in approximately 95% of CD 
patients. The most important risk factor for 
CD is the DQ2.5 haplotype [4]. Alpha and 
beta chains of this heterodimer are encoded 
together in cis (DQA1*05, and DQB1*02) 
on a DRB1*03 haplotype. Other DQ 
heterodimers that are encoded in trans on 
DR7 haplotypes are related to the DQ2.2 
haplotype (DQA1*0201/DQB1*02) [5-13]. 
The CD patients who do not carry the DQ2 
heterodimer and are encoded by the DR4 
haplotype carry HLA-DQ8 (α1*0301, 
β1*0302) [4]. HLA-DQ2 is common in 
Europeans and is expressed by 25-30% of 
the healthy European population. 
Consequently, the estimated HLA 
contribution to the development of CD is 
estimated to be approximately 35% [5-13].  
Most of the CD patients who do not 
carry either DQ2.5 or DQ8, carry half of 
the DQ2.5 or DQ2.2 molecule (that is 
either HLA-DQA1*05 or HLA-
DQB1*02), suggesting that carrying part of 
the risk molecules still has functional 
implications for the risk of CD [13]. 
There are several ethnic groups, such as 
Persian, Kurd, Lur, Arab, Turkmen, 
Baloch, and Turk, living in Iran. Most 
Iranians are Muslims but Zoroastrians, 
Jews, Armenians, and Nestorians also live 
in this large country. Based on previous 
studies in Iran, the most common HLA 
haplotype in the different ethnic groups is 
DQ2 and DQ7 with prevalences of 22.1% 
and 25%, respectively [14-17] (fig 1).  
These studies were performed in 
healthy populations in different parts of the 
country and showed considerable 
similarities in the distribution of HLA class 
II haplotypes with European countries. 
Recently, Monsuur et al. [13] described an 
HLA-tagging single nucleotide 
polymorphism (SNP) method for detecting 
the HLA risk alleles for CD. Using six 
SNPs, HLA genotyping for specific CD 
genotypes could be performed in a high 
throughput mode. The results of Monsuur 
et al. [13] and Koskinen et al. [12] showed 
that the sensitivity and specificity of this 
test in recognizing DQ2.2, DQ2.5, DQ7, 
and DQ8 haplotypes was >99% in the 
Dutch population and >98% in UK, 
Spanish, Finnish, Hungarian, and Italian 
populations.  
We report the first attempt to type HLA 
in the Iranian population by this tagging 
SNP method, in both healthy individuals 
and in patients affected by CD.  
Patients and Methods 
Patients  
A total of 59 CD patients (21 male 
and 38 female, median age 30.54 years, 
range 7–67 years) were included: 12 
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patients from East Iran (Zahedan 
Province, Baloch ethnicity), 13 from 
North Iran (Mashhad Province, Fars), 10 
from West Iran (Lorestan & Kurdistan 
Provinces, Lour and Kurd ethnic groups), 
and 24 patients from Tehran, in the 
center of Iran (Fars). All patients had 
positive tTGA and/or EMA antibodies 
and histology according to the Rostami-
Marsh classification (Marsh I-IIIc) [18]. 
Controls 
A total of 151 healthy controls (78 
females and 73 males, median age 30.54 
years, range 5–83 years) were selected 
from those who were negative for CD 
serological screening in the study areas 
(25 from Zahedan Province, 30 from 
Mashhad, 26 from Lorestan & Kurdistan 
provinces, and 70 from Tehran). None of 
them had a personal or family history of 
cancer or autoimmune diseases. The 
study was approved by the ethical 
committees of the Gastroenterology and 
Liver Diseases Research Centers, Shahid 
Beheshti University of Medical Sciences, 
Tehran, and all the participants (or their 
parents/guardians) were informed about 
the study according to the study protocol 
and gave their written informed consent. 
 
Figure 1. HLA haplotype frequencies in different ethnicities of Iran (refs 14-17). 
 
 
 Studied population City Ethnicity HLA typing 
 
HLA typing 
 in this study 
Tehran Fars HLADQ2/7/8 
Mashhad Fars HLADQ2/7/8 
Lorestan Lur HLADQ2/7/8 
Kurdistan Kurd HLADQ2/7/8 
Sistan Baluchestan Baloch HLADQ2/7/8 
 
HLA typing  
from previous 
studies 
Fars Fars HLA DQ7 
Kurdistan Kurd HLA DQ7 
East and West Azarbaijan 
& Ardebil 
Azari HLA DQ7 
Sistan Baluchestan Baloch HLA DQ2 
Kerman & Yazd Zoroastrian HLA DQ2 
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HLA typing 
DNA was extracted using the phenol 
chloroform method [19].  
The six HLA-tagging SNPs reported 
by Monsuur et al. [13] were genotyped 
using 5 ng of DNA of the Iranian cohort, 
and using TaqMan chemistry and custom 
assays from Applied Biosystems (ABI, 
Foster City, CA, USA, 
www.appliedbiosystems.com), including 
DQ2.2 (rs2395182 and rs7775228 SNPs 
for DQ2.2 and rs4713586 SNP to 
exclude DQ4 from the DQ2.2 group), 
DQ2.5 (rs2187668 SNP), DQ7 
(rs4639334 SNP), and DQ8 (rs7454108 
SNP). DNA was genotyped using a 
standard protocol provided by Applied 
Biosystems. The PCR assays and allelic 
discrimination were run using an ABI 
PRISM 7900HT Sequence Detection 
System (SDS) machine. All individuals 
were run on the same 384-well plate to 
avoid biased results due to technical 
issues. The data was analyzed using SDS 
program 2.3 (Applied Biosystems).  
Validation 
The HLA alleles for 20 CD cases and 
30 controls were also typed using a 
commercial kit (BAG, Germany). The 
BAG kit makes it is possible to identify 
individuals who are carriers of 
DQB1*02, DQB1*0301, DQA1*05, 
DQA1*0201 alleles for HLA-DQ2; 
DQB1*0302, DQA1*03 for HLA-DQ8; 
and DQB1*0301 for HLA-DQ7. We 
could thus distinguish DQ2.5-positive 
individuals from those who have DQ2.2. 
Analysis  
For the prediction of HLA alleles, we 
inferred the DQ types from the tag SNPs 
according to the method described by 
Monsuur et al. [13]. Only individuals 
with no missing data (59 cases) were 
entered in this study. The statistical 
analysis was performed using the Fisher 
exact test. A P value of less than 0.05 
was considered statistically significant. 
Results 
Validation of the tag SNPs 
Twenty random CD cases and 30 controls 
were first typed using both the BAG kit 
and the tag SNPs to test the validity of the 
tag SNP approach in the Iranian 
population. Nine cases and three controls 
showed discordant results between the two 
tests. Eight CD samples, which the tagSNP 
approach classed as non-DQ2/DQ8, were 
typed as DQ8 with the BAG kit. The 
results of the validation showed that the 
sensitivity to detect DQ2 and DQ7 was 
100% and 84.6% for DQ8, while the 
specificity was 97% for DQ2 and DQ7, 
and 86.4% for DQ8 (table 1). These results 
suggest that DQ2 and DQ7 can be inferred 
using the tag SNP method, but that the 
detection of DQ8 is less sensitive and less 
specific. Heterozygotes and homozygotes 
of these haplotypes cannot be determined 
by the BAG kit for all samples, especially 
when the parallel haplotypes are unknown 
(DQX).  
Testing the tag SNPs  
We then evaluated the 59 CD patients and 
151 controls for prediction of related HLA 
genotypes by TaqMan SNPs. We observed 
that 83.03% of cases and 42.4% of controls 
were carriers of an HLA-DQ2 heterodimer, 
either homozygously or heterozygously. 
The patterns of the specific HLA-DQ 
haplotypes in the CD patients were as 
follows: 23.7% of CD patients were 
heterozygous DQ2.2 including DQ2.2/DQ2.5 
compound heterozygosity, 1.7% of CD 
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patients were homozygous DQ2.2/DQ2.2, 
28.8% of CD patients were heterozygous 
DQ2.5 including, DQ2.5/DQ8 compound 
heterozygosity, and 27.1% of CD patients 
were homozygous DQ2.5/DQ2.5. 
 
Table 1. Validation results in the Iranian 
population using BAG kit compare to TagSNP 
 Celiac patients Controls 
 BAG 
Kit 
Tag 
SNP 
BAG 
Kit 
Tag 
SNP
No. of patients 20 59 30 151 
 DQ 2.2     
Sensitivity 100 100 100 100 
Specificity 100 100 100 100 
False results 0 0 0 0 
 DQ 2.5     
Sensitivity 100 100 100 100 
Specificity 97.8 97.8 96.7 96.7 
False results 1 1 1 1 
 DQ 8     
Sensitivity 100 86.4 100 100 
Specificity 100 86.4 93.3 97.1 
False results 0 8 2 1 
 
DQ8 heterozygosity was predicted in 13 
patients, of which seven were DQ8/DQ2.5 
carriers and two were homozygous 
DQ8/DQ8.  
The HLA-DQ pattern in the controls was 
as follows: heterozygous DQ2.2 in 28.5%, 
non-homozygous DQ2.2/DQ2.2, and 
heterozygous DQ2.5 in 16.5%, and 
homozygous DQ2.5/DQ2.5 in one. DQ8 
was positive in the heterozygous state in 30 
controls and in the homozygous state in 
four controls.  
Table 2 shows the frequency of HLA-
related CD genotypes in the healthy 
controls and the prevalence of the different 
HLA-related CD genotypes in our Iranian 
CD patients. DQ2.2 and DQ7 can only 
confer risk to CD when both are present 
together or with DQ2.5 [13]. Based on this 
description, DQ2.2 and DQ7 haplotypes 
were present together or with DQ2.5 in 
23.7% of CD patients and 11.9% of 
controls. A DQ2-DQ8-negative genotype 
was seen in 66 controls and two cases.   
DQ2.5/DQ2.2, DQ2.5/DQ2.5, DQ2.5/DQ8 
and DQ2.5/DQX were detected as 
significant in the cases (P < 0.05) and 
DQ7/DQ7 and DQ7/DQX were observed 
as significant in the controls (P < 0.05). 
Accordingly, we can conclude that CD 
patients carry more HLA risk alleles than 
controls (table 2). 
 
Table 2. The frequency of HLA genotypes in 
Iranian cases and controls* 
Genotypes Cases (%) Controls (%) P-value 
DQ2.2/DQ2.2 1(1.7) 0 0.28 
DQ2.2/DQ7 4(6.8) 8(6) 0.76 
DQ2.2/DQX 3(5.1) 22(14.6) 0.06 
DQ2.5/DQ2.2 7(11.9) 5(3.3) 0.04 
DQ2.5/DQ2.5 8(13.6) 1(0.6) <0.001 
DQ2.5/DQ7 3(5.08) 5(3.3) 0.69 
DQ2.5/DQ8 7(11.9) 5(3.3) 0.04 
DQ2.5/DQX 16(27.1) 10(6.6) <0.001 
DQ7/DQ7 0 17(11.2) 0.004 
DQ7/DQX 0 17(11.2) 0.004 
DQ8/DQ2.2 0 8(5.3) 0.11 
DQ8/DQ7 1(1.7) 9(6) 0.29 
DQ8/DQ8 2(3.4) 4(2.5) 0.67 
DQ8/DQX 5(8.5) 8(6) 0.54 
DQX/DQX 2(3.4) 32(21.2) 0.001 
Total 59(100) 151(100)  
* The frequency of DQ8/DQ2.2 in the cases was 0% 
and this number may be less reliable. This may be due 
to differences in the patterns of linkage disequilibrium 
blocks in Iranians or may result from low 
concentrations of DNA samples (the concentration of 
the samples was reduced when they were sent to 
UMCG for genetic analysis). We concluded that DQ2 
worked well, but DQ8 needs to be interpreted more 
carefully with the tagSNP. 
 
Risk groups 
Based on the outcome of the HLA-
DQ2/DQ8 prediction using tagging SNPs, 
we divided the Iranian population into 
three risk groups: low risk (these were 
DQ2/DQ8-negative) (13.5% of cases, 
43.7% of controls), intermediate risk (these 
were homozygous for DQ2.2 and DQ8, or 
heterozygous for DQ8, DQ2.5 or DQ2.2) 
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(57.6% of cases, 39.07% of controls), and 
high risk (these were homozygous DQ2.5 
or DQ2.5/DQ2.2) (25.4% of cases, 4% of 
controls) (Fig 2). The differences were 
statistically significant for all the risk 
groups when comparing cases to controls 
(P < 0.05). We also confirmed that CD 
patients carry more HLA risk alleles than 
healthy controls and this difference was 
statistically significant for the DQ2.5 
haplotype distribution between cases and 
controls (P = 0.0001). 
 
Ethnic heterogeneity 
Based on sampling from four diverse areas 
in Iran (North, West, East and Center) with 
different ethnicity and in keep with 
previous studies which were introduced 
only the DQ2 for Baloch ethnic (15) and 
DQ7 for Kurd ethnic (17) both in healthy 
subjects of Sistan Baluchestan and 
Kurdistan provinces respectively, the 
outcome of the HLA prediction using 
tagging SNPs showed that HLA-
DQ2/DQ8/DQ7 are presented in all studied 
areas in both cases and controls. Although 
the HLA-DQ2 is principal genotype in 
cases and HLA-DQ7 in controls in these 
areas, but there is no statistically difference 
for the HLA haplotypes distribution 
between cases and controls according to 
their ethnic (P>0.5). 
 
Marsh classification 
Fourteen patients with Marsh I histology 
and 12 with Marsh II were compared to 33 
patients with Marsh III (including 14 
Marsh IIIa, 7 Marsh IIIb and 13 Marsh 
IIIc) in relation to their HLA-DQ 
haplotypes. Table 3 shows the distribution 
of HLA haplotypes according to the 
Rostami-Marsh classification [18]. Of the 
25 patients demonstrating only minor small 
bowel mucosal changes (i.e. Marsh I and II 
histology), two (3.4%) were negative for 
DQ2 and DQ8. According to these 
findings, there were statistically significant 
correlations between the presence of 
 
Table 3. Distribution of HLA haplotypes according to the degrees of mucosal changes 
 Rostami-Marsh classification   
 Marsh I Marsh II Marsh III Total P-value 
HLA DQ2.2/DQ2.2 0 0 1 1 0.73 
  DQ2.2/DQ7 0 2 2 4 0.46 
  DQ2.2/DQX 1 0 2 3 0.2 
  DQ2.5/DQ2.2 1 3 3 7 0.06 
  DQ2.5/DQ2.5 1 2 5 8 0.46 
  DQ2.5/DQ7 2 0 1 3 0.2 
  DQ2.5/DQ8 1 1 5 7 0.78 
  DQ2.5/DQX 5 2 9 16 0.96 
  DQ8/DQ7 0 1 0 1 0.04 
  DQ8/DQ8 0 0 2 2 0.53 
  DQ8/DQX 0 2 3 5 0.13 
  DQX/DQX 1 0 1 2 0.64 
Total 12 13 34 59  
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DQ8/DQ7 haplotypes and a histology 
abnormality compatible with Marsh II (P = 
0.04). Our result thus confirmed that 
patients with Marsh I or II histology carry 
low HLA risk alleles, such as HLA DQ8. 
We saw no statistically significant 
correlations between the other haplotypes 
and different Marsh classifications. 
Discussion 
Several epidemiological studies 
indicate that CD is a common disorder in 
the Iranian population with a prevalence of 
1% [20-22], but there are no data on the 
frequency of HLA-related CD-
predisposing alleles. We examined the 
frequency of the HLA-DQA1 and HLA-
DQB1 haplotypes in Iranian CD patients 
and compared them to a matched, healthy 
control group. 
A simple PCR-based SNP approach has 
been developed for large-scale population 
screening (Monsuur et al. 2008 [13]) and 
this method can be applied to different 
Caucasian populations [12].  
A major advantage of this PCR-based 
SNP method is its ability to distinguish 
HLA-DQ2 and HLA-DQ8 homozygotes 
and heterozygotes which, in turn, translates 
into differences in the risk for CD. We 
tested the transferability of this method to 
the Iranian population and found that the 
sensitivity and specificity to detect the CD 
risk alleles was 100% and 97% for HLA-
DQ2 and HLA-DQ7, respectively, but 
slightly lower for HLA-DQ8 (86.4%).  
The lower sensitivity and specificity for 
HLA-DQ8 in the Iranian population might 
be attributable to differences in the patterns 
of linkage disequilibrium blocks in 
Iranians and Europeans. The frequency of 
the HLA haplotypes in Iran is not 
necessarily different from Europeans but 
the tagging SNP method might not be the 
ideal test to establish the frequency of CD-
associated HLA-DQ8 haplotypes in this 
population. 
As described for other populations [23-
25], the most frequent haplotype in Iranian 
CD patients was HLA-DQ2.5 (69.5%) and 
this frequency is very similar to that in 
European CD populations. 
Surprisingly, in contrast to the low 
population prevalence of HLA-DQ8 
reported in the literature (0.6% in 
Cameroon, 2% in Italy, 2.3% in Hungary, 
4.2% in USA, 6.4% in Finland and 7.6% in 
Japan) [12, 26], we found a rather high 
prevalence of this genotype in the Iranian 
CD population (25.4%). Our result is 
compatible with those presented by Catassi 
et al. in 2008 for Turkey (22%), North 
American Indians (25.3%), Mexico 
(28.3%) and Bushman (30%) [27].  
Karell et al. and Polvi et al. suggested 
that only a small number of CD patients 
(6%) carry neither DQ2 nor DQ8 [28, 29]. 
Our study supports these figures, as we 
only found two CD patients (3.4%) who 
were DQ2-DQ8-negative.  
Several studies have shown that 
individuals homozygous for HLA-DQ2.5 
or heterozygous for HLA-DQ2.5/DQ2.2 
genotypes have an increased risk for CD 
compared to those homozygous for HLA-
DQ2.2 or heterozygous for HLA-DQ2.5 or 
for HLA-DQ2.2 [30-32]. Similarly, our 
results show that 25.4% of cases lie within 
the high risk group for CD compared to 
44.9% in the low risk group. The 
frequencies of intermediate risk and high 
risk groups were, as expected, higher in 
cases than controls (Fig. 2).  
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Figure 2. Distribution of the HLA risk groups 
in cases and controls according to tagSNP 
prediction. Low risk for those negative for 
DQ2/DQ8; intermediate risk for those 
homozygous for HLA-DQ2.2 or DQ8, 
heterozygous for DQ2.5 or DQ2.2; high risk for 
those homozygous for DQ2.5and DQ2.5/DQ2.2 
 
In conclusion, despite a small study 
population as limitation of this study, the data 
presented in this study offer the first step 
towards defining the genetic structure of 
HLA in the Iranian population with celiac 
disease and provide information that can be 
used in family screening. In addition, our 
data suggest that the Iranian population, as a 
non-European Caucasian population, does 
share certain HLA class II genetic 
components with the populations of 
European countries. Iranians are more similar 
to Italian CD patients, given their increased 
frequency of HLA-DQ8 carriers. Further 
work, with larger sample sizes, on HLA 
polymorphisms among people living in 
different parts of Iran will provide more 
information about the genetic background of 
the Iranian population and its relationship to 
other populations in the world.  
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ABSTRACT 
 
Background: Celiac disease (CD) may present in a variety of different ways. The aim 
of this study was to explore the etiology of gastrointestinal and non-gastrointestinal 
disorders in a large cohort of symptomatic patients with CD from a multi-center study 
which conducted across Italy and Romania from Europe and Iran from Middle East.   
Methods: This is a multi-center study in which, data were collected in the period May 
2009-May 2011 from Iran, Romania and Italy. For each center, only those confirmed 
CD with endoscopic procedures and small bowel biopsies and positive serology were 
included.  
GI symptoms such as abdominal pain, diarrhoea, constipation, nausea and vomiting, 
weight loss and flatulence as well as additional signs and symptoms such as iron 
deficiency anaemia, osteoporosis, hypertransaminasemia, and other related 
abnormalities were collected.  
Contingency tables, chi-square statistic and Fisher’s Exact Test were employed to 
assess the association between the patient's country and the GI or Non-GI symptoms. 
T-test was used to comparison the numeric variable.  
Results: Overall, 323 women and 127 men mean age at diagnosis 34.2±16.47 years, 
included in this study. 157 patients (34.9%) reported at least one gastrointestinal 
symptoms of disease. The main presenting GI symptoms of the majority of cases were 
diarrhea (13.6%), dyspepsia and constipation (4.0%). 168 patients (37.3%) reported 
other symptoms or diseases. The most presenting non-GI symptoms of the majority of 
cases were anaemia (20.7) and osteopenia (6%). Statistically significant differences 
between most symptoms were observed when comparing the reported clinical 
symptoms in different countries.  
Conclusion: This multi-center study indicated that Upper abdominal disorders such as 
abdominal pain and dyspepsia were the most common primary complaints in European 
patients, while for Iranian patients, diarrhea and bloating were considered the classic 
presentations of CD. Between non-GI symptoms, anemia was highest for both Iranian 
and Italian patients, however in Iranian data, it was significantly higher. 
Keywords: Celiac disease, multi-center, Clinical presentation. 
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Introduction  
Celiac disease (CD) is the result of 
intestinal mucosal damage caused in 
susceptible subjects by the gluten content 
of some cereals. Celiac disease is often 
atypical or subclinical on clinical ground, 
so, many cases remain undiagnosed and 
become exposed to the increased risk of 
autoimmune disease (1). CD is a disease 
with the highest incidence (1in 100 to 1 in 
300) in European countries (2, 3), and 
prevalence of 1 in 166 in apparently 
healthy blood donors in Iranian population 
(4). The frequency of CD in Iraqi type 1 
diabetic patients was 11.2% (5). In another 
study from the Middle East, in Kuwait, CD 
accounted for 18.5% of cases of chronic 
diarrhea in children (6). CD may present in 
a variety of different ways: recurring 
abdominal pain and bloating, chronic 
diarrhea, constipation (in a few patients), 
excessive rectal gas, weight loss, mouth 
sores, fatigue, anemia (iron deficiency), 
osteopenia (osteomalacia, osteoporosis), 
swelling, fluid in the abdomen, behavior 
changes, mood disorders, growth 
retardation or with few or no apparent 
symptoms at all (7). This may have 
important health consequences, as dietary 
avoidance of gluten results in complete 
remission of the disease and avoids the two 
major complications, malignancy and 
osteoporosis (8) as well as resulting in a 
decreased mortality of patients with CD (9) 
and most of celiac patients are 
asymptomatic members of high-risk 
groups, such as patients with diabetes 
mellitus or thyroid disease and close 
relatives of patients with celiac disease 
(10). The recognition that there is a high 
prevalence of undiagnosed silent celiac 
disease in Western populations is already 
leading some experts to call for universal 
screening (11). 
The aim of this study was to explore 
the etiology of gastrointestinal and non-
gastrointestinal disorders in a large cohort 
of symptomatic patients with CD from a 
multi-center study which conducted across 
Italy and Romania from Europe and Iran 
from Middle East.  
Patients and Methods 
This is a part of a retrospective multi-
center study in which, data were collected 
in the period May 2009-May 2011 from 
Iran (100 patients from Research institute 
of Gastroenterology and Liver Diseases, 
Taleghani Hospital, Tehran), Romania 
(100 patients from Fundeni Clinical 
Institute, Clinical of Gastroenterology and 
Hepatology, Bucharest), and 5 different 
areas in Italy, including 50 patients from 
Brescia (Spedali Civili Brescia), 50 
patients from Bologna (St Orsola-Malpighi 
Hospital, University of Bologna), 50 
patients from Messina (Regional Celiac 
Center, University Hospital ‘‘G. Martino’’, 
Messina), 50 patients from Perugia 
(Gastroenterology and Hepatology Section, 
Department of Clinical and Experimental 
Medicine, University of Perugia) and 50 
patients from Milan. For each center, only 
those confirmed CD with endoscopic 
procedures and small bowel biopsies and 
positive serology were included.  
All centers used the cutoff of:  >25 
intraepithelial lymphocytes per 100 
enterocytes for (Marsh I), increased 
intraepithelial lymphocytes accompanied 
by crypt hyperplasia (Marsh II), partial 
(Marsh 3A), subtotal (Marsh 3B) and total 
villous atrophy (Marsh 3C) as described in 
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modified classification by Rostami et al 
(12). The final diagnosis of CD was 
considered when patients with abnormal 
mucosal findings were serologically 
positive for tTGA and/or EMA.  
During the same period, the number of 
biopsy sample taken from each center and 
their clinical data were compared. For each 
specimen, the following information was 
available: sex and age of the patient, 
location and sample provider, summary of 
the clinical history, serology/genetic and 
histopathological findings.  
GI symptoms such as abdominal pain, 
diarrhea, constipation, nausea and vomiting, 
weight loss and flatulence as well as additional 
signs and symptoms such as iron deficiency 
anemia, osteoporosis, hypertransaminasemia, 
and other related abnormalities were collected.  
Contingency tables, chi-square statistic 
and Fisher’s Exact Test were employed to 
assess the association between the patient's 
country and the GI or non-GI symptoms. T-
test was used to comparison the numeric 
variable. 
Results 
Overall, 323 women (71.8% of total 
patients) and 127 men mean age at 
diagnosis 34.2±16.47 years, median age 
(age range 1–87 years) with a diagnosis of 
CD were included in this multi-center 
study from Italy, Romania and Iran. 
Romanian patients were the oldest, with a 
mean age of 38.9± 12.3 yrs, and Iranian 
patients were the youngest (31±13.6 yrs). 
In all participating countries females were 
predominant (Table 1).  
Marsh I and II lesions were noted in 
26.4% of patients, Marsh 3A was found in 
21.8%, Marsh 3B was found in 19.3% and 
Marsh 3C in 32.4% of study subjects. 
There was a statistically difference for 
marsh classification across the countries 
(Table 1). 
29 patients (6.4%) reported the family 
history of CD, however, in Romanian data 
no reported about family history was 
registered. 157 patients (34.9%) reported at 
least one gastrointestinal symptoms of 
disease. The main presenting GI symptoms 
of the majority of cases were diarrhea 
(13.6%), dyspepsia and constipation 
(4.0%). Up to 62% of Iranian patients 
reported GI symptoms and the most 
frequent GI symptoms in Iranians were 
diarrhea (32%), bloating (11%), 
constipation (8%), etc. In Italian patients 
about 32% had any GI symptoms in which 
abdominal pain (32%) was predominant 
followed by dyspepsia (14%) and diarrhea 
(8.4%). In Romanian patients with 15% 
reporting GI symptoms, diarrhea was more 
than other symptoms (8%) and after that, 
abdominal pain (6%) and weight loss (5%) 
were predominant (Table 2). 
168 patients (37.3%) reported other 
symptoms or diseases. The most presenting 
non-GI symptoms of the majority of cases 
were anaemia (20.7) and osteopenia (6%). 
Iranian patients had reported up to 79% of 
any type of non-GI symptoms including 
anemia (55%), osteopenia (25%), 
Neurological symptoms (21%), menstrual 
abnormality (14%) etc. in Italian patients 
with 34.8% of non-GI symptoms the 
frequents ones were anemia (15.2%), 
osteopenia (4%) and thyroiditis (4%). In 
Romanian data the non-GI symptoms was 
only asthenia (2.0%) and other symptoms 
were not reported (Table 3). besides, 79 
patients (17.9%) have had the combination 
of at least one GI symptom and non-GI 
symptom (Table 3). Statistically significant 
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differences between most symptoms were 
observed when comparing the reported 
clinical symptoms in different countries 
(Table 2 & 3).  
In spite of the variability of symptoms 
among different countries which illustrated 
in this study, no statistical correlation was 
found between total GI or non-GI 
symptoms and their combination with 
demographic factors including sex and age 
group in this multi-center study. Also this 
correlation was not significant for 
histology type too (Table 4). 
 
Table4. Demographic factors: GI and Non-GI 
symptoms in Modified Marsh classification  
 GI Symp. P-
value
Non-
GI 
P-
value 
Total P-
value 
Age Group      
<15 26.3  
0.32 
38.6  
0.97 
10.5  
0.24 15-30 37.6 36.8 20.8 
>30 35.4 37.3 17.5 
Sex       
Male 36.2 0.74 33.9 0.39 16.5 0.78 
Female 35.4 38.7 18 
Marsh Classification     
I 31.7  
0.58 
34.9  
0.71 
15.9  
0.78 II 42.9 42.9 23.2 
IIIA 37.8 39.8 18.4 
IIIB 31 39.1 17.2 
IIIC 33.6 33.6 15.8 
Discussion 
Table1. Gastrointestinal symptoms in different countries 
GI Diseases or Symptoms Country (%) Total P-value 
 Iran Italy Romania   
Abdominal pain 3 (3.0) 8 (32.0) 6 (6.0) 17 (3.8) 0.41 
Diarrhea 32 (32.0) 21 (8.4) 8 (8.0) 61 (13.6) <0.001 
Constipation 8 (8.0) 9 (3.6) 1 (1.0) 18 (4.0) 0.04 
Weight loss 5 (5.0) 6 (2.4) 5 (5.0) 16 (3.6) 0.33 
IBS 0 (0.0) 5 (2.0) 0 (0.0) 5 (1.1) 0.13 
Malabsorption 0 (0.0) 4 (1.6) 2 (2.0) 6 (1.3) 0.4 
Bloating 11 (11.0) 1 (0.4) 0 (0.0) 12 (2.7) <0.001 
Dyspepsia 3 (3.0) 36 (14.0) 0 (0.0) 39 (8.7) <0.001 
Gastritis 7 (7.0) 6 (2.4) 0 (0.0) 13 (2.9) 0.01 
Any GI  Symptoms 62 (62.0) 80 (32.0) 15 (15.0) 157 (34.9) <0.001 
 
Table2. Non-Gastrointestinal symptoms in different countries 
Non-Gastrointestinal Signs or Symptoms Country (%) Total PValue 
 Iran Italy Romania   
Anemia 55(55.0) 38(15.2) 0 93(20.7) <0.001 
Dermatitis herpetiformis 3 (3.0) 4 (1.6) 0 7 (1.6) 0.23 
Osteoporosis 2 (2.0) 10 (4) 0 12 (2.7) 0.10 
Osteopenia 25(25.0) 2 (0.8) 0 27 (6.0) <0.001 
Hypertransaminasemia 4 (4.0) 7 (2.8) 0 11 (2.4) 0.16 
Thyroiditis 1 (1.0) 10 (4.0) 0 11 (2.4) 0.52 
Aphtosis 3 (3.0) 7 (2.8) 0 10 (2.2) 0.23 
Diabetes Mellitus 0 (0.0) 4 (1.6) 0 4 (0.9) 0.20 
Food allergy 1 (1.0) 1 (0.4) 0 2 (0.4) 0.56 
IgA deficiency 0 (0.0) 3 (1.2) 0 3 (0.7) 0.30 
Neurological symptoms 21(21.0) 2 (0.8) 0 23 (5.1) <0.001 
Menstrual abnormality 14(14.0) 0 (0.0) 0 14 (3.1) <0.001 
Asthenia 0 (0.0) 4 (1.6) 2(2) 6 (1.3) 0.40 
Failure to thrive 7 (7.0) 4 (1.6) 0 11 (2.4) 0.003 
Low B12/Acid folic 0 (0.0) 3 (1.2) 0 3 (0.7) 0.29 
Any non-GI Symptoms 70(79.0) 87(34.8) 2 (2) 168(37.3) <0.001 
Combination of GI and non-GI Symptoms 46(46.0) 32(12.8) 1 (1) 79(17.6) <0.001 
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In our study, females represented 72% 
of all patients, which is similar those 
observed in the United States, Europe and 
Middle-East with a female predominance 
(13-15).  The reason behind this female 
predominance is unknown, but could be 
explained by the fact that the prevalence of 
immune mediated diseases in general is 
higher in women than in men (16).  
In this study no difference was 
observed among male and female 
according to GI or non-GI symptoms, 
while some studies presented more GI 
symptoms for male and more non GI 
symptoms for female (16).  
This multi-center study indicated that 
Upper abdominal disorders such as 
abdominal pain and dyspepsia were the 
most common primary complaints in 
Italian or Rumanian patients similar to 
other European countries (17), while for 
Iranian patients diarrhea and bloating were 
considered the classic presentations. 
Studies indicated that CD is the most 
common cause of adult chronic non-bloody 
diarrhea in Tehran (18) and this is a 
common presentation for CD in the Middle 
East (6, 19). 
In non-GI symptoms, anemia was 
highest for both Iranian and Italian 
patients, however in Iranian data, it was 
significantly higher. Osteopenia was 
accounted for 25% in Iranian patients.  
We know that wheat and barley are the 
major diet for most of Middle Eastern 
population and there are very few 
alternative diets to gluten-containing crops 
(4). Therefore the severity CD maybe 
higher in these area, compared to western 
countries in the form of anemia or 
osteopenia (20).  
Some studies report a high number of 
neurological disorders in patients with CD 
(21, 22). In contrast to Italian and 
Romanian patients, neurological symptoms 
were the third highest non-GI presentation 
in Iranian database. The link between CD 
and neurological disorders might be 
attributed to the genetic background, most 
importantly the HLA region and other 
markers (22).  
 There are some limitations in this 
multi-center study; some information about 
symptoms for Romanian patients was not 
completed, we did not have access to 
socioeconomic or racial data and 
moreover, information regarding the type 
of sedation used during the procedure was 
absent.  
This multicenter study was performed 
in different populations where CD is 
very common and shows that the clinical 
picture of CD might be variable. In 
conclusion, we found that the lower GI 
symptoms and anemia were higher in 
Middle Eastern population and upper 
abdominal symptoms such as abdominal 
pain and dyspepsia were the most 
common primary complaints in European 
patients. There was a significant 
association with non-GI conditions like 
diabetes type I, abnormal liver enzymes 
and other autoimmune conditions in 
Italian patients. It is, therefore, likely 
that a significant number of patients 
undergoing endoscopy for GI and non-GI 
symptoms, such as diarrhea, dyspepsia 
and anemia might have celiac disease. 
This study suggest, a high index of 
suspicion for CD would be required to 
detect CD in patients with chronic 
diarrhea, osteopenia and anaemia in 
Iranian patients. Similarly dyspepsia, 
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anaemia and other upper GI symptoms 
were more likely to be consistent with 
CD in European countries and may 
warrant screening for CD. 
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ABSTRACT 
 
Aim: The aim of this study was to assess the prevalence of celiac disease (CD) in 
dyspeptic patients. 
Background: Although severe mucosal abnormality with villous atrophy (lesions Marsh 
III) is the gold standard for the diagnosis of CD, non-specific microenteropathy (Marsh I-
II) with positive serology is also common in patients with dyspepsia.  
Patients and methods: From November 2007 to October 2008, 407 randomly chosen 
patients who underwent diagnostic upper gastrointestinal endoscopy for dyspeptic 
symptoms (193 male, 214 women; mean age 36.1 years) were studied. Small bowel 
biopsies were performed in all of them. Histologic characteristics in duodenal biopsy 
specimens for CD were evaluated according to the modified Marsh classification. All 
the patients were also tested for serum total immunoglobulin A and anti-
transglutaminase (tTG) antibodies. Those with IgA deficiency were tested for IgG tTG. 
Results: Duodenal histology showed Marsh I-IIIc lesions in 6.4% cases. Four patients 
(0.98%) were IgA deficient and none of them were positive for IgG tTG. Serology 
showed positive results for tTGA in 8% of the patients and 2.5% of them had abnormal 
histology (Marsh I-IIIc) compatible with CD. 
Conclusion: The results of this study showed that milder enteropathy (Marsh 0-II) 
have a low specificity for CD. The prevalence of CD among dyspeptic individuals is 
significantly (2.5%) higher than in the general population (1%) and CD should be 
investigated in these patients. 
Keywords: Dyspepsia, Celiac disease, Antibody. 
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Introduction  
Coeliac disease (CD) and dyspepsia are 
common conditions, and consume 
considerable resources in both 
investigation and treatment. In the last 
years, a considerable change in 
epidemiology of CD has been observed. A 
marked increase in CD prevalence and 
incidence with milder enteropathy has been 
reported (1, 2), which can be at least 
partially explained by both the 
development of more sensitive serological 
tests and a high degree of disease suspicion 
(3, 4).  The variability of in particular 
clinical (5) and histological aspects of CD 
may face the clinician often with 
uncertainty as some of the features might 
not quite fit in the diagnostic models in the 
current guidelines.  
Malabsorptive symptoms, such as 
weight loss, diarrhea/steatorrhea and 
abdominal distension may not be 
necessarily observed in many celiac 
patients (6). Atypical forms of CD have 
increased considerably (7) and the 
presence of dyspepsia as a unique 
symptom has been frequently attributed to 
CD (8). In classical CD with prominent 
malabsorptive features, dyspepsia may be 
also one of the symptoms. It has been 
reported that the frequency of CD in 
people with dyspeptic complaints is 1.1-
3%, which is two to nine times higher than 
in the general population (6, 8-12). The 
frequency of CD in the Iranian general 
population is considered to be around 1% 
(9). 
In the present study we described the 
prevalence of celiac disease in dyspeptic 
patients.  
Patients and Methods 
Between November 2007 and October 
2008, 5732 patients aged 15 years or more 
attended the Gastroenterology section of 
the Taleghani hospital of Tehran, Iran. 
Four hundred and seven patients (193 men 
and 214 women) randomly chosen patients 
with dyspepsia were prospectively studied. 
The study was approved by the 
institutional ethics committees of 
Gastroenterology and Liver Diseases 
Research Center, Shahid Beheshti 
University of Medical Sciences, and all 
participants signed a written informed 
consent. 
Individuals were considered dyspeptic 
if they complained of persistent pain or 
uneasiness in the upper abdomen. Upper 
GI endoscopies were performed in these 
patients to diagnose common causes of 
dyspepsia including esophagitis, peptic 
ulcers, duodenitis and cancer. In addition, 
CD was identified by histological 
alterations characteristic of gluten sensitive 
enteropathy and by consistent CD 
serology. 
Gastric biopsies were obtained for 
H.pylori detection and biopsies from the 
second part of the duodenum for 
histological processing. 
Histological diagnosis of CD was 
based on the presence of intraepithelial 
lymphocytes, crypts hyperplasia and/or 
villous atrophy. Biopsy results were 
classified as absence of CD (Marsh 0) or 
suggestive of CD (Marsh II to IIIc), 
according to modified Marsh criteria (13, 
14). The histological specimens were 
examined by two pathologists who did 
not know the endoscopic results and 
clinical history of the patients. The sera 
of these patients were analyzed for IgA 
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class human antitissue transglutaminase 
(tTG) antibody and total serum IgA 
values according to standardized 
methods (15). Serological data were 
correlated to the endoscopic results and 
to the histological pattern observed in the 
small intestine. All patients with 
confirmed CD diagnosis were treated 
with a gluten free diet and followed.  
Statistical analysis was performed 
using SPSS software, version 13.5. 
Descriptive variables such as mean, 
median and standard deviation were 
determined. Chi-square (χ2) test was 
performed to find out the association 
between CD and risk factors. 
Results 
The mean age of the patients was 36.1 
years. The gastroenterology symptoms in 
the subjects were: 78% abdominal pain, 
70% bloating, 58% heart burn, 46% early 
satiety, 32% nausea, 32% flatulence, 31% 
weight loss and 22% anorexia. Recurrent 
abdominal pain, heart burn and bloating 
were present in 60%, 45% and 31% of the 
patients, respectively (figure 1). 
 
Figure 1.  Current endoscopy findings in study 
population  
 
Helicobacter pylori was detected in 
90.5% cases. There were 26 cases with 
enteropathy (12 Marsh I, 4 Marsh II, 2 
Marsh IIIa, 6 Marsh IIIb and 2 Marsh IIIc). 
Four of 407 dyspeptic patients were IgA 
deficient and all of them were negative for 
IgG tTG. Thirty three (8.1%) of the 407 
patients tested had tTGA level more than 15 
u/ml and considered as tTGA positive. 
Twenty three of 33 seropositive had normal 
small bowel mucosa. 
The demographic, histologic and 
serologic characteristics of 33 patients with 
serology positive and 26 with abnormal 
histology are shown in table 1. 
In 10 of 33 tTGA positive patients, CD 
was confirmed by histological analysis of 
the intestinal biopsy samples, giving a 
prevalence of CD of 2.45%. Five of these 
10 celiac patients were Marsh IIIa-c 
followed by 3 Marsh I and 2 Marsh II. The 
highest rate of histological abnormalities 
and of CD seropositivity was found in the 
age categories of 21-30 years and 10-20 
years respectively (table 2).  
 
Table 1. Clinical and laboratory features of 
seropositive patients 
Subjects  Abnormal 
histology patients 
Seropositive 
patients 
No. of cases 26 33 
Mean age 37.9 42.6 
Gender    
Male  11 15 
Female  13 20 
GI 
symptoms 
  
abdominal discomfort             
18 
25 
anorexia 6 8 
weight loss 11 9 
nausea 5 9 
heart burn 14 10 
early satiety 8 9 
flatulence 7 8 
bloating 12 15 
 H. pylori 21 26 
Coeliac 
disease 
10 10 
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Table 2. Cases with histology and serology 
consistent with celiac disease 
Marsh 
classification 
No. of 
patients
Gender Mean 
age Female Male
Marsh I 3 2 1 27.3 
Marsh II 2 1 1 39 
Marsh III (a-c) 5 4 1 26.8 
tTG +ve with 
normal histology 
23 12 11 48.3 
Discussion 
Dyspepsia is a highly prevalent and 
heterogeneous disorder (16). We know that 
damages in CD are not confined to the 
small intestine (17) and not every celiac 
patient develop severe mucosal small 
bowel abnormality. Several studies have 
demonstrated that chronic exposure to 
gluten may damage the structure and 
function of the gastric mucosa in CD 
patients (18, 19). Other surveys indicate 
that approximately 20% of patients with 
dyspeptic symptoms have erosive 
esophagitis, 20% are estimated to have 
endoscopy-negative reflux disease, 10% 
have peptic ulcer, 2% have Barrett 
esophagus and 1% or less have malignancy 
(20) and the results of the present study 
suggest that at least 2-3% CD in dyspeptic 
patients should be e added to the list. 
However, the proportion of celiac 
autoantibodies in dyspepsia seems to be 
even higher (serology>8%) and the 
question is whether these antibodies are 
representing a different form of gluten 
related disorders or belong to the spectrum 
of false positivity.  
The most important identifiable causes 
underlying dyspeptic symptoms in our 
study group were duodenitis (13%), 
gastritis (12%), esophagitis (9%) and 
peptic ulcer disease in 10% Malignancies 
of the upper gastrointestinal tract were not 
found. Approximately, 60% of patients 
with dyspepsia showed no abnormality in 
their mucosa but the majorities were 
positive for H. Pylori.  
It is important to note that serology at 
high level (when 10x >cut-off of 
normality) is a far more specific marker for 
atypical CD compared to microenteropathy 
(Marsh I-II) which seems to have a non-
specific nature (23). With other words the 
specificity of serology at high level for CD 
seems to be close to 99% in many studies 
(24). Similarly histology represents the 
gold standard for CD diagnosis only in 
cases with severe mucosal abnormality 
(Marsh IIIa-c). A better definition and 
differentiation of true value of milder 
positivity of both histology and serology 
would be useful in clarifying the 
expectation of each test (25, 26).  
We are aware that there is not a single 
perfect test available to diagnose CD in its 
own. Histological abnormalities ranging 
from mild to severe were found in the 
small bowel of 6.4% of our patients. 
Despite high specificity of autoantibodies, 
this finding would provoke the discussion 
on seronegative cases and question the 
sensitivity of serological tests. Although, 
microenteropathy could be a result of any 
other intestinal disorder, from previous 
experience we learned those negative 
serological tests were less reliable in 
symptomatic cases presenting with a 
milder enteropathy (21, 27, 28). 
Serology at weak positive level and 
milder histology (microenteropathy) are 
both nonspecifics for CD. A combination 
of clinical presentation, histology, serology 
and HLA typing would contribute in 
making a more accurate diagnosis. The 
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limitation of this study was lack of second 
serological test in particular using 
Endomysial antibodies after tTG and lack 
of HLA typing for exclusion of non-celiac 
cases. Coeliac disease with flat mucosa 
based on which the gold standard was 
introduced >50 years ago is still a rare 
condition. It is time to recognize that for a 
good proportion of CD cases histology is 
non-specific and hence the pathologist is 
unable to make the definite diagnosis in his 
own. Serology at high level and histology 
with severe abnormalities are both reliable 
markers for CD. Milder enteropathy and 
low positive antibodies require a better 
identification. Future studies would be 
needed to assess whether dyspeptic 
patients presenting with positive antibodies 
and normal histology would benefit from a 
GFD?  
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To the Editor  
Recently we studied celiac disease 
(CD) in patients with GI symptoms in 
Iranian community [١]. According to our 
findings and similar studies, related 
malabsorptive symptoms, such as 
diarrhea/steatorrhea and abdominal 
distension may not be observed in many 
cases necessarily [1, 2] but growth 
failure in terms of length (or height) or 
weight may be the earliest sign of the 
disease [٣].  
In this paper, we have studied body 
mass index in celiac patients diagnosed 
in a population-based study, using a 
well-matched case-control analysis in 
order to obtain updated information 
regarding the underweight in celiac 
patients [1, 4, and 5]. 
From total of 670 individuals with GI 
symptoms 25 individuals were positive 
for tTGA [1]. Total of 70 healthy people 
selected from the same database [5].  
These healthy people were selected 
from the population in which CD 
patients drawn up but without any signs 
of GI symptoms. They matched 
according to demographic factors (sex 
and age group) with CD patients in order 
to compare height, weight and body mass 
index. The study was approved by the 
Ethics Committee of RCGLD. 
 A positive tTGA test was found 
in 22 out of 670 investigated subjects (17 
women, 5 men), and positive tTGG test 
was found in 3 of 8 IgA deficient and 
matched with 70 healthy subjects (44 
women, 22 men) entered to this case 
control study.  
The mean±sd for body mass index in 
tTG positive patients and in healthy 
subjects were 23.7±2.38 and 26.8±4.3 
respectively (P<0.001). Twenty two 
patients were observed with BMI<25, 
three patients in overweight group (BMI: 
25-30) and no patient observed in obese 
group (BMI>30), in contrast of control 
group where 26 subjects were observed 
with BMI<25, 26 subjects in overweight 
group and 18 subjects in obese group 
(P<0.001).  Table 1 showed 
anthropometric measurements including 
weight, height and BMI according to sex 
group, indicating that all anthropometric 
measurements were significantly low in 
CD patients compared to health controls 
in both men and women.     
In contrast with Dickey and Kearney 
study [6] which state that few celiac 
patients are underweight at diagnosis 
time; our results indicated that a large 
group of CD patients in our community 
are underweight and there were 
differences in anthropometric 
measurements between CD patients and 
healthy controls, however other studies 
reported at least up to 33% of CD 
patients underweight [7, 8].  
Given the fact that all patients who 
entered in this study were diagnosed for 
the first time and most of them are in 
adulthood, it can be concluded that the 
low weight and height in adult CD 
patients in our community are associated 
with a lower total daily energy intake 
because of misdiagnosed of disease.  
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We did not consider dietary 
components and life stress. This is 
potential limitations of this study.  
On the other hand the high numbers 
of underweight individuals must draw 
the attention of physicians, during 
clinical practice, to consider celiac 
disease at the top of list of causes of low 
body weight and there is a real necessity 
for providing clinical practice and 
screening program for early diagnosis of 
celiac disease in the community and 
finally treatment with a gluten-free diet.  
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Table 1. The mean ±sd of Anthropometric measurements for 22 CD patients and 70 sex- and age-matched 
healthy control subjects 
Women Men  
P-
Value 
Control 
subjects 
Patients P-
Value 
Control subjects Patients  
0.03 68.5 ± 11.1 62.0 ± 8.2 <0.001 76.8 ± 13.3 55.0 ± 5.5 Weight (kg) 
0.02 158.4 ± 8.5 163.2±5.5 0.04 173.1 ± 17.9 162.0 ± 5.9 Height (cm) 
<0.001 27.4 ± 4.4 23.2 ± 2.4 <0.001 25.8 ± 4.1 20.9 ± 0.7 BMI (kg/cm2) 
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ABSTRACT 
 
Celiac disease (CD) is characterized by sensitivity to gluten, which is found in dietary 
wheat, barley, and rye. Many extra-intestinal manifestations have been described in 
association with CD. Liver disease and CD share widespread risk factors. Liver 
disorders such as autoimmune hepatitis, elevation of liver enzyme levels, primary 
biliary cirrhosis, nonspecific hepatitis, primary sclerosing cholangitis, and 
nonalcoholic fatty liver disease have been reported in patients with CD. In this review, 
we provide information regarding liver disorders that may be found in association with 
celiac disease and the effect of the treatment of CD on these disorders. 
Keywords: Celiac disease, Liver damage, Epidemiology. 
   
 Celiac disease, Epidemiology, Genetic and Clinical Behavior in Iran 
 
97 Part III Associated Disorders 
Introduction  
Celiac disease (CD) is defined as a 
condition that affects the morphology of 
the mucosa of the small intestines, and it is 
improved if the patient consumes a gluten-
free diet and relapses if gluten is 
reintroduced in the diet (1). 
The prevalence of CD is high in the 
general Iranian population (1 in 166) (2), 
and the disease is currently considered the 
result of a complex interplay between 
inherent and environmental factors. The 
typical or classical form of CD is due to 
the interaction between gliadin and 
antibodies to tissue transglutaminase 
(tTG), and it results in the flattening of the 
villi in the small intestinal mucosa (3).  
Although CD is known to affect the 
small intestine, it is a multisystem disorder 
and can involve other organs such as the 
skin, thyroid, pancreas, heart, liver, joints, 
muscles, bones, the reproductive system, 
the central and peripheral nervous systems 
(4-13). 
The occurrence of liver impairment in 
CD is well established and must be 
regarded as one of the various 
extraintestinal presentations of gluten-
sensitive enteropathy (14- 17). The 
association between CD and liver 
manifestations was first reported in 1977 
(14). In this study, 30 of 74 adults newly 
diagnosed with CD had elevated levels of 
serum aminotransferase enzymes, which 
normalized after adherence to gluten-free 
diet in most cases. In this study, signs of 
reactive hepatitis were noted in 5 of 13 
patients, and different types of histologic 
lesions were found in 7 patients.  
Since the 1990s, a close association 
between CD and autoimmune liver 
disease has been clearly indicated in 
relevant studies (18-21). 
Searches were performed in PubMed 
and SID (for Persian papers) for articles 
published in English- and Persian-
language journals from 1977 to November 
2010; the following keywords were used 
alone or in combination: 
“celiac disease,” “liver disorders,” “liver 
abnormality,” “liver injury,” “hepatitis,” 
“anti-tTG,” “anti-endomysial,” and 
“cholangitis.” The aim of this review is to 
discuss the major forms of liver 
abnormalities associated with CD and to 
evaluate the prognosis of these 
abnormalities. 
Liver Dysfunction related to Celiac 
Disease 
Patients with CD have damaged gut 
mucosa, which can lead to malabsorption 
and increased permeability. A wide 
variety of liver injuries may occur in CD 
(22), and the principal conditions are 
listed in Table 1. 
 
Table 1. Characterization of cryptogenic liver 
disorders related to CD 
cryptogenic liver 
disorders 
High liver enzymes due to 
gluten induced reactive 
hepatitis 
Autoimmune 
liver disease 
autoimmune hepatitis (AIH) 
autoimmune overlap 
syndrome 
primary sclerosing 
cholangitis (PSC) 
primary biliary cirrhosis 
(PBC) 
nonalcoholic fatty liver 
  
Conditions such as nonalcoholic fatty 
liver disease (NAFLD), nonalcoholic 
steatohepatitis (NASH), hepatitis C virus 
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(HCV)-related liver disease, and hepatitis 
B virus (HBV)-related liver disease are 
very common in the general Iranian 
population (23-25), and their incidence in 
patients with CD is likely a coincidence 
rather than a true correlation. Recently, 2 
different types of liver injury, namely 
cryptogenic liver disorder (mild or severe 
type) and autoimmune liver disorder, have 
been found to be strongly related to CD. 
Cryptogenic liver disorder can be 
distinguished from autoimmune liver 
disorder on the basis of its positive 
response to gluten-free diet (GFD).  
 
Cryptogenic liver disorder  
1- Mild liver damage (gluten induced 
hepatitis) 
The first report of gluten-induced 
hepatitis, published in The Journal of 
Pediatric Gastroenterology and Nutrition in 
1986, was the case of a young girl with 
persistent cryptogenic elevation of serum 
aminotransferase levels and mild 
inflammation of the portal tract (26). A 
diagnosis of CD, suggested in this case by 
a high titer of antireticulin antibody, was 
confirmed by duodenal biopsy. Bardella et 
al. performed a similar study and found 
that 13 (9%) of 140 screened patients 
tested positive for antigliadin antibody 
(AGA) and anti-endomysial antibody 
(EMA). The relative risk of CD in these 
patients (18.6%) was significantly greater 
than that in the general population. 
Antibodies associated with CD 
disappeared after 12 months of consuming 
a GFD, but liver enzyme levels normalized 
in only 1 patient (27). This form of CD was 
once called “gluten-induced hepatitis” (28) 
and is now suggested to be celiac hepatitis, 
which is characterized by mild periportal 
inflammation with Kupffer cell 
hyperplasia, mononuclear cell infiltration, 
absence of any clinical features suggesting 
chronic liver disease, absence of 
hypergammaglobulinemia, absence of 
serum autoantibodies, presence of mild 
lobular and portal tract inflammation, and 
absence of hepatomegaly, splenomegaly, 
or both; this form is reversible if a GFD is 
consumed. In the majority of patients with 
hypertransaminasemia at diagnosis, liver 
enzymes returned to normal levels within 6 
months of starting a strict GFD (29) and in 
almost all cases, returned to normal levels 
within 12 months of gluten withdrawal. 
Occasionally, hypertransaminasemia might 
be the only sign of CD, which is 
manifested without any gastrointestinal 
(GI) symptoms. The results of a study by 
Volta et al. showed that 9% of patients 
with increased levels of transaminase of 
unknown origin had asymptomatic CD 
(28). Furthermore, evaluation of 110 
patients with cryptogenic 
hypertransaminasemia showed that 10% of 
patients with elevated transaminase levels 
were also positive for silent CD (29). 
On the basis of the high prevalence of 
CD (9.3%) in patients with unexplained 
increases in serum transaminase levels, 
Bardella, et al. confirmed that cryptogenic 
hypertransaminasemia could be a possible 
extraintestinal sign of CD (30). Furthermore, 
investigators found that children with 
unknown causes of hypertransaminasemia 
had asymptomatic CD. By consuming a 
GFD, patients experienced rapid 
improvements in both hepatic and 
intestinal biochemical/histologic signs, 
thus confirming that the liver damage was 
gluten-dependent (31). In a few studies, it 
was reported that some patients on a GFD 
 Celiac disease, Epidemiology, Genetic and Clinical Behavior in Iran 
 
99 Part III Associated Disorders 
for 12 months newly experienced increases 
in their liver enzyme levels, and this 
increase was probably because of the high 
quantities of lipids contained in some 
gluten-free foods (31, 32). 
2- Severe liver damage 
Severe histological diseases, including 
chronic hepatitis, severe fibrosis, and 
cirrhosis have been reported in adults and 
children (14, 25, 31). CD was detected in 
some patients with severe liver damage of 
unknown origin, and surprisingly, clinical 
improvement in the liver condition was 
noted when the patients consumed a GFD 
(33-35). The prevalence of CD in patients 
with chronic liver disease is higher than in 
the general population. Lindgren et al. 
reported that in 327 patients with chronic 
liver disease, the prevalence of CD was 
1.5%, which is 15 times higher than that in 
the general population (36). 
In a Finnish study, CD was reported in 
4 adult patients (3 men and 1 woman) with 
severe liver disease, who were waiting for 
liver transplantation (33). Two of them had 
progressive hepatitis, congenital liver 
fibrosis, and massive hepatitis steatosis. 
Clinical symptoms, including ascites and 
jaundice, improved in all patients after 6 
months of consuming a GFD. Of 185 
Finnish patients who underwent 
transplantation, 8 (4.3%) were found to 
have CD; this rate is 4–10 times higher 
than that found in the general population 
(33). During the study for a transplant 
programin a 28-year-old woman with 
severe cryptogenic liver failure had a 
complete recovery of liver function after a 
few months of following a GFD (34). 
3- Autoimmune liver diseases  
3.1-Primary biliary cirrhosis 
The relationship between CD and 
primary biliary cirrhosis (PBC) is well 
documented, and it was first reported by 
Logan, et al. in 1978 (37). Consequently, 
PBC patients have been extensively 
screened for CD. The reported prevalence 
of CD in PBC varies between 0 and 11%, 
and about 6% of individuals with CD may 
be affected by PBC (20, 38, 39). In a 12-
year epidemiological study of a British 
population of 250,000, Kingham and 
Parker (38) accessed a large registry of 
patients with PBC and CD. They found 
that CD was identified in 4 of 67 (6%) 
patients with PBC and that 4 of 143 (3%) 
patients with CD were affected by PBC. In 
another study conducted in UK, in which 
4,732 CD patients were matched with 
23,620 controls, the prevalence of PBC 
was found to be 0.17% in patients with CD 
versus 0.05% in controls (39). This trend 
was confirmed by 2 large population-based 
studies from Danish and Swedish cohorts 
(40). In these studies, EMA antibody tests 
were positive in 11% of PBC patients. The 
titer of mitochondrial antibodies, which are 
markers of PBC, did not change after 
gluten removal. Various case reports on the 
association between CD and PBC have 
shown that a GFD induces a stable clinical 
and biochemical improvement because of 
the normalization of intestinal absorption, 
but it does not seem to adjust the course of 
the liver disorder (41-49). However, some 
studies have shown that there is no 
association between CD and PBC (50, 51), 
but these studies tended to have small 
numbers of studied patients. In addition, 
numerous investigations have reported the 
positive effect of a GFD in primary biliary 
cirrhosis, thereby suggesting that all 
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patients with PBC should be screened for 
CD (8, 13-20, 52-55). 
3.2-Primary sclerosing cholangitis 
No distinguishing autoantibody has 
been found in patients with primary 
sclerosing cholangitis (PSC). Using 
cholangiography as a diagnostic tool, the 
characteristics of the biliary lesion can be 
evaluated in biopsy tissue or the 
appearance of the intra- and extrahepatic 
biliary tree can be assessed (12). Several 
studies have found a positive correlation 
between PSC and CD; however, these 
studies involve small numbers of 
investigated patients, and also, surveillance 
bias has not been taken into account. This 
association was first suggested by Hay, et 
al. in 1988 (56), who described the cases of 
3 PSC patients (confirmed by 
cholangiopancreatography retrograde 
endoscopy and liver biopsy) with 
steatorrhea as a severe form of 
malabsorption. Diarrhea was ameliorated 
after the diagnosis of CD and consumption 
of a GFD, but the course of PSC did not 
improve. In a recent study by Volta, et al. 
positive anti-EMA antibody was found in 1 
of 61 patients with PSC, thus showing a 
prevalence of 1.6% for CD (20). The 
relationship between PSC and CD has not 
been extensively studied. In a study of 
13,818 patients with CD and 66,584 age- 
and sex-matched individuals from the 
general Swedish population, the prevalence 
of PSC in CD patients was 4.46%, a rate 
4–8 times higher than that of the general 
population (57). 
 In another survey, CD was found in 
3% patients with PSC (58). Subsequently, 
the association between PSC and CD has 
been reported in several case reports (59-
63). Liver enzyme levels in a 54-year-old 
man with CD, PSC, ulcerative colitis, and 
Hashimoto’s thyroiditis were noticeably 
improved and finally normalized after 14 
months of treatment with a GFD (64. A 
repeated liver biopsy showed marked 
improvement in liver histological 
characteristics. 
In addition, in 2 studies, GFDs were 
reported to cause a significant 
improvement in hepatic histological 
characteristics and cholestasis in 3 patients. 
The small number of studied cases does 
not allow the formation of a definite 
conclusion as to whether diet slows down 
the progression of this autoimmune liver 
disorder (57, 60). 
Further studies are needed to accurately 
determine the strength of the association 
between PSC and CD. 
3.3- Autoimmune hepatitis 
In the late 1970s, sporadic findings of 
CD in patients with autoimmune hepatitis 
(AIH) were reported for the first time (65-
67). To evaluate the incidence of CD in 
patients with AIH, Volta, et al. studied the 
sera of 157 patients with type 1 AIH and 
24 patients with type 2 AIH; CD was found 
in patients with both types of AIH and 
EMA antibody was identified in 8 AIH 
patients (4%). CD was diagnosed in 5/8 
patients who underwent a duodenal biopsy 
(19). However, the benefit of a GFD to the 
clinical course of AIH patients was not 
reported. This study was performed 
through cooperation between the Mayo 
Clinic (Rochester, USA) and the 
University of Bologna (Italy). 
In another study, the prevalence of CD 
in patients with AIH was 6.4% (21). In a 
multicenter study in Italy, AIH occurred in 
1.1% of 909 children with CD and no case 
was found in either healthy populations or 
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in patients with an alternate gastrointestinal 
ailment such as Crohn’s disease (68). 
Jacobsen, et al. studied 101 patients with 
CD (69) and detected chronic active 
hepatitis in 5 patients (2.3%) of 37 patients 
who underwent histologic evaluation. In 
addition, in a study by Novacek, et al. 3 
(1.6%) of 178 patients with CD 
investigated for the presence of abnormal 
liver enzyme levels had documented AIH 
(70). In a study done at King’s College, 
London, the prevalence of CD in 96 
children with AIH was 3.4%, which was 
significantly higher than expected (71). 
4.3- Autoimmune cholangitis  
An association between CD and 
autoimmune cholangitis (AIC) has been 
described (72). Intestinal biopsies of 
patients with CD and AIC usually show 
either mild atrophy or an increased number 
of intraepithelial lymphocytes. 
In a 60-year-old woman who was 
evaluated for chronic elevations of serum 
liver biochemical parameters and 
unexplained iron deficiency anemia, a 
diagnosis of CD was made; subsequently, 
treatment with a GFD led to resolution of 
these abnormalities (73). These studies 
suggest that CD should be considered in all 
patients diagnosed with AIC, as a GFD 
may avoid the need for 
immunosuppressive therapy. 
Other liver disorders in CD 
1-Viral Hepatitis 
Hepatitis B and C are prevalent in Iran 
(74-77). It is estimated that between 1.2% 
and 19.7% of the general population have 
hepatitis B surface antigen (HBs Ag) and 
0.12–0.89% have anti-hepatitis C virus 
antibodies, corresponding to 1.5–2.5 
million HBV cases and 0.5 million chronic 
carriers of HCV (75, 76). In a study 
recently published in Iran, 88 patients with 
chronic hepatitis B (CHB) were 
serologically tested for celiac 
autoantibodies, and 9 seropositive patients 
underwent duodenal biopsy (78). 
Compared with the general population, the 
prevalence of celiac autoantibodies in CHB 
(11.3%) is relatively high, and most 
autoantibody-positive patients were 
asymptomatic for CD. 
Fifty-five percent of children and 68% 
of adults do not respond to standard 
vaccination regimens for hepatitis B virus. 
This lack of response to hepatitis B vaccine 
may be related to the genetic background 
of celiac patients, which seems to be linked 
to human leukocyte antigen (HLA) DQ2 
(79, 80). Some authors have suggested that 
large follow-up studies with large sample 
sizes are necessary to clarify how HBV 
infection affects the development of CD 
and to identify principal prevention 
strategies (81- 83). There is no convincing 
evidence that patients with viral hepatitis 
are at increased risk of developing CD (84, 
85), but an association between HCV 
infection and CD in adults has been 
reported. Indeed, HCV is suggested to be 
the most common liver disease associated 
with CD. Two hundred and fifty-nine 
patients who were consecutively evaluated 
with chronic hepatitis C (CHC) and 221 
healthy volunteers underwent serologic 
screening for CD, and seropositive patients 
underwent duodenal biopsy (86). The 
results of this study showed that the 
prevalence of CD in patients with CHC 
was 1.2%, while only 0.4% of healthy 
volunteers had CD. In another study, the 
prevalence of antibodies to tTG in 462 
patients with CHC was higher than that in 
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1,350 healthy controls (87). A third study 
showed that the prevalence of CD in 534 
patients affected by CHC was 1.3% (88). 
A recent study of patients having both 
CD and HCV described a well-defined 
route of transmission in most of these 
subjects, raising the hypothesis that the 
link between these diseases may be biased 
by the route of transmission of hepatitis C 
infection (89). An association between 
HCV infection and CD has been 
hypothesized, but some studies show that 
there is no correlation between these 2 
disorders. Thus, a clear association of CD 
and HCV is lacking. In a cross-sectional 
study, 827 multiparous pregnant women 
were serologically screened for CD and 
HCV antibodies by enzyme-linked 
immunosorbent assay (ELISA). Twenty-
seven (3.26%) women had antibodies to 
tTG, but only 2 (0.24%) had antibodies to 
HCV and one of these also had antibodies 
to tTG. This result suggests that routine 
screening of HCV in CD patients is not 
efficient (90). Both interferon and ribavirin 
may enhance type 1 helper T cell immune 
responses via signal transducers and 
activators of the transcription-dependent 
pathway, which subsequently induces the 
expression of interferon (91-94). 
Cammarota, et al. reported 2 cases of CHC 
that displayed various features of CD 
during treatment with interferon. 
Symptoms and histological disorders 
improved after the interferon treatment was 
stopped and a GFD was consumed (92). 
Therefore, it is suitable to start treatment 
for HCV after CD diagnosis, and after a 
year of GFD, improvement of the intestinal 
disease can be achieved. Since HCV is a 
very common disorder and may be 
correlated to CD, the presence of 
undetected CD should be ruled out before 
starting treatment of interferon in 
combination with ribavirin. Furthermore, 
CD should be considered in patients with 
unexplained diarrhea during or after 
interferon/ribavirin therapy. 
2- NAFLD/NASH 
Some conditions such as NAFLD 
and/or NASH are very common (up to 
25%) in the general population (95), and its 
occurrence in patients with CD is likely to 
be a coincidence rather than a true 
correlation (96). Some studies declare a 
clear association between CD and fatty 
liver and suggest performing serological 
screening and continually evaluating 
biochemical abnormalities for CD in 
NAFLD patients (18, 96). Bardella, et al. 
investigated 59 patients with 
hypertransaminasemia and NAFLD, and 
38 (64%) were diagnosed with NASH by 
anti-EMA and anti-tTG antibodies. HLA-
DQ typing and endoscopy were performed 
in 2 anti-EMA positive patients (3.4%) and 
6 anti-tTG positive patients (10%). On the 
basis of histological findings, CD was 
confirmed only in 2 patients (3.4%) who 
were positive for both anti-EMA and anti-
tTG. After 6 months of a GFD, liver 
enzyme normalized in both cases (96). 
However, other studies do not recognize 
associations between CD and NAFLD 
(97). Nehra, et al. attempted to determine 
whether any relationship exists between 
NASH and CD by investigating the 
serology of 47 NASH patients, in whom 
NASH was confirmed by liver biopsy. 
Only one patient was EMA-positive, 
thus indicating that there is no association 
between positive CD serology and NASH 
(97). In contrast, Valera, et al. found 
positive CD markers in 3 of 38 NAFLD 
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patients (7.9%), and histological evaluation 
showed Marsh I in 1 patient. The result of 
this study has indicated a high prevalence 
of positive tTG in patients with NAFLD 
(98). In an Italian study, the prevalence of 
silent CD in 59 consecutive patients with 
NAFLD was 3.4% (99), which suggested 
that screening with EMA is preferred to 
tTG antibodies since tTG positivity, in the 
absence of confirmatory anti-EMA 
antibodies, is not sufficient to perform 
diagnostic endoscopy.  
3- CD and Haemochromatosis 
CD and hemochromatosis are genetic 
disorders, but CD is paradoxically 
associated with iron deficiency anemia. 
Most published papers regarding these 
disorders together are case reports (100). 
Singhal et al. reported the cases of 2 
patients who developed both CD and 
hereditary hemochromatosis (101). In the 
first case, CD was diagnosed first and 8 
years later, a routine blood screen showed 
elevated mean corpuscular and alanine 
transaminase (ALT) levels. Additional 
examinations showed transferrin saturation 
and increased levels of ferritin and iron. 
Genetic analysis showed homozygosity for 
the C282Y gene mutation, which 
confirmed hemochromatosis. Liver biopsy 
showed an index consistent with 
hemochromatosis. The patient responded 
satisfactorily to venesections, with the 
serum ferritin levels presently maintained 
around 50 mg/L. The second case was that 
of a 54-year-old woman referred with 
abnormal ALT levels, but the rest of the 
liver profile and other biochemical tests 
were satisfactory. Screening tests for 
hepatitis B and C and the autoimmune 
profile were negative, but her serum 
ferritin level was noticeably raised. 
Heterozygosity for the H63D and C282Y 
mutations was shown in a genetic study. 
The patient rapidly responded to 
venesection, but the level of ALT remained 
high. Because of increasing upper 
abdominal discomfort, she underwent 
endoscopy, and histological evaluation 
confirmed CD. After 3 months of treatment 
with GFD, her liver disorders resolved 
completely and her ALT levels normalized 
(101).  
Butterworth et al. investigated 145 CD 
patients and 187 matched controls for the 
presence of HFE gene mutations. The 
number of mutated C282Y and/or H63D 
genes were significantly higher in patients 
with CD (48.3%) compared to controls 
(32.6%). Nevertheless, none of the patients 
with CD showed a clinical presentation of 
hemochromatosis. The results of this study 
showed that HFE gene mutations are more 
frequent in the CD population and may 
provide a survival benefit by ameliorating 
the iron deficiency seen in these patients 
(102). The present studies show that there 
is a rare association between CD and 
hemochromatosis, and therefore, more 
studies in this field are necessary to 
substantiate this observation. 
Pathogenesis of liver dysfunction in CD  
The mechanism(s) of liver injury in CD 
is still undefined. Intestinal permeability is 
increased in CD; this may enable the entry 
of toxins, antigens, and inflammatory 
materials to the portal circulation, and 
these mediators may have a role in the liver 
involvement seen in patients with CD (14, 
28, 29, 56, 99). Although liver dysfunction 
occurs not only in patients with CD but 
also in those with irritable bowel disease 
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(IBD), cow milk enteropathy, and food 
allergies, patients with tropical sprue and 
increased intestinal permeability do not 
present with liver enzyme abnormalities as 
frequently as CD patients (56) (Figure 1). 
Most patients with liver injury associated 
with CD have no symptoms or signs of 
liver disorder at the time of diagnosis, 
although nonspecific symptoms such as 
malaise and fatigue are common (14, 27, 
28). The sensitivity and specificity of each 
sign is variable, but a combination of signs 
may otherwise raise the suspicion of CD. 
However, mild to moderate elevations in 
serum levels of aspartate aminotransferase 
(AST) and/or ALT are the most common 
and often the only laboratory 
manifestations of liver injury in patients 
with CD. In a study of 98 confirmed CD 
patients with varied LFT, there was an 
increase in only ALT levels in 8 patients 
and AST levels in 5 of these 8 patients 
(unpublished data). After adherence to a 
GFD for 6 months, elevations in serum 
aminotransferase levels were normalized, 
thus explaining the correlation between 
liver injury and intestinal damage. 
Moreover, in view of the response to 
GFDs in hypertransaminasemia patients 
and abnormal ALP of suspected hepatic 
origin in CD patients, a liver biopsy may 
be useful. However, liver biopsy 
performance is dependent to some extent 
on factors such as patient age, associated 
co-morbid conditions, and the clinical 
significance of the liver test abnormality. 
Before interaction between environmental 
and genetic factors lead to irretrievable 
liver injury, early recognition of CD would 
allow complete recovery from hepatic 
lesions. 
 The following mechanisms have been 
suggested to have roles in establishing liver 
injury in CD: malabsorption and long-
standing malnutrition, increased intestinal 
permeability, small intestine bacterial 
overgrowth, chronic intestinal 
inflammation, and a common genetic 
predisposition. 
Furthermore, patients with CD who are 
exposed to gluten during a gluten challenge 
are at higher risk to develop autoimmune 
disease than those without further exposure 
(1, 103).  
 
 
Figure 1. Possible pathogenesis mechanisms of 
liver abnormality in CD 
 
Genetic Correlation   
Genetic predisposition has an important 
role in the development of cryptogenic 
liver disorders in response to autoimmune 
hepatic injuries, and this might also 
contribute to the association between CD 
and liver disease (57). Different studies 
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reflect the importance of genetic factors in 
the pathogenesis of CD, which is 
associated with HLA class II molecules 
encoded by genes of the HLA complex on 
chromosome 6 (104). In this region, a large 
group of autoimmune diseases are linked to 
specific alleles or combinations of 
haplotypes (105). The main genetic marker 
of CD is the HLA-DQ2 (α1*0501, 
α1*0201) heterodimer, which is present in 
approximately 95% patients with CD, and 
the remaining patients have HLADQ8 
(α1*0301, β1*0302) (106). HLA-DQ2 is 
in strong linkage with HLA-DR3, which 
is also the major HLA risk factor for 
AIH (107). In addition, AIH is associated 
with HLA-DR4 and HLA-DR52 (108, 
109). The same HLA class II molecule 
has an important role in the pathogenesis 
of PSC and CD. A shared immune-genetic 
predisposition to autoimmunity may 
account for the association between these 
diseases (33, 110, 111). In a multicenter 
study in Europe, it was found that the 
frequencies of the HLA-DR3, HLA-
DR13, HLA-DQ2, HLA-DQ8, and HLA-
DQB1*0603 haplotypes were higher in 
patients with PSC compared with 
matched controls (112). In Finnish adults 
who had undergone liver transplantation, 
the frequency of HLA-DQ2 and HLA-
DQ8 in patients with PSC, autoimmune 
hepatitis, or acute liver failure was 56–
75% compared with 39% in controls 
(33). Therefore, we suggest that there is 
a closer association between CD and 
AIH/PSC than between CD and other 
liver disorders. 
 
Figure 2. Approach to the diagnosis of liver abnormalities in celiac disease 
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Conclusions  
Liver abnormality may be one of the 
associated extra-intestinal manifestations 
of CD. However, because of the high 
frequency of CD in the general population, 
an accidental association between CD and 
the liver cannot be excluded. The liver 
damage in CD ranges from mild hepatic 
abnormalities to severe liver disease and 
may be seen in 15–55% of patients. The 
mechanisms underlying liver abnormalities 
in CD are not defined clearly. However, 
consumption of a GFD is an effective 
treatment for most patients with CD and 
liver disorders. After excluding other 
causes of liver disease and because of the 
high prevalence of liver disorders in CD, 
the levels of liver enzymes should be 
evaluated in all patients at the time of CD 
diagnosis (Figure 2). 
In cases of cryptogenic 
hypertransaminasemia, transaminase levels 
will be normalized, and it is recommended 
to re-check the liver enzyme levels after 6–
12 months of a strict GFD. Fatty liver also 
may be associated with CD, although it is 
unclear whether this is a cause, an effect, 
or a serendipitous association. The 
important point is that 10–20% of this 
group may show hypertransaminasemia 
again after 2 or more years of GFD 
because of metabolic changes in the liver 
owing to the high amount of lipids found in 
commercially available gluten free foods. 
For this reason, monitoring of transaminase 
levels once a year is recommended, 
especially in patients gaining weight. Since 
the association of CD with liver 
autoimmunity has been largely validated, 
the first step is requesting a serology test 
for CD in all cases of autoimmune liver 
disorders such as AIH, PBC, and PSC. 
Indeed, CD can be present in 3–7% of 
these patients. 
EMA is more specific but slightly less 
sensitive than anti-tTG (113), and as is 
well known, false-positive results for anti-
tTG are found in patients with liver and 
autoimmune disorders (114). Therefore, 
determination of the levels of EMA is 
preferred to that of anti-tTG in patients 
with cryptogenic and autoimmune liver 
disease. An exception is in children with 
inflammatory liver disease of unknown 
cause, where investigation for CD should 
be started by determining the anti-tTG 
levels. In conclusion, serological 
evaluations for CD should be part of the 
general workup of patients with 
unexplained elevated liver enzyme levels 
when other causes of liver disease have 
been ruled out, and at the time of CD 
diagnosis, liver dysfunction should be 
concurrently evaluated.  
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To the Editor  
It is well established that both celiac 
disease (CD) and Toxoplasma gondii (TG) 
infection induce a strong neutrophil- 
mediated immune response that can affect 
pregnancy outcome. Most cases of 
toxoplasmosis in immune-competent 
individuals are asymptomatic, but TG can 
cause a chronic infection and abortion in 
adults and a fatal illness in immune-
deficient patients (1). On the other side, 
interleukin-8 (IL8) selectively stimulates 
the ability of neutrophil and T lymphocytes 
injured or inflamed tissue (2). 
To establish possible association 
between CD and TG, 827 pregnant women 
were recruited from the Reproduction 
Section. 
Samples were taken at mean pregnancy 
duration of 5.5 months. Enzyme-linked 
immunosorbent assay was used to 
determine Toxoplasma -specific 
immunoglobulin (Ig) G and IgM (Trinity-
Biotech Toxo IgG & IgM, NY) and the 
level of IL8 (Human IL8/ NAP-1 enzyme-
linked immunosorbent assay, Bender 
MedSystems, Vienna, Austria) according 
to the manufacturer ’ s instructions as well 
as IgA anti-tissue transglutaminase 
antibodies for CD as described previously 
(3). 
After childbirth, those anti-tissue 
transglutaminase- positive patients who 
were satisfied for follow-up submitted to 
biopsy specimens, and their biopsies were 
evaluated according to Marsh-Rostami 
classification (4). The results of this study 
show that 27 subjects (3.3 % confidence 
interval: 1.2 – 4.3) with a mean age of 27 
years and mean pregnancy duration of 4.8 
months were anti-tissue transglutaminase 
positive. Eight of the 27 CD-serology 
positive subjects underwent endoscopy and 
6 of them had abnormal histology, 
including two Marsh I, three Marsh IIIa, 
and one Marsh IIIc. 
One hundred and fifty four (31 %) and 
58 (7 %) pregnant women had positive 
total IgG and IgM for TG serology, 
respectively. Interestingly, 16 out of 27 (59 
%) CD-serology positive subjects were 
infected by T. gondii compared with 57 out 
of 800 (32 %) non- CD pregnant women 
(odd ratio = 3.07, 95% confidence interval: 
1.4 – 6.7), showing a significant 
relationship between CD-serology positive 
and TG incidence (P = 0.04). 
Three patients with Marsh I, IIIa, and 
IIIc were also positive IgG for TG. On the 
other side, the level of IL8 was high in TG 
infected patients, especially in those IgM 
positive, irrespective of the CD status. In 
this study, CD-serology positive or TG 
serology was associated with poor 
pregnancy outcome.  
As 9 out of the 27 (33.4 %) subjects 
with CD-serology positive had unfavorable 
medical history and more than half of them 
had history of miscarriage (4/9) and low 
birth weight (3/9), we can say that CD-
serology positive was correlated with 
increased risk of low birth weight and 
miscarriages irrespective of T. gondii 
infection.  
So according to the results, we suggest 
that both conditions predispose 
unfavorable pregnancy outcomes. 
The results of this study show that the 
TG infection rate was also higher among 
subjects with CD-serology positive than 
among patients with negative CD serology, 
but CD did not cause increasing of 
proinflammatory cytokines, such as IL8. 
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This suggests that CD may predispose 
the risk of TG infection. We postulate that 
CD predisposes to TG infection and may 
facilitate distribution of the ingested TG 
oocysts beyond small bowel lesions 
(Figure 1) and somehow could increase 
sensitivity to gluten. On the other hand, TG 
may precipitate the development of CD in 
susceptible individuals in keeping with 
studies that suggest that other enteric 
infections can predispose to the 
development of CD among susceptible 
individuals (5). 
In conclusion, our results suggest that 
CD increases the risk of T. gondii infection 
during pregnancy and it is possible that the 
observed association in Iran may be 
dependent on geography, genetics, or other 
environmental factors.  
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ABSTRACT 
 
Background: we assessed the prevalence, the related symptoms, and the endoscopic 
and histologic gastric features of celiac disease (CD) in patients with Helicobacter 
pylori (Hp).  
Methods: 450 dyspeptic patients were studied. Biopsies of gastric antrum and 
duodenum, CD serology, and total IgA were obtained. Histological findings were 
scored with the Marsh-Rostami criteria. 
Results: 411 (91.3%) patients were Hp positive. Duodenal histology was normal in 
385 (85.6%) patients, 124 (27.5%) had duodenitis and 28 (6.2%) showed duodenal 
abnormalities (Marsh I-IIIc). Twenty three/28 (82.1%) patients with malabsorption 
pattern were also Hp positive. Serological analysis: 12 of 31 (38.7%) positive patients 
had abnormal histology (Marsh I,-IIIc). Nine out 450 patients were IgA deficient; none 
of them was serologically positive for CD. 
Conclusion: although a high prevalence of Hp infection was found in this study, the 
relationship between Hp infection and CD was similar to that reported in other 
geographic areas. 
Keywords: Celiac disease, H. pylori. 
   
 Celiac disease, Epidemiology, Genetic and Clinical Behavior in Iran 
 
119 Part III Associated Disorders 
Introduction  
(CD) is frequently associated with 
abnormalities in gastric function and 
histology (1-8). Helicobacter pylori (Hp) is 
the causative agent in more than 90% of 
cases of chronic gastritis, peptic ulcer 
disease, primary gastric mucosa-associated 
lymphoid tissue (MALT) lymphoma, and 
gastric cancer (9). Ahigh prevalence of this 
infection would be also expected in 
patients with celiac disease (1-8). Atrophic 
gastritis with an increased prevalence of 
parietal cell antibodies seems to be 
common in some studies (1), but others 
have found little evidence to support this in 
CD (10). 
Although the pathogenesis of CD is 
relatively well understood, the possibility 
that a chronic gastric infection capable of 
inducing duodenal ulcers could influence 
the inflammatory and immune responses in 
the small intestine and, therefore, the 
development and evolution of CD, should 
be considered (11,12). 
Hp is now recognized as a major 
etiological factor in most patients with 
non-autoimmune chronic gastritis (2). In 
developing countries, Hp infects the 
majority of the population; for instance, the 
Iranian population displays a rate of 
infection of more than 90% (13). 
Even though epidemiological studies 
have failed to reveal a connection between 
gastritis and CD (11,12), some studies 
showed that patients with Hp gastritis are 
more likely to have increased numbers of 
intraepithelial lymphocytes in the duodenal 
mucosa, and that this can be reversed by 
the eradication of H. pylori (14,15). Other 
works have focused on Hp-related 
lymphocytic gastritis in CD (16-19) and on 
the link between anemia and Hp infection 
in celiac patients (20, 21). 
Purposes of the present study were to 
assess the prevalence of celiac disease, its 
related symptoms, and endoscopic features, 
and to compare the histopathological and 
clinical features in patients with associated 
Hp infection.  
Patients and Methods 
In the period January 2007-December 
2008, four hundred and fifty patients (211 
men, 239 women, mean age 36 years, 
range 15-83 years) who underwent upper 
endoscopy for dyspeptic symptoms were 
recruited in the out-patient clinic of 
Taleghani hospital. After obtaining a 
written informed consent from all subjects 
upper endoscopy with gastric and duodenal 
biopsies was carried out. Two biopsy 
specimens were obtained from the gastric 
antral mucosa and two to four samples 
from different portions of the duodenum. 
Biopsies were fixed overnight in buffered 
formalin, embedded in paraffin, cut to 3-
μm thickness, and stained with 
hematoxylin-eosin for routine histological 
evaluation. Giemsa staining was also used 
for gastric specimens, to identify Hp. The 
slides were blindly evaluated by two expert 
gastrointestinal pathologists. 
In accordance with the Updated Sydney 
System (22), the degree of gastric mucosal 
inflammation, polymorphonuclear cell 
infiltration, glandular atrophy, and 
intestinal metaplasia was classified into 
four grades as follows: 0 = none, 1 = mild, 
2 = moderate and 3 = severe. 
Hp infection was considered positive if 
present at least in one of the biopsies 
examined. The diagnosis of CD was based 
on the characteristic histological finding of 
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increased intra-epithelial lymphocytes, 
villous atrophy, and crypt hyperplasia, 
classified according to the standard 
classification proposed by Marsh (23,24) 
and subsequently modified by Rostami et 
al. (25) (Table I). 
Before endoscopy, a blood sample was 
drawn for serum anti-tissue 
transglutaminase (tTGA) and stored at - 70 
°C until tested. Patients who had normal 
biopsies, but tested positive for tTGA in 
their serum, were asked to undergo retest 
and an intestinal biopsy 12 months later. 
IgA-tTGA levels were measured by a 
commercially available ELISA method 
(AESKULISA tTGA, Germany). Serum 
values of tTGA higher than 15 U⁄mL were 
considered positive. Total serum IgA 
values were measured by an 
immunoturbidometric assay (Pars Azmoon, 
Iran), and serum levels below 70 U/mL 
were considered indicative of IgA 
deficiency. Immunoglobulin G (IgG) tTG 
values were further obtained in individuals 
with IgA deficiency by an ELISA method 
(AESKULISA tTGG, Germany). 
Results 
Out of 450 patients 411 (91.3%) were 
Hp positive; associated symptoms/diseases 
were diabetes 26 (5.8%), anorexia 99 
(22%), weight loss 143 (31.5%), nausea 
and vomiting 145 (32.2%), heartburn 261 
(58%), bloating 320 (71.1%), flatulence 
140 (31.1%), a concomitant stressful 
condition 117 (26%), and abdominal 
discomfort 351 (78%). Nine out of 450 
recruited patients were IgA deficient and 
none of them were positive for IgG tTG. 
Duodenal histology was normal in 385 
(85.6%) patients, 124 (27.5%) had 
duodenitis, and 28 (6.2%) showed mucosal 
abnormalities compatible with CD (Marsh 
I-IIIc) (Table II). 
Twenty three out of 28 patients (82%) 
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with positive histology for CD had gastric 
biopsies positive for Hp (Fig. 1). The 
prevalence of Hp in patients without CD 
(86.2%) was slightly but not significantly 
higher. Hp infection was more prevalent in 
patients younger than 40; as expected, 
most (91.4%) Hp-positive patients had 
moderate to severe chronic gastritis, 
whereas only 12 out of 39 (30.7%) Hp-
negative patients had moderate or severe 
chronic gastritis. 
Serological analysis showed that 12 out 
of 31 (38.7%) tTGA-positive patients had 
abnormal histology (four Marsh I, two 
Marsh II (Fig. 2) one  
Marsh IIIa, three Marsh IIIb (Fig. 3) 
and two Marsh IIIc (Fig. 4). In this group, 
one had mild chronic gastritis, three 
moderate chronic gastritis, two moderate 
active chronic gastritis, three severe 
chronic gastritis, and the last three had 
severe active chronic gastritis.  
 
Figure 1. Active gastritis with positivity for Hp 
(arrows). H&E x 10 
 
Figure 2. Marsh Type 1 lesion. A. H&E x 20. 
B. Immunohistochemistry for CD3 x 20 
Discussion 
In this study we found that, in this 
geographic area of the Middle East, the 
prevalence of Hp infection in dyspeptic 
patients was higher than 90%. Patients with 
a malabsorption pattern had 42.8% positive 
serologies for CD, with sensitivity values 
ranging from 33.4% in Marsh IIIa patients 
to 100% in Marsh IIIc, which is in 
agreement with previously published results 
(26-28).  
According to literature results, in our 
seriealso only 33.4% of Marsh I patients 
showed positive serology. The Marsh 
degree in 5 patients who were Hp-negative 
included one Marsh I, one Marsh II, two 
Marsh IIIa and one Marsh IIIc.  
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Moderate chronic gastritis was more 
prevalent in Hp-infected patients. 
Out of 31 serology positive patients, 19 
patients had normal histology. In contrast, in 
the 28 patients with a malabsorption pattern, 
16 had negative serology. Therefore, only 
12 patients had both abnormal histology and 
positive serology related to CD. 
Hp has been positively identified as the 
main cause of active chronic gastritis and its 
major complications (peptic ulcer disease, 
gastric adenocarcinoma, and primary gastric 
MALT lymphoma), with numerous studies 
carried out to explore the possible 
etiological role of this bacterium in a variety 
of both gastrointestinal and extra-intestinal 
conditions (28, 29). Investigations on the 
relationship between Hp infection and CD 
have yielded conflicting results (11, 12), 
probably because of the different prevalence 
of Hp in the populations studied. 
As shown in table II, in our series 23/28 
patients with a malabsorption pattern 
(Marsh I-IIIc) were also Hp-positive. 
Histological findings in these patients 
included six mild chronic gastritis, eight 
moderate chronic gastritis, three moderate 
active chronic gastritis, two severe chronic 
gastritis, and four severe active chronic 
gastritis cases.  
The four patients with Marsh I (two 
patients), Marsh II and IIIb who were 
positive for Hp and tTG-A had mild 
chronic gastritis, moderate active chronic 
gastritis, and severe active chronic 
gastritis, respectively. Two patients with 
Figure 3. Marsh type 3A-3B. A. H&E x 20. B. Immunohistochemistry for CD3 x 20 
Figure 4. Marsh type 3C. A. H&E x 20. B. Immunohistochemistry for CD3 x 20 
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Marsh II had moderate chronic and 
moderate active chronic gastritis. For 
Marsh IIIa, one patient had severe chronic 
gastritis. Three patients with Marsh IIIb 
had moderate chronic gastritis, severe 
chronic gastritis and severe active chronic 
gastritis. Two patients with Marsh IIIc 
had severe active chronic gastritis. These 
results showed that 9 out of 12 with 
serology positive for CD were infected 
with Hp. On the other hand 24/31 tTG 
positive were also positive for Hp. 
It should be noted that, concerning Hp 
positivity, the percentage of Hp-positive 
celiac patients is lower than that of non-
celiac patients and, as recently shown 
(29), the clinical features of CD patients 
are unrelated to the simultaneous presence 
of Hp gastritis, and there is no relation 
between gastritis and severity of mucosal 
damage in CD. 
In conclusion, the prevalence of Hp 
infection in Iranian patients complaining 
of dyspeptic symptoms is high, and the 
relationships between Hp and CD are 
similar to those described in other 
geographic areas. 
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ABSTRACT 
 
Background: The association between celiac disease and infertility is controversial in 
the literature. The aim of this study was to determine the prevalence of celiac disease 
among the couples with unexplained Infertility. 
Methods: Serum samples from 100 Iranian couples with unexplained Infertility were 
evaluated for celiac disease by anti- tissue transglutaminase antibody (t-TGA). Two 
hundred couples not reporting reproductive problems and having delivered at least one 
uncomplicated birth served as controls. Total IgA was also obtained to investigate IgA 
deficiency. Those with IgA deficiency were tested with IgG tTG. Those cases with 
positive tTGA or tTGG (IgA deficients) underwent upper gastrointestinal endoscopy. 
Results: Positive results of tTGA were detected in 13 infertile subjects (6.5%, 6 males 
and 7 females) and 11 controls (2.8 %, 4 males and 7 females) (P= 0.027). The odds 
ratio of celiac disease in unexplained infertile couples was 2.39 (95% CI: 1.15-5.01) 
compared with fertile couples. IgA deficiency was identified in 14 infertile cases and 
11 controls. Only 5/24 tTGA-positive and 4/24 IgA-deficient infertile subjects and 
controls accepted to undergo duodenal mucosal biopsy. Celiac disease was confirmed 
by biopsy in 3 (1.5%) of unexplained infertile patients. 
Conclusion:  The results of this study show that there is a higher seroprevalence of 
celiac disease in those with infertility in comparison to those with normal fertility. 
Keywords: Celiac disease, unexplained Infertility, Tissue transglutaminase 
antibodies (tTGA). 
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Introduction  
Celiac disease may be accompanied 
with several extra intestinal manifestations/ 
complications, with an adverse 
reproductive outcome (1, 2). Determining 
the cause of unexplained infertility is a 
challenge in reproductive medicine. When 
the results of standard infertility evaluation 
are normal, practitioners labeled the case 
as unexplained infertility (3). Some cases 
of unexplained infertility may be due to 
systemic diseases that have subtle effects 
on the reproductive system (4), among 
which celiac disease is of utmost 
importance. Some studies indicated that 
celiac disease may account for a significant 
percentage of unexplained infertility (5). 
However, other studies did not find any 
association between the two conditions (6). 
The likelihood for a causal relationship 
between celiac disease and reproductive 
problems including infertility, recurrent 
abortions and intrauterine growth 
retardation (IUGR) has received support in 
a number of reports (7). Some reports 
indicated a 4% to 8% prevalence of celiac 
disease in women with unexplained 
infertility (8, 9); others suggest that 
treating celiac disease with a gluten-free 
diet can improve fecundity (10, 11). 
Nevertheless, robust evidence has not yet 
been provided. Some researchers 
recommend that screening for celiac 
disease should be routine in all couples 
with unexplained infertility. Culturally, 
infertility is a significant health problem 
for young couples, while referring to 
infertility centers have been widely 
increased during the recent years. 
However, celiac disease has not found its 
role as a possible cause of unexplained 
infertility among couples. Therefore, we 
have evaluated the correlation of gluten 
related auto-antibodies in infertile couples 
and assessed in which proportion celiac 
disease may account for unexplained 
fertility disorders between men and 
women. 
Patients and Methods 
Infertile couples referred to the 
Infertility Department of Alzahra Hospital 
(Tabriz University of Medical Sciences, 
Tabriz, Azerbaijan) were evaluated by a 
standard infertility protocol between 
October 2006 and September 2007. 
Endocrine status was evaluated using 
serum levels of follicle-stimulating 
hormone (FSH), luteinizing hormone (LH), 
prolactin, and thyroid hormone. 
Ultrasound, urinary LH, and/or luteal 
phase progesterone confirmed the presence 
or absence of ovulation. Tubal patency was 
assessed with hysterosalpingography. 
Hysteroscopy or laparoscopy was 
performed, when appropriate. All male 
partners underwent semen analysis 
according to the World Health 
Organization criteria (12). In case of 
abnormal findings in the above-mentioned 
investigations, couples were labeled 
unexplained infertility. Using this protocol, 
100 unexplained infertile couples were 
randomly selected.   
The control group consisted of 200 
apparently healthy couples lacking 
reproductive problems with at least one 
child delivered and attending the hospital 
or gynecology offices for routine screening 
visits. All subjects were requested to 
complete a questionnaire regarding 
infertility duration, drugs consumption, 
history of diabetes, abortion, infertility 
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treatment, chronic diarrhea, anemia, 
autoimmune disease, hyper- and 
hypothyroidism and previous diagnosed 
celiac disease.  
Five milliliters of fasting blood was 
obtained, and then serum was separated 
and divided into 2 aliquots and 
immediately stored at -20°C. Anti-tissue 
transglutaminase IgA antibodies (tTGA) 
were determined by enzyme-linked 
immunosorbent assay (ELISA) with human 
recombinant tTGA as antigen, using a 
commercial kit (Eu- tTG IgA, Eurospital, 
Trieste, Italy). Results were considered 
positive when higher than 7 AU/mL. tTGA 
is not appropriate for IgA-deficient patients 
and since 2-3% of celiac population is IgA-
deficient (13), the serum IgA level should 
be determined before the serological tests 
such as tTGA. This would eliminate false-
negative results. The total serum IgA level 
was determined as described previously 
(14).  
The tTGA positive and IgA deficient 
subjects were asked to undergo an upper 
gastrointestinal endoscopy. Four biopsy 
samples, taking from distal duodenum, 
were evaluated by a pathologist who was 
unaware of the tTG test results. 
Intraepithelial lymphocytes, Crypt 
hyperplasia and villous atrophy were 
classified according to Marsh -Rostami 
criteria (15). 
Symptomatic patients with positive 
serology and some degrees of mucosal 
abnormalities have been classified as celiac 
disease according to most recent studies. 
(16). Although histology has a non-specific 
nature specially in those with mild 
abnormality, serology has a very high 
positive and negative predictive value and 
currently those symptomatic patients with 
positive serology (tTG and or EMA) with 
lymphocytic enteritis (Marsh I-II) should 
be treated as celiac disease. 
The Statistical Package for Social 
Science (SPSS, version 11.5, USA) was 
used for data analysis. Chi-square, t-test 
and logistic regression analysis were used, 
when appropriate. P values <0.05 were 
considered statistically significant.  
The study protocol was approved by 
the Ethics Committee of the Tabriz 
University of Medical Sciences and an 
informed consent was obtained from each 
subject.  
Results 
Serological screening for celiac disease 
based on tTGA was performed on 100 
unexplained infertile couples aged 
29.06±6.09 years and 200 fertile couples 
aged 29.91±9.54 years (NS). The mean 
duration of infertility in study group was 
5.25± 3.94 years (a range, 1 to 20 years). 
Positive results of tTGA were 
respectively detected in 13 infertile 
subjects (6.5%, 5 males and 8 females) and 
11 control (2.8%, 4 males and 7 females). 
The difference was statistically significant 
for tTGA positive in cases compare to the 
controls (P=0.027). IgA deficiency was 
identified in 14 (7%) infertile couples (6 
male and 8 female) and 11 (2.8%) controls 
(4 male and 7 female); however, the 
difference did not reach a statistically 
significant level (NS). Three of 14 infertile 
cases (3 females) with IgA deficiency and 
three of 11 controls (2 females and one 
male) were serologically positive for 
tTGG. The odds ratio of celiac disease in 
unexplained infertile couples was 2.39 
(95% CI: 1.15-5.01) when compared with 
fertile couples based on serological 
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screening adjusted for age. There was no 
significant association between positive 
tTGA results and gender in either case or 
control group. Table 1 represents results of 
serologic screening together with age and 
extra intestinal manifestations of celiac 
disease in cases and controls.  
Totally, 5 tTGA-positive and 4 IgA-
deficient cases underwent duodenal 
mucosal biopsy (3 tTGA-positive and 2 
IgA-deficient were belong to infertile 
patients and 2 tTGA-positive and 2 IgA-
deficient patients were from control 
group). Due to no remarkable clinical 
presentation, the rest of seropositive 
patients were unwilling to undergo 
duodenal mucosal biopsy. The biopsy 
samples revealed Marsh IIIb in one of 
tTGA-positive and Marsh I in two IgA-
deficient subjects in infertile patients and 
Marsh I in one tTGA positive subjects in 
control group (table 2). Therefore, celiac 
disease was suggested by biopsy and auto-
antibodies test in 3 (1.5%) cases of 
unexplained infertility compare to 1 
(0.25%) in control group. All infertile 
celiac disease patients were female versus 
those control fertile was male. 
 
Table 1. Clinical characteristics of unexplained infertile patients compared with healthy fertile controls. 
Characteristics Unexplained Infertile Patients Control group P 
Number 200 400   
Age (mean±SD#)  29.06±6.09 29.91±9.54  0.1* 
tTG¶ positive 13 (6 males and 7 females) 11 (4 males and 7 females) 0.027† 
IgA deficiency 14 (4 males and 10 females) 11(4 males and 7 females) 0.15 
History of chronic diarrhea 1 (0.5%) 0 0.3 
History of anemia 5 (2.5%) 20 (5%) 0.14 
History of hyperthyroidism 2 (1 %) 1(0.2%) 0.21 
History of autoimmune disease 2(1%) 1(0.2%) 0.22 
* Student’s t-test; † χ2 test; # Standard deviation; ¶ tissue transglutaminase 
Table 2. Tissue-transglutaminase antibodies, IgA deficiency and histological aspects in infertile patients 
underwent duodenal mucosal biopsy 
Case Gender 
(male/female) 
Clinical 
symptoms 
tTGA IgA 
deficiency 
tTGG Histological 
aspects 
Endocrine status 
FSH LH PL TH 
1 Female Bloating Positive Negative --- Marsh ΙΙΙb 2.6 8.1 12.6 2.2 
2 Male none Positive Negative --- Normal --- --- --- --- 
3 Female Constipation Positive Negative --- Normal 1.2 18.9 19.8 0.7 
4 Male Abdominal 
pain 
Positive Negative --- Marsh Ι --- --- --- --- 
5 Female none Positive Negative --- Normal 7.2 4.6 9.4 0.4 
6 Female none Negative Positive --- Normal 4.8 10.2 8 0.3 
7 Female Abdominal 
pain 
Negative Positive Positive Marsh Ι 5.4 8.2 16.4 0.9 
8 Female Abdominal 
pain, weight 
loss 
Negative Positive Positive Marsh Ι 3.7 8.5 10.8 3.1 
9 Female none Negative Positive Positive Normal 6.7 9.2 17.3 1.3 
FSH; follicle-stimulating hormone, LH; luteinizing hormone, PL; prolactin, and TH; thyroid hormone 
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Discussion 
In the present study, the frequency of 
celiac disease autoantibodies among 
unexplained infertile patients 
serologically was 8% (13 tTGA+ & 3 
tTGG +) which was significantly higher 
than controls (3.5%, [11 tTGA+ & 3 
tTGG +]). Furthermore, the likelihood of 
celiac disease in infertile patients was 
2.39 times higher than controls. We used 
tTGA for screening which is a highly 
sensitive and specific serological marker 
(17).  
Similarly, an increased prevalence of 
celiac disease in infertile patients has 
been reported in previous studies in 
Europe and Middle East (6-9, 18, 19). 
Collin et al. in Finland investigated the 
prevalence of sub clinical celiac disease 
in women with infertility or recurrent 
miscarriage by serological screening 
tests (9).  
In their series, no cases of celiac 
disease were identified in the control 
group of 150 fertile women, however, 
2.7% (four of 150) of infertile women 
were found to have sub clinical celiac 
disease. When infertile couples in Italy 
were evaluated for sub clinical celiac 
disease, an increased prevalence of 3% 
was found (3/9). This rate of disease was 
much higher compared with the general 
population (17 cases among 1607 
women; 1.06%) (8). Celiac disease has 
been also found to be more prevalent 
among the Arab infertile female. When a 
group of 192 Arab women suffering from 
unexplained infertility were tested for 
serologic markers of celiac disease, 
2.65% were affected. This figure was 
five times higher than the controls 
(0.5%) (18). A study from Israel 
investigated pregnancy outcome in 
patients with celiac; no statistically 
significant differences were noted 
between the groups regarding fertility 
treatments (0% among patients with 
known celiac versus 2.5% among 
patients without known celiac sprue; 
p=0.267) (19).Tiboni et al (20) 
investigated the prevalence of celiac 
disease in women undergoing assisted 
reproduction techniques by tTGA. Five 
(2.5%) cases and 2 (1.0%) controls were 
revealed to have celiac disease (P=0.44). 
In a cohort study among women with 
unexplained infertility in United State 
population, tissue transglutaminase and 
endomysium antibodies (EMA) were 
assessed among whom only EMA was 
positive in one (0.8%) which is 
approximately as prevalent as the general 
population in United State (<1%) (6).  
In present study, none of the infertile 
patients with celiac disease had 
remarkable gastrointestinal complaints 
consistent with studies performed by 
Tiboni et al (20) and Collin et al (9). 
Moreover, there was no significant 
association between positive TGA results 
and gender. Regardless of risk factors 
such as GI symptoms, individuals 
experiencing unexplained infertility 
could significantly benefit from 
awareness of disease status as 
management has demonstrated improved 
fertility outcomes (7). There are growing 
evidence to prove that celiac disease may 
affect reproduction at various points in 
both men and women. Farthing’s study 
(21) of men with celiac disease 
demonstrated an increased incidence of 
hypogonadism, sexual dysfunction and 
poor semen quality in almost half of his 
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cohort, resulting in an increased 
incidence of infertility. Women with 
celiac disease can also have major 
menstrual problems. One report from 
Italy showed 34 newly diagnosed celiac 
women suffered from significantly 
delayed menarche (13.5 vs. 12.1 years of 
age; P = 0.000), more frequent secondary 
amenorrhoea (38.8% vs. 9.2%; P = 
0.001) and a trend towards earlier 
menopause (45.5 vs 49.5 years of age) 
(22). In our study the prevalence of 
celiac disease was not same in males and 
females and all of the confirmed celiac 
disease in infertile group was female. 
Two recent studies by Kurppa, et al 
have elegantly demonstrated that even 
those who are serology positive but 
having no villous abnormality do 
respond to gluten free diet (23, 24). 
Likewise, some studies have suggested 
that treating celiac disease with a gluten-
free diet can improve fecundity in these 
patients (10, 11). In a study examining 
the effect of celiac disease on 
reproduction, patients on a normal diet 
were found to be at increased risk for 
infertility in comparison to patients on a 
gluten-free diet (11). The potential of a 
gluten-free diet to exert a positive effect 
on reproduction is rationalized by the 
possibility that nutritional imbalance 
especially malabsorption of selective 
nutrients including zinc, selenium, iron 
and folate may underlie celiac disease-
mediated reproductive disorders (2). 
There is little doubt that untreated celiac 
disease adversely affects both male and 
female reproduction. It also seems that 
patients with minimal symptoms have a 
considerably increased risk of problems. 
However, good evidence exists regarding 
the effectiveness of GFD in returning 
reproduction to normal. Several studies 
have indicated a potential association 
between celiac disease and infertility (6, 
10, 11, 19, and 25), often recommending 
celiac disease screening of some or all 
patients with unexplained infertility.  
The present study, in agreement with 
prior reports, showed higher frequency 
of celiac disease among unexplained 
infertile couples compare to fertile 
couples in Tabriz, Iran.  
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ABSTRACT 
 
Objectives: Study in children suggests that Rotavirus (RV) may be linked to coeliac 
disease (CD). The aim of this study was to determine CD serology and rotavirus by 
PCR in adults with non-specific gastrointestinal complaints. Methods: The study 
comprised 5176 randomly selected individuals living in Tehran, Iran during 17 Sep 
2006- 17 Sep 2007. 670 Individuals with GI symptoms were identified with a 
questionnaire and invited for a further study comprising blood and stool sampling. 
Stool samples were examined for detection of RV by amplification of specific gene 
(VP6) and by light microscopy and formalin-ether concentration methods for parasite 
detection. The subjects also tested for CD including anti-transglutaminase (tTG) 
antibodies and total immunoglobulin A (IgA). Results: VP6 gene was detected in 
150(22.3%) individuals. IgA tTG antibody was positive in 22 individuals (95% CI 2.3-
5.1) and IgG tTG antibody in 3 individuals who were IgA deficient. Amplification of 
VP6 gene was positive in 8 (32%) out of the 25 patients with positive, and in 
142(22%) out of the 645 with negative CD serology. This difference was not 
statistically significant (p=0.2). Conclusion: This study shows that RV infection is 
common among Iranian patients with non-specific gastrointestinal symptoms. 
However, in contrast to studies in children, this study shows that active rotavirus 
infection was not statistically significantly different between individuals who were tTG 
antibody positive and those who were tTG antibody negative. 
Keywords: Rotavirus, Coeliac Disease, Gastrointestinal Symptoms, VP6. 
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Introduction  
Coeliac disease (CD) is an autoimmune 
disorder characterized by gluten sensitivity 
in genetically susceptible individuals.1 The 
classic manifestations appear in the small 
intestine, but CD patients may also suffer 
from extraintestinal manifestations such as 
neurological, reproductive, and 
endocrinological disorders.2 
An increased intestinal permeability 
permits the absorption of intact gliadin 
molecules which may initiate the immune 
process leading to CD. 3 On the other hand, 
intestinal infection and inflammation may 
increase the intestinal permeability. Few 
studies have investigated the role of 
specific infectious agents in the 
development of CD.  
The prevalence of rotavirus (RV) 
infection is ranged from 3.3% to 63.6% in 
different parts of the world.4-٦ This 
infection is one of the most common 
causes of acute gastroenteritis worldwide.٧ 
A prospective study by Stene et al.٨ 
suggests that rotavirus predisposes to 
celiac disease in genetically susceptible 
host by either molecular mimicry or by 
repeated infections in childhood. 
The objective of this study was to 
assess the prevalence of rotavirus and 
coeliac serology among Iranian adults with 
non-specific gastrointestinal symptoms.  
Patients and Methods 
This cross sectional study in Iran, 
Tehran province was designed to assess the 
association between RV and CD. 9-12 
During 17 Sep 2006- 17 Sep 2007, a total 
of 5176 adults drawn up randomly from 
the population of Tehran on the basis of the 
list of postal cods in which the random 
samples of these postal codes and their 
related address were drawn from the 
databank registry of Tehran central post 
office, approximately 1000 households 
selected and all members (5176 persons) 
surveyed in each corresponding address. 
Interviewers asked them regarding 8 
gastrointestinal symptoms (yes or no) 
including abdominal pain, constipation, 
diarrhea, bloating, dyspepsia, nausea and 
vomiting, weight loss and Heart burn. 
Those who reported at least one of these 8 
gastrointestinal symptoms were selected 
for participation in this study. Altogether 
670 (mean age 40, range 14 to 83 years) 
with GI symptoms comprised the actual 
study group; 427 (63.7%) were women 
(mean age 42 years). Those with similar 
symptoms but a stabilised diagnosis like 
IBD, pancraetitis or GI malignancy were 
excluded.  
 Blood and stool samples were collected 
from each of them: the samples were 
transferred to National Research 
Department of Food borne Diseases 
(NRDFD) located in Research Center of 
Gastroenterology and Liver Diseases, 
Shaheed Beheshti University, M.C., Tehran, 
Iran. 
The sera were assayed within 24 hours 
after collection or stored at −80°C until 
analysis. Determinations of IgA anti-tTG 
antibody were carried out using a 
commercially available kit (AESKULISA 
tTG, Germany) and an enzyme-linked 
immunosorbent assay (ELISA) method and 
total serum IgA values were evaluated by 
an immunoturbidometric assay (Pars 
Azmoon, Iran). IgA class human antitissue 
transglutaminase (tTG) antibody and Total 
serum IgA values for CD were measured 
as described previously.13 
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Stool sample were kept in closed 
containers, refrigerated at 4˚C, rapidly sent 
to NRDFD and stored at -20˚C until 
processed. 
Viral RNA-extraction: 
For preparation stool samples, the 
cured fecal samples (0.5ml) were diluted 
with 150 µl of phosphate-buffered saline, 
vortex for 10 sec and incubated at room 
temperature with gentle mixing for 15 min. 
For RNA extraction QIAamp viral RNA 
mini kit (Qiagen/ Westburg, Leusden, the 
Netherlands) was used according to the 
manufacturer's instruction. 
RV VP6-specific PCR: 
A reverse transcriptase polymerase 
chain reaction (RT-PCR) was performed to 
amplify a 382 bp of segment 6 RNA. This 
region was chosen to determine group a 
specific VP6 protein of RV as previously 
described by Gomara et al. 15 
Parasites Detection: 
Specimens preserved in SAF (sodium 
acetate, glacial acetic acid and formalin) 
were sent to NRDFD where the stools were 
examined using light microscopy and the 
formalin–ether concentration method for 
detection of protozoa and of geohelminth 
eggs. 16 Also modified acid-fast staining 
was used to identify Cryptosporidium 
parvoum.  
The study was approved by the 
Institutional Ethics Committees of 
Research Center for Gastroenterology and 
Liver disease, Shaheed Beheshti 
University, M.C. and all participants 
signed a written informed consent. 
Statistical analysis 
Descriptive statistics was performed to 
depict the results. Fisher exact test was 
carried out using SAS software P value 
0.05 was considered statistically 
significant.  
Results 
Of the total of 670 symptomatic GI 
patients, who participated in this screening, 
we found an organic etiology in 290 cases; 
380 reported self-limiting symptoms of 
short duration. tTG antibody was found in 
17 women and 5 man (22 subjects (3.3%)). 
Also three IgA deficient were positive for 
IgG tTG. The prevalence of tTG antibody 
in the screened samples was thus 3.7% 
when including IgA-deficients with 
positive tTGG.  
One hundred and twenty six (19 %) 
isolates were positive for pathogen and 
non-pathogen parasites separately 53 
pathogen, 73 non-pathogen and 544 
negative.  
Among pathogen parasite, Giardia 
labmlia was the most common intestinal 
pathogen (41/670) followed by Blastocystis 
hominis (30/670), Iodomoeba butchelii 
(13/670), Entamoeba histolytica/ 
Entamoeba dispar complex (11/670) and 
Cryptosporidium parvoum (3/670). Among 
non-pathogen parasites Entamoeba coli 
was the most prevalent species (39/670) 
followed by Endolimax nana (34/670). 
Altogether 150 (22.3 %) out of 670 
subjects had positive RT-PCR testing for 
the RV VP6 gene in their stool samples (76 
female and 74 male). Eight (32%) of 25 
positive CD serology cases were infected 
by RV; the frequency was not statistically 
significantly higher.  
The most frequent GI symptom in 150 
cases positive for RV were heartburn 
(47/150, 31%), and in 25 positive CD 
serology were abdominal pain (n=10, 
40%). Table 1 shows the clinical signs and 
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symptoms, and associated conditions in 
RV-infected patients and positive CD 
serology patients. 
 
Table 1. Clinical signs and symptoms, and 
associated conditions in RV-infected patients and 
positive CD serology patients*  
Symptom, Sign, 
Associated 
Condition or, 
Test 
Rotavirus- 
positive 
(N = 142)
positive 
CD 
serology 
(N = 17) 
P value 
Diarrhea 4 (2.8%) 1 (5.9%) 0.43 
Abdominal pain 36(25.3%) 10(58.8%) <0.001 
Nausea & 
vomiting 
3 (2.1%) 8 (47%) 0.07 
Constipation 27 (19%) 6 (35.2%) 0.12 
Weigh loss 7 (4.9%) 4 (23.5%) 0.02 
Heart burn 46 (39.4%) 9 (52.9%) 0.10 
Bloating 32 (22.5%) 8 (47%) 0.01 
Dyspepsia 3 (2.1%) 0  
* 8 patients whom diagnosed with both CD and RV 
excluded from the analysis 
 
There was a statistically significant 
relationship between the weight loss and 
abdominal pain and positive serological 
marker for CD autoimmunity (P<0.05) and 
between the RV positive and bloating 
(P<0.05). There was no obvious difference 
in the symptoms between RV infected and 
non-infected individuals. 
Discussion 
Rotavirus is an important cause of 
diarrhea in children but asymptomatic 
carriage state is also known. This is the 
first report of RV infection in Iranian 
adults and our results are similar to those 
obtained in other population studies. But in 
this study what has been shown is just 
reflects the prevalence of rotavirus 
infection among adults with non-specific 
GI symptoms and not with only diarrhea.  
22.3% of our subjects were positive to RV, 
compared to the prevalence of 20–40% of 
RV reported elsewhere such as Brazil, 
Tunisian and India.16-18  
From birth, individuals can be infected 
by RV and upon reaching the age of 3 years, 
the majority have been in contact with the 
virus and have developed antibodies.6 In 
one study from Tehran, from total of 1250 
stool samples that were collected from 
children under five years old, RV was 
detected in 32.3%.19 Comparing the results 
of our study with the above study in 
children in Tehran, RV seems to be more 
prevalent in children. This may partly 
explain why RV found to be associated with 
CD in children. Repeated infections are also 
common, detectable by an increase in the 
level of RV specific antibodies and RT-PCR 
(PCR).20, 21 
Spread by fecal-oral transmission, RV 
infection in adults typically manifests with 
nausea, malaise, headache, abdominal pain, 
diarrhea, and fever. Infection can also be 
symptomless.22 The most common 
symptoms for patients with evidence of RV 
in the current survey were heartburn and 
abdominal pain, suggesting atypical 
carriage. There was, however, a significant 
correlation between RV and bloating. 
Bloating is a non-specific symptom, but it 
is possible RV infection may be the 
causative factor for some of these 
individuals. There were statistically 
significant difference in incidence of 
weight loss (P= 0.2) and abdominal pain 
(P= 0.001) in patients with positive CD 
serology compared to infected individuals 
with RV. 
Altogether 3.7% of our subjects were 
positive CD serology. We have no 
histological confirmation for CD in these 
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subjects, but tTG antibodies are highly 
specific for the condition. 22 Within the 
limitations of the present study (lack of 
performing small bowel biopsy), one can 
infer that the prevalence of undiagnosed 
CD autoimmunity among adults with non-
specific GI symptoms is 2 to 3 times higher 
than the general population in Iran. 23  
In contrast to the study in children this 
study did not find a significant correlation 
between CD and RV infection. 
Nevertheless, the infected cases with RV 
scored higher in patients with positive tTG 
with 32% versus 22% in those with 
negative CD serology (p=0.2). One of the 
reason for the lack of this association 
might be the lower prevalence of RV 
infection in adult with non-specific 
symptoms compared to children with 
specific symptoms like diarrhea.8 Further 
studies in larger population in adults with 
specific symptoms would be required to 
identify the possible triggering role of RV 
in CD.  
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ABSTRACT 
 
Background: Coeliac disease (CD) is an autoimmune disorder of the small intestine 
that occurs in genetically predisposed people of all ages. The objective of this study is 
to investigate the relation between demographic and clinical factors with coeliac 
disease using probit and logit models.  Methods: During the period of January to 
December 2008, 396 patients were recruited for this study. Histologic characteristics in 
duodenal biopsy specimens were evaluated in those with serology positive for coeliac 
disease according to the modified Marsh Classification1999. Results: From all of 369 
cases in our study 26 (7.1%) had coeliac disease according to pathology results. Both 
of models had the same result indicated a negative association between BMI and CD 
but other factors were not significant. Conclusion: Coeliac patient had less BMI 
compare with rest of study population. Results from probit and logit models were 
similar to each others, indicated that probit analysis can be employed as a logit model 
to analyze the relationship between clinical and demographic factors and CD. 
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Introduction  
Coeliac disease (CD) is an autoimmune 
enteropathy characterized by chronic 
inflammation of the small intestinal 
mucosa and by presence of typical auto 
antibodies (1). It develops in genetically 
predisposed individuals after mucosal 
contact with gluten and secondarily 
hitherto unknown triggering factors (1, 2, 
and 3). Because CD is caused by a reaction 
to gliadin, a gluten protein found in wheat, 
the only effective treatment is a lifelong 
gluten-free diet.  According to last study 
the prevalence of CD increased in last few 
years (4, 5) and as well as in Iran (6). So 
there are lots of studies which investigate 
different clinical and demographic factors 
that may be influence on CD.  
The most frequent statistical tool to 
address the relationship among a 
dichotomous response and other covariates 
are log linear models such as logistic 
regression and probit regression. Logit 
analysis used for analyses in which there 
are one or more categorical dependent 
variables. Probit regression is an 
alternative log-linear approach to handle 
categorical dependent variables. Its 
assumptions are consistent with having a 
categorical dependent variable assumed to 
be a proxy for a true underlying continuous 
normal (7). The aim of this study was to 
assess relation between clinical and 
demographic factors in coeliac patient, 
using logit and probit analysis.  
Materials and Methods 
Patients with dyspeptic symptoms, 
attended at the Gastroenterology ward of 
the Taleghani Hospital of Tehran, Iran for 
diagnostic endoscopy of the upper 
gastrointestinal tract, were prospectively 
evaluated between Januarys to December 
2008. The Ethnic committee of research 
center for gastroenterology and liver 
disease, Shahid Beheshti University, M.C 
approved the protocol of study and 
informed consent was obtained from all 
participants in this study. 
Patients who were informed of their 
high possibility of having CD and 
underwent gastrointestinal endoscopies 
with duodenal biopsies. Two or three 
mucosal biopsies were obtained. The 
specimens were read by two pathologists. 
Biopsy results were evaluated according to 
Marsh criteria (8) and subsequently 
modified by Rostami et al (9). 
Relation between age, sex, body mass 
index and some clinical factors including 
diabetes, chronic obstwctiv, hepatitis, renal 
failure, cardiovascular disease, abdominal 
pain, anorexia, increasing weight, weight 
loss, nausea-vomiting, heart burn, bloating, 
early satiety, flatulence and stress  with CD 
analyzed retrospectively using logit and 
probit. Logistic regression is a technique 
for making predictions when the dependent 
variable is a dichotomy, and the 
independent variables are continuous 
and/or discrete logit analysis is based on 
log odds while probit uses the cumulative 
normal probability distribution and the 
function used is the inverse of the standard 
normal cumulative distribution. SAS 
program version 9.1 was employed for 
analysis.  
Results 
From all of 369 cases in our study 26 
patients (7.1%) had coeliac disease (8 men 
and 18 women). The result of probit and 
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logit models appeared in Table 1. 
According to both logit and probit analysis 
a significant relation was fund between 
BMI and CD. The p-value of   abdominal 
pain in both models was very close with a 
criterion (0.05) which means that maybe it 
had a significant effect on CD. Other 
demographic and clinical factors were not 
significant. The coefficient of BMI was 
negative which means the relation between 
BMI and CD was inversing and all cases 
with positive CD had lees BMI than the 
others. According to the results, tow 
models were more similar to each other but 
in logit model odds ratio estimated and can 
be used for interpretation the coefficients. 
Table 1. Demographic and laboratory features 
of celiac patients 
subjects Gender 
Male/female 
Age 
(y) 
Weight 
(kg) 
Height 
(cm) 
tTGA 
level  
Case 1 F  27 55 158 44.3 
Case 2 M  18 66 159 34.5 
Case 3 M   45 77 180 67.2 
Case 4 M  25 58 17 111.2 
Case 5 F  68 66 155 53.1 
Case 6 F 17 48 155 42.9 
Case 7 M  35 55 150 94.5 
Case 8 M  45 65 177 31.2 
Case 9 M  35 55 164 71.8 
Case 10 F  51 77 154 84.3 
Case 11 F  24 59 157 42.1 
Case 12 F  40 85 178 145.6 
Case 13 F  20 75 168 19.9 
Case 14 F  25 80 170 25.7 
Case 15 F  29 50 155 93.5 
Case 16 F  47 72 160 67.8 
Case 17 M  30 67 170 194.9 
Case 18 F  67 50 152 69.3 
Case 19 F  60 51 155 55.6 
Case 20 F  50 88 179 79 
Case 21 F  21 67 160 64.7 
Case 22 M  55 92 177 18.4 
Case 23 M  24 60 177 81 
Case 24 F  40 50 167 49.5 
Case 25 F   50 75 167 69.4 
Case 26 M  50 57 70 70.2 
Discussion 
Logit and probit models are special 
cases of general linear models to better treat 
the case of dichotomous and categorical 
variables. Although Probit is a variant of 
Logit modeling based on different data 
ssumptions, results of probit analysis are 
rarely reported in the original units. Logit is 
the more commonly used, based on the 
assumption of equal categories. Probit may 
be the more appropriate choice when the 
categories are assumed to reflect an 
underlying normal distribution of the 
dependent variable, even if there are just 
two categories (7). Coeliac disease is a 
genetically mediated autoimmune proximal 
enteropathy triggered by the ingestion of 
gluten. Last study in Tehran province 
showed that the prevalence of CD in this 
population in the serologically screened 
samples excluding IgA- deficient was 3.3% 
and 3.7% when including those IgA 
deficient with positive tTGG (5). 
This paper examined relation between 
CD and demographic and clinical factors 
Using logit and probit models. Although 
probit model is not well-known for 
researchers in the filed of medical science, 
there are some studies using these models to 
interpret the relation between prognostic 
factors and a binary response. Costa-Font et 
al examined the influence of obesity jointly 
with other determinants on the prevalence of 
four chronic conditions, type 2 diabetes, 
cardiovascular disease, hypertension, and 
high cholesterol, using probit regression 
(10). Shelton Brown et al investigated the 
relation between diabetes and employment 
with probit model (11) and Shahrabani et al 
studied the impact of vaccinated in the past 
perceive influenza to prevent flu infection 
by probit analysis (12). In addition 
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Pourhoseingholi et al examined the relation 
between gastrointestinal cancers and 
demographic factors with these two models 
(13). In reality, the difference between two 
models was not too important: both models 
need to have diagnostics done afterwards to 
check that the assumptions of the model 
have not been violated and use maximum 
likelihood. In general, the logit coefficients 
are larger than the probit coefficients. 
Because of the probit function is the inverse 
cumulative distribution function (CDF), or 
quantile function associated with the 
standard normal distribution. It has 
applications in exploratory statistical 
graphics and specialized regression 
modeling of binary response variables (4). 
In probit model we don’t estimate odds ratio 
and describe models with coefficient 
directly. Negative and positive coefficients 
and significance are very important in 
describe of models. So probit regression can 
be one of useful statistical method for 
describe relationship between binary 
response and explanatory factors.  
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ABSTRACT 
 
Atypical presentation is the most common form of celiac disease (CD). Although the 
terminologies like latent, silent and potential have expressed different aspects of 
clinical and pathological behaviour of CD, they also have contributed in some extent to 
confusion between clinicians and patients due to the multiple definitions and 
uncertainty around them. In the light of new advances and the discovery of entities 
such as non-celiac gluten sensitivity, using subclinical instead of silent and atypical 
instead of potential / latent may simplify the understanding behind the clinical 
behaviour of atypical CD. The evidence behind a lower threshold for starting a gluten 
free diet (GFD) in non-celiac gluten sensitive patients would strongly support applying 
a GFD treatment strategy in any forms of CD. 
Keywords: Subclinical, Celiac disease, Atypical, Microscopic enteritis, Gluten 
sensitivity. 
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Introduction  
Using multiple terminology in defining 
atypical celiac disease (CD) has confused 
many of the clinicians to recognise atypical 
forms of this common disorder. CD is not 
considered an uncommon disorder any 
longer and is not a disease of essentially 
European origin (1). Nevertheless, 
recognising the existence of atypical forms 
known under the old terminologies like 
latent, silent and potential CD has 
introduced a new insight on clinical 
behaviour of this condition. That way the 
age of presentation of the disease has 
changed dramatically (1, 2) and the factors 
responsible for this change are mainly 
attributed to advances in diagnostic tools in 
recognising atypical and subclinical forms 
of disease. Adult presentation is 
increasingly common, and subclinical CD 
can occur at any age. Population screening 
with serological tests, have shown a CD 
screening prevalence of the order of 1% in 
the western hemisphere (3). European and 
Asian studies involving healthy blood 
donors found a prevalence rate of 1 in 166-
330 (4, 5) subclinical CD. According to the 
previous studies, screening based on 
antibodies only would underestimate the 
prevalence of CD due to false-negative 
results caused by the low sensitivity of tests 
(6-10). However, some studies suggest that 
the overestimation of CD frequency could 
also result from antibody based screening 
programmes due to a high rate of false 
positives (11).  
Sub-clinical Celiac Disease 
Terminologies like latent, silent and 
potential celiac disease can be confusing 
for clinicians and patients. Silent CD is not 
absolutely silent after all; patients show 
signs of CD with no significant symptoms. 
Potential and latent are defined differently 
in different studies. T-cell-mediated 
autoimmune processes are initiated by 
gluten exposure, leading to both intestinal 
and atypical extraintestinal manifestations. 
More and more diseases are proven to be 
associated with CD. In these conditions, 
screening is strongly recommended. 
However, a typical CD patient today has 
merely mild abdominal symptoms. 
Malabsorption can be silent like a mild 
anaemia (better defined under subclinical), 
or there is usually only moderate 
malabsorption, if any at all. Diagnostic 
difficulties may further emerge when 
minor mucosal changes are found (12). 
Should the presence of CD be ascertained 
in every symptomatic patient with atypical 
presentation? Since gluten sensitivity is no 
longer limited to overt villous atrophy, and 
given the results of many studies (13- 15), 
we believe the answer is yes.  
Subclinical or so called silent CD cases are 
being detected in increasing numbers 
because of raised awareness of the disease. 
Presentations with atypical symptoms are 
the dominant form of disease manifestation 
and these comprise the sole and main part 
of the celiac iceberg (16). Whether they 
have positive serology with negative 
biopsy or increased γδ T Cells receptors 
with symptoms compatible with CD they 
could be classified as atypical CD. We are 
moving towards a lower threshold in 
implementing a gluten free diet (GFD). 
Villous atrophy is not mandatory any 
longer to qualify a patient for GFD. In fact 
a large number of patients present with 
non-celiac gluten sensitivity with 
completely normal biopsy and negative 
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Figure 1. Celiac and non-celiac gluten 
sensitivity 
*Suclinical: previously known as silent and atypical 
as known under latent and potential CD 
 
serology. They also seem to benefit from a 
GFD. In such circumstances there is a need 
to re-define the terminologies according to 
the modified treatment strategy in gluten 
related disorders. The main strategy for 
treatment should target symptomatic 
typical or atypical patients, and not 
asymptomatic cases. We propose a 
simplified classification by dividing and 
replacing previous terminology to typical, 
atypical and subclinical instead of 
silent/latent and potential. (See figure 1). 
Immunogenetics involvement 
in Celiac Disease  
The spectrum of gluten related 
disorders seems to be beyond HLA DQ2-8. 
Our knowledge of CD pathogenesis has 
made significant progress in the last 
decade. The disorder is now considered the 
result of a complex interaction between 
genetic and environmental factors such as 
gluten that classified from subclinical to 
severe malabsorption. In contrast to gluten 
sensitivity celiac disease development has 
a strong genetic component with a sibling 
relative risk (lambda (s)) of 30. Recent 
studies using the human genome screening 
technique in families with multiple siblings 
suffering from CD have suggested the 
presence of at least 4 different 
chromosomes in the predisposition to 
suffer from CD (17). One susceptibility 
locus is the MHC (major 
histocompatibility complex) region, with a 
particular association with the HLA-DQ 
alleles DQA1*0501 and DQB1*0201. 
However, shared-haplotype studies suggest 
that genes within the MHC complex 
contribute no more than 40% to the sibling 
familial risk of disease. Early studies 
showed that gliadin elicits an inflammatory 
T-cell reaction when added to intestinal 
biopsy specimens of celiac patients in vitro 
and a link to the genetic predisposition was 
provided by the isolation of gliadin-
specific HLA-DQ2-restricted T-cell clones 
from CD mucosa (18, 19). However, the 
prevalence of HLA-DQ2 is high in the 
normal population (25-45%), suggesting 
the involvement of additional, and 
probably non-HLA-linked genes in CD 
pathogenesis. 
Microscopic enteritis  
The pathologic spectrum of the 
mucosal abnormalities seen on small 
intestinal biopsies, range from microscopic 
enteritis (Marsh 0-II) to macroscopic forms 
(Marsh IIIa-c) (20). Not every gluten-
sensitised individual inevitably develops 
CD and not every celiac patient develops 
the destructive lesions such as Marsh III. 
Celiac disease is not exclusively due to 
antibody production either. A large 
proportion of the patients present with 
microscopic enteritis (Marsh I-II) whose 
*Subclinical 
Atypical 
Classical 
Gluten sensitivity 
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diagnoses may actually be missed (20-23). 
Five major histopathological features that 
define CD have been recognized in the 
previous study. These 6 distinct and 
sequential phases of the CD are 
microscopic enteritis (ME) Marsh (0-II). 
Marsh 0 with normal small bowel mucosa 
where intraepithelial lymphocytes are 
below 25/100 entrecotes. Some patients 
could still have subtle abnormalities at this 
stage like increased γδ T cells receptors or 
alteration of enterocytes and microvillis. i) 
Recruitment of T-lymphocytes     >25/100 
enterocytes (intestinal-intraepithelial 
lymphocyte or IEL; Marsh I), ii) 
lymphocyte infiltration and crypt 
hyperplasia (Marsh II), iii) macroscopic 
enteritis (Marsh IIIa-c) partial villous 
atrophy (Marsh IIIa), iv) subtotal villous 
atrophy (Marsh IIIb) and v) total atrophy 
(Marsh IIIb) and total villous atrophy 
(Marsh IIIc) (6,8). This sequential cascade 
suggests that a T-cell response to gliadin 
precedes, and very likely produces, the 
complete pattern of CD. The statistical 
comparison between antibody-positive and 
antibody-negative cases shows that the 
appearance of antibodies was seen 
predominantly in cases with serious 
mucosal damage in which IELs was highly 
increased. However, it is hard to rule out 
the contribution of antibodies in genesis of 
an autoimmune condition like CD.  
The screening value of autoantibodies 
has been too optimistically overestimated, 
especially those on tissue transglutaminase 
antibodies (tTGA) (24, 25). However, 
comparing the tTGA to EMA and AGA, 
the sensitivity of tTGA does not offer any 
advantages over EMA for screening of the 
populations at high risk of CD (26- 28). It 
is time to re-evaluate our perception of 
intestinal pathology (29) in such terms, 
rather than by continued use of subjective 
degrees of villous atrophy (VA), since 
absence of VA is not evidence of absence 
of CD. Such terminology obscures the 
recognition of fundamental changes 
occurring within small bowel mucosa. In 
simple words, increased density of IEL’s 
and crypt hyperplasia form an essential 
phase in the disease pathogenesis sequence 
of progression. As CD with milder 
enteropathy is the most common form, 
histology cannot be considered as the gold 
standard any longer. Therefore, treatment 
should target the symptoms and not the 
immunohistology (29-32).   
Gluten sensitivity and Celiac 
disease 
Gluten sensitivity (GS) is 
characterised by negative antibodies and 
normal histology; it is defined as a non-
allergic and non-autoimmune condition 
in which the consumption of gluten can 
lead to symptoms similar to those seen in 
CD. Until recently the terms GS and CD 
were used synonymously in literature 
(33) and it is not clear yet whether 
patients affected by GS will have some 
subtle intestinal and mucosal changes 
consistent with microscopic enteritis. Yet 
we know very little about the pathogenic 
mechanism behind gluten sensitivity. 
Some GS patients would tolerate even 
more than 5g gluten/day and still remain 
symptom free with negative serology 
(34, 35). 
GS patients are gluten intolerant and 
gluten consumption does not lead to 
small intestinal damage, so it is not 
accompanied by the concurrence of tTG 
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autoantibodies or autoimmune disease. In 
the study by Kaukinen et al. out of 94 
adults with GI symptoms, 63% were 
affected by gluten foods and did not 
classified as CD or as allergic (36).  
On the other hand around 50% of the 
GS patients were DQ2/DQ8 positive, 
which is similar to that of the general 
population, while celiac patients carry 
more than 95% in most regions of the 
word. However, while the prevalence of 
CD is roughly 1% within the general 
population, GS is thought to affect 6 to 
10% of the general population (37). In 
some cases GS can present with normal 
or milder enteropathy seen as increased 
intestinal permeability, IBS, abdominal 
discomfort, pancreatic disorders, pain or 
diarrhoea; or it may present with a 
variety of extraintestinal symptoms 
including lymphoma, attention deficit 
disorder and neuropathy, autism and 
schizophrenia, infertility, IBD, muscular 
disturbances as well as osteopenia and 
osteoprosis (38-42). Conform with 
current literature a GFD is recommended 
to gluten sensitive cases with/without 
enteropathy. This policy includes a range 
of symptomatic gluten sensitive cases 
with atypical presentation including 
those with small bowel microscopic 
changes (Marsh 0-II) who have negative 
antibody or characteristic feature for 
other conditions.  
Conclusion  
The spectrum of gluten related 
disorders is widening.  This is because 
these common systemic disorders have 
multifactorial etiology with a multitude of 
symptoms and complications inside and 
outside the small bowel. We still don’t 
know how seriously subclinical CD will be 
affected by the long term complications if 
they are not treated with GFD.  
A marked increase in the prevalence of 
CD, especially the subclinical CD forms 
and non-celiac gluten sensitivity, seem to 
become a major health problem (43-46). 
The clinician may often face the variability 
of histological and clinical aspects of CD 
(46) with uncertainty, as they might not 
quite fit in the diagnostic models in the 
current guidelines. Accumulated evidence 
supports decreasing the treatment threshold 
for atypical CD and those with gluten 
sensitivity as the life quality of these cases 
will improve with GFD and the long-term 
health benefit of this strategy would 
perhaps be also cost effective.  
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ABSTRACT 
 
Background and Study Aims: Celiac disease is an immune mediated condition that 
leads to small bowel atrophy that resolves with a gluten free diet. Extra-intestinal 
manifestations of celiac disease include hypertransaminasemia. In this study the effects 
of a gluten free diet on hypertransaminasemia in patients with newly diagnosed celiac 
disease were studied. 
Patients and Methods: Ninety eight consecutive patients with a new diagnosis of 
celiac disease were studied. All patients with celiac disease were treated with a gluten 
free diet Patients with hypertransaminasemia, at diagnosis, had a cirrhosis screen 
performed. Patients with a negative cirrhosis screen were reviewed, 6 months after the 
introduction of a gluten free diet, and serum levels of liver transaminases were 
measured again. 
Results: Nine patients had hypertransaminasemia. One patient was HBsAg positive 
and was excluded from this study. The 8 remaining patients had no obvious cause for 
the hypertransaminasemia. Mean (± SD) AST and ALT levels were 42.6±16.5 IU/L 
(range: 16-66 IU/L) and 69.3±9.3 IU/L (range: 52-81 IU/L). Six months after treatment 
with a gluten free diet, mean AST and ALT levels decreased to 24.5±5.1 IU/L (range: 
18-31 IU/L) (p < 0.05) and 24.6±6 IU/L (range: 17-32 IU/L) (p: 0.01), respectively. In 
7 patients the hypertransaminasemia, at diagnosis had resolved.  
Conclusion: This study provides further evidence that some patients with celiac 
disease have a reversible hypertransaminasemia that resolves with a gluten free diet. 
Keywords: Celiac disease; Gluten-free diet; Hypertransaminasemia; Liver. 
   
 Celiac disease, Epidemiology, Genetic and Clinical Behavior in Iran 
 
159 Part IV Effect of Gluten Free Diet 
Introduction  
Celiac disease (CD) is an immune-
mediated disease, leading to small bowel 
atrophy that resolves upon the introduction 
of a gluten free diet. Symptoms can include 
steatorrhea, weight loss, and fatigue. CD 
can also be asymptomatic. CD affects 
approximately 1 % of the Iranian general 
population (1) (2). CD can affect 
extraintestinal organs, such as the skin, 
pancreas, heart and liver (3). Previous studies 
have suggested that up to 9% of patients with 
hypertransaminasemia and negative 
investigations to identify chronic liver 
disease, have CD (4). Studies have reported 
that patients with CD have an increased 
incidence of auto-immune and cryptogenic 
liver disease compared to the general 
population (5) (6). The cytogenetic liver 
disorder associated with CD is 
characterized by hypertransaminasemia 
with non-specific histological changes (7). 
The mainstay of treatment of CD is 
adherence to a gluten-free diet (GFD)(2). 
Mild liver dysfunction often improves with 
introduction of a GFD. Kaukinen K, et al. 
showed that GFD may inhibit progression 
to hepatic failure, even in cases being 
considered for liver transplantation (8). 
The aim of this study was to evaluate the 
prevalence of liver dysfunction in patients 
with newly diagnosed CD patients and the 
effects of a GFD were studied.  
Patients and Methods 
Patients with newly diagnosed with 
CD, referred to Taleghani Hospital, 
Tehran, Iran, between September 2007 and 
September 2010 were recruited. The 
diagnosis of CD was based on duodenal 
biopsies with histological abnormalities 
characteristic of CD (the presence of any 
of the following: intraepithelial 
lymphocytes, crypts hyperplasia and 
villous atrophy) and serology consistent 
with a diagnosis of CD (positive IgA class 
human anti-tissue transglutaminase (tTGA) 
antibody, endomysial antibody (EMA) and 
total serum IgA (If IgA deficient and tTGG 
was positive)) (9, 10). Liver function tests 
(LFTS), serum bilirubin, aspartate 
aminotransferase, alanine aminotransferase 
and alkaline phosphatase, were measured 
in all patients. The serum levels of 
bilirubin (normal range: 0.2-1.3), aspartate 
aminotransferase (AST, normal range: 15–
35 IU/L), alanine aminotransferase (ALT, 
normal range: 11–35 IU/L) and alkaline 
phosphatase (ALP, normal range: 64-306 
for adults and 180-1200 for children) were 
measured by routine laboratory methods.  
Patients with hypertransaminasemia 
had a cirrhosis screen performed to 
investigate possible causes of liver 
dysfunction. The cirrhosis screen consisted 
of measuring serological markers for viral 
hepatitis, metabolic liver diseases and 
serum protein electrophoresis. Serologic 
markers for viral hepatitis, including 
HBsAg (Hepatitis B surface antigen) and 
HCVAb (Hepatitis C virus antibody) were 
determined with commercially available 
ELISA kits (DIA PRO Diagnostic 
Bioprobes, Srl., Italy). Serum levels of 
Ferritin, TSH, caeruloplasmin, copper, 
ANA (anti-nuclear antibody), ASMA (anti 
smooth muscle antibody), AMA (anti 
mitochondrial antibody) and aFP (alpha- 
fetoprotein) were evaluated. History of 
taking medications, using alcohol, 
exposure to hepatic toxins and co-
morbidities, such as diabetes mellitus, were 
considered. Body mass index (BMI) was 
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calculated in patients to detect overweight 
or obese patients. Ultrasonography of 
hepato-biliary system was done. Levels of 
AST and ALT higher than 35 IUL, 
increased serum bilirubin greater than 2 
mg/dL and/or elevated serum alkaline 
phosphatase above 306 IU/L for adults and 
1200 for children were considered as 
evidence of liver dysfunction. In patients 
with abnormal ALP values, serum levels of 
calcium and phosphate were determined. 
Patients with a specific diagnosis that 
might be responsible for altering LFT were 
excluded. Liver biopsy was performed in 
those patients with hypertransaminasemia 
and a negative cirrhosis screen. 
All CD patients were treated with a 
gluten free diet (GFD). Patients with 
undiagnosed causes of abnormal LFT were 
reviewed after 6 months and Serum levels 
of AST, ALT, billirubin and ALP were 
rechecked. We have asked all patients 
about continuing GFD each month.  
The patients were assured that their 
private information would be kept 
confidential and a written informed 
consent was obtained from them. The 
study was approved by the Ethics 
Committee of the Research Center for 
Gastroenterology and Liver Diseases, 
Shahid Beheshti University of Medical 
Sciences.  
Data were analyzed by SPSS software 
ver.16 (Chicago, USA). Wilcoxon signed-
ranks test used to compare mean before 
and after treatment. P<0.05 was considered 
significant.  
Results 
Ninety eight patients with confirmed 
CD (40 Males and 58 females) with mean 
age of 32 ± 17.1 were studied. Nine of 
these patients had hypertransaminasemia. 
One patient with HBsAg was exclude in  
this survey and referred to 
gastroenterologist for further evaluation. 
Therefore 8 patients (five females and 3 
males) with mean age of 26.4±4.8 years 
(range: 19-33 years) were studied and 
maintained GFD. Marsh II was reported in 
two patients, Marsh IIIa in three, Marsh 
IIIb in two and Marsh IIIc in one. None of 
the patients with abnormal LFT had 
deficiency in total IgA serum. There was 
no medical history of significant co-
morbidities, excess alcohol consumption or 
exposure to knwon hepatotoxic agents. 
None of the patients were overweight or 
morbidly obese. Ultrasonographic 
evaluation of these 8 patients had no 
significant findings. Liver biopsy was 
unremarkable. None of the biopsies 
showed evidence of steatohepatitis. 
At the beginning of study, All 8 (8.1%) 
CD patients with undiagnosed liver 
dysfunction had normal billirubin levels 
with mean value of 0.95±0.2 mg/dL 
(range: 0.7-1.3 mg/dL). Eight patients had 
abnormal ALT level and 5 of these 8 
patients had abnormal AST. Also ALP 
levels were abnormal in 2/8 patients. Mean 
(± SD) AST and ALT levels were 
42.6±16.5 IU/L (range: 16-66 IU/L) and 
69.3±9.3 IU/L (range: 52-81 IU/L). Mean 
(± SD) concentration of ALP was 
240.3±118.7 IU/L (range: 108-428 IU/L). 
Two of 8 patients with elevated levels of 
ALP had low levels of calcium, 
representing metabolic disorder.  
Six months after using GFD, mean 
AST and ALT levels decreased to 24.5±5.1 
IU/L (range: 18-31) (p: 0.04 IU/L) and 
24.6±6 IU/L (range: 17-32 IU/L) (p: 0.01), 
respectively. Billirubin levels decreased to 
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0.9±0.2 mg/dL (range: 0.7-1.1 mg/dL), 
although not significant differences was 
found (p: 0.33). Concentration of ALP 
reduced to 180.3±50.6 IU/L (range: 108-
260 IU/L) 6 months after using GFD and 
there was no significant differences with 
ALP values before GFD (p: 0.09). Except 
one case with persistent abnormal LFT’s, 
the rest of 7 cases LFT’s have normalized 
after 6 month of GFD. The prevalence of 
reactive hepatitis in this cohort was 8% 
with almost complete resolution following 
GFD. Table 1 represents the serum levels 
of billirubin, AST, ALT and ALP before 
and after following GFD. 
Discussion 
This study showed that CD may be 
associated with hypertransaminasemia in 
the absence of other possible causes of 
liver dysfunction. Furthermore introduction 
of a GFD can improve the 
hypertransaminasemia and normalise the 
liver enzyme abnormality.  
The pathogenesis of 
hypertransaminasemia in CD is 
unidentified, several mechanisms have 
been proposed. We are aware of a link 
between CD and autoimmune disorder like 
autoimmune hepatitis, sclerosing 
cholangitis and primary biliary cirrhosis. 
However, most CD patients with elevated 
serum transaminases have no evidence of 
autoimmune disorder (11). It has been 
suggested that the hypertransaminasemia in 
CD patients may be multifactorial and a 
complication of prolonged existence of 
malabsorption, small intestinal bacterial 
overgrowth, iron overload disorder, hepatic 
steatosis, chronic intestinal inflammation 
and enhanced absorption of toxic 
substances (6, 11 and 12). 
In this study, 8 percent of adult CD 
patients had cryptogenic liver disorder and 
we did not find any evidence of 
autoimmune liver diseases. In a 
comparable study, Dicky W, et al. reported 
a  hypertransaminasemia in 15% of 
patients with newly diagnosed CD, (13). In 
previous studies, the frequency of elevated 
transaminases in patients with CD was 36-
55% (7, 14, 15). Possible explanations for 
this high prevalence of a 
hypertransaminasemia in other studies may 
Table 1. Serum levels of billirubine, AST, ALT and ALP among CD patients with hypertransaminasemia 
and no other causes of hypertransaminasemia, before and 6 months after GFD 
Patients Total billirubin 
(mg/dL) 
Normal range: 0.2-
1.3 
AST (IU/L) 
Normal range: 15–
35 IU/L 
ALT(IU/L) 
normal range: 
11–35 IU/L 
ALP(IU/L) 
normal range: 64-306 
 Age Sex Before 
GFD 
6 months 
after 
GFD 
Before 
GFD 
6 months 
after 
GFD 
Before 
GFD 
6 months 
after 
GFD 
Before 
GFD 
6 months 
after 
GFD 
1 21 M 0.8 0.7 66 24 81 31 243 218 
2 19 F 1.1 0.9 31 22 76 24 145 164 
3 24 F 0.7 0.7 48 30 63 27 428 216 
4 29 M 0.9 1 52 31 72 19 255 260 
5 33 F 1 0.8 16 24 65 17 108 124 
6 27 F 1.3 1.1 46 18 77 32 398 166 
7 27 M 0.7 0.9 27 29 52 29 137 108 
8 31 F 1.1 1.1 55 18 68 18 208 186 
* AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; CD: Celiac Disease 
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include the very diferent populations 
studied. European patients may be more 
likely toocnsume excess alcohol and have a 
greater prevalence of non-alcoholic 
staetohepatitis than our Iranian population.  
The prevalence of hypertransaminases 
among children with CD is higher than 
adult patients (14, 16, 17). Di Biase, et al 
evaluated a large population of children 
with CD in a prospective study. They 
found that isolated hypertransaminasemia 
is present in 40% of CD patients and that 
autoimmune liver hepatitis is present in 2% 
of cases, while no other autoimmune liver 
diseases were found (16). It has been 
reported that hypertransaminasemia might 
be an initial presentation of CD (18). 
Assessment of hypertransaminasemia in 
some studies has led to a diagnosis of CD 
in 10 % of patients, using serological 
methods (14, 19). Bardella et al study, 13 
out of 140 patients with elevated 
transaminases were seropositive for gliadin 
and endomysial antibodies (14).  
In a similar study, Volta et al. reported 
that in 55 patients with unexplained 
hypertransaminasemia, 5 had CD. In a 
similar studiy, Abdo et al. reported that CD 
serology was positive in 9% of patients 
with unexplained hypertransaminasemia 
(4).  We feel these studies suggest that 
clinicians should consider CD in the 
evaluation of patients with 
hypertransaminasemia (19). In our study, 2 
of the patients with newly daignosed CD 
patients had elevated ALP values, a result 
comparable to the Bardella et al, study 
(14). This was secondary to hypocalcaemia 
induced by chronic malabsorption.  
 
 
Conclusion 
Our study suggests that the 
hypertransaminasemia associated with CD 
resolves with the introduction of a GFD. 
This is in keeping with other studies that 
have reported an improvement in effects in 
the hypertransaminasemia associated with 
CD provided there was no evidence of 
underlying autoimmune, metabolic or viral 
liver disease (8, 16, 14, and 19). We 
suggest that clinicians need to consider the 
diagnosis of CD, when patients present 
with hypertransaminasemia. Furthermore 
we suggest that this hypertransaminasemia 
resolves with the introduction of a GFD.  
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ABSTRACT 
 
The aim of this study is to investigate the relation between Celiac disease (CD) and 
unexplained dysfunctional uterine bleeding (DUB) in celiac women. The celiac 
patients were selected from women who referred to celiac department. Controls were 
selected from those women without any signs of celiac and matched with age. 
Meanwhile, a trained physician was ready to explain the study, and then in case of 
their allowance, a questionnaire was completed by the physician. 24% of celiac women 
reported a past history of at least one menstrual cycle disorder v.s 10% of controls 
reported these problems (P=0.038) and higher percentage of unexplained DUB has 
been observed in celiac women. All celiac patients were undergoing with gluten free 
diet for at least 3 months and the celiac patients who reported the history of DUB again 
interviewed for any signs of unexplained DUB. From 12 celiac women with DUB, 10 
patients reported no more unexplained DUB after getting gluten-free diet (83.3%). The 
occurrence of a significant correlation between CD and DUB suggests the possibility 
of considering CD as one of the potential causes of abnormal uterine bleeding. 
Therefore, celiac disease must be seriously considered in the screening of patients with 
reproductive disorders. 
Keywords: Celiac disease, Dysfunctional uterine bleeding, Gluten Free Diet. 
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Introduction  
Celiac disease (CD) is an autoimmune 
disorder characterized by gluten sensitivity in 
genetically susceptible individuals (1, 2). CD 
causes small bowel inflammation and is 
associated with increased small bowel 
permeability. It is associated with both 
intestinal and several extra-intestinal 
manifestations/complications, including 
infertility and adverse pregnancy outcomes 
(2-4).  Celiac disease can affect women's 
reproductive life. Previous studies have 
suggested that women with undiagnosed 
CD to have 9-fold relative risk of multiple 
abortions and low birth weight babies 
compared to women with treated CD (5). 
Aside from adverse pregnancy outcomes, 
CD may present with a persistent iron 
deficiency and abnormal weight loss 
during a first, but more often, second 
pregnancy (2).  
Dysfunctional uterine bleeding (DUB) 
is a common problem amongst women 
and accounts for 20% of gynecology 
office visits (6). It is defined as abnormal 
uterine bleeding in the absence of organic 
disease (excessively heavy, prolonged, or 
frequent intervals of bleeding), 
complications of pregnancy or systemic 
disease (7, 8).  
The spectrum of abnormal uterine 
bleeding comprises of menorrhagia (heavy 
periods; blood loss >80 mL), metrorrhagia 
(prolonged, irregular periods), 
polymenorrhoea (frequent periods), 
oligomenorrhoea (scanty and infrequent 
periods), amenorrhoea (absent menstrual 
periods), intermenstrual bleeding and 
postcoital bleeding. 
There is limited data on reproductive 
implications in Iranian women with CD. 
The aim of this study is to investigate the 
relation between CD and unexplained 
DUB in celiac women who were referred 
to celiac department of Taleghani hospital. 
We also studied the effect of gluten-free 
diet on reducing the complications of DUB 
in women diagnosed with CD.  
Patients and Methods 
This study was designed as a case-
control study. The celiac patient’s group 
was selected from those who referred to 
celiac department of Taleghani hospital 
with diagnosis of celiac disease with or 
without dysfunctional uterine bleeding. 
Celiac disease was diagnosed based on 
positive serology and confirmation by 
histological assessment of small bowel 
biopsies. For this purpose, 5cc heparinized 
blood were be obtained. Blood sample was 
delivered to the laboratory within 2 hours. 
IgA class human anti-tissue 
transglutaminase (tTG) antibody using 
recombinant human tTG and Total serum 
IgA values were measured. Determinations 
of IgA anti-tTG antibody were carried out 
using a commercially available kit 
(AESKULISA tTG, Germany) and an 
enzyme-linked immunosorbent assay 
(ELISA) method. According to the 
manufacturer’s indications, the result was 
considered positive when a value higher 
than 15.0 U/ml was recorded. Total serum 
IgA values were measured by an 
immunoturbidometric assay (Pars Azmoon, 
Iran) and serum levels below 70 U/L were 
considered indicative of IgA deficiency. 
Immunoglobulin G (IgG) tTG values were 
further obtained in individuals with IgA 
deficiency by an ELISA method, and using 
the commercially available kit 
(AESKULISA tTGG, Germany). Those 
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serology positive for CD will be underwent 
biopsy specimens processing too. 
Histological diagnosis of CD was based on 
the presence of intraepithelial lymphocytes 
(Marsh I), crypts hyperplasia and/or villi 
atrophy (Marsh II to IIIc). Biopsy results 
were classified according to modified 
Marsh criteria by Rostami et al. (1).  
Control group was selected from those 
women who had not celiac disease with or 
without dysfunctional bleeding and 
referred to GI clinics and matched with 
age. Inclusion criteria for enrolling case 
and control group were; - Age range of 18-
45 years old; - celiac disease which 
diagnosed and confirmed by serology and 
biopsy after that in symptomatic cases; - 
dysfunctional uterine bleeding that 
diagnosed when abnormal uterine bleeding 
ruled out any pathology in endometrial 
biopsy, normal hormonal levels of 
prolactin and thyroid stimulating hormone 
(TSH) and normal pelvic ultrasound. 
Exclusion criteria were: -any pathology 
contributed in abnormal uterine bleeding; -
abnormal levels of TSH or prolactine; 
systemic disease confounding in diagnosis 
of celiac disease or DUB. Meanwhile, a 
trained physician was ready to explain the 
aim of study, and then in case of their 
allowance, a questionnaire was completed. 
The study was approved by the 
institutional ethics committees of Research 
Institute for gastroenterology and liver 
disease, Shahid Beheshti University of 
Medical sciences, and all participants 
signed a written informed consent.  
Results 
A total number of 50 celiac women 
who diagnosed for the first time (mean 
age±sd: 32.1±15.2) and 70 healthy control 
(mean age±sd: 31.7±12.7) were entered to 
this study. All celiac patients were new 
cases who diagnosed in Taleghani hospital, 
Research Institute for Gastroenterology 
and Liver Diseases and referred to 
department of celiac disease for 
intervention. Celiac patients and the age-
matched healthy control were interviewed 
for clinical and demographic factors. 
59.4% of patients and 67.3% of controls 
were married and the mean±sd of BMI in 
patients was 21.3±4.4 and in healthy 
controls was 21.5±5.9 (no statistically 
difference). Infertility was reported in 4% 
of celiac women and 2.9% of controls 
respectively (P=0.73). Also 6% of patients 
and 8.6% of controls reported a past 
history of at least one abortion (P=0.59) 
respectively (Table 1). 
   
Table 1.  The demographic factors and 
characteristics of celiac and non celiac groups  
Characteristics Celiac 
(n=50) 
Non-Celiac 
(n=70) 
P-
Value 
Age 32.1±15.2* 31.7±12.7 0.90 
BMI 21.3±4.4 21.5±5.9 0.89 
Married 33 (67.3)† 41 (59.4) 0.38 
DUB 12 (24.0) 7 (10.0) 0.03 
Infertility 2 (4.0) 2 (2.9) 0.73 
History of 
Abortion 
3 (6.0) 6 (8.6) 0.59 
* Mean±SD; † percent  
 
A higher percentage of unexplained 
DUB has been observed in celiac women. 
Twelve out of 50 cases of celiac group 
(24%) had DUB but in control group 7 out 
of 70 controls (10%) had DUB that is 
significant (P vaue=0.038). logistics 
regression analysis indicated that the crude 
risk of DUB was increasing 2.84 times for 
women with celiac disease compared to 
healthy women (95% CI: 1.03-7.84). Also 
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the adjusted risk of DUB was 3.83% for 
celiac women according to multivariate 
logistics analysis (95% CI: 1.19-12.33). 
According to the histology of CD 
patients who reported DUB, 1 patient was 
in Marsh 0; four patients were in Marsh I, 
two patients in Marsh II and three patients 
in Marsh IIIc.  
We also investigated the distribution of 
gastrointestinal complications and other 
diseases (which had been registered in CD 
patient's documents) with DUB (Table 2). 
The results indicated that there is a 
significant association between DUB and 
weight loss (P=0.03), which means that 
patients with lower weight, experiencing 
higher risk of unexplained DUB. Other 
symptoms and diseases were not 
significance.  
All celiac patients were undergoing 
with gluten free diet for at least 3 months. 
After 3-4 months, the celiac patients who 
reported the history of DUB interviewed 
again for report of repeated abnormal 
bleeding. In fallow up of the patients on 
gluten free diet, approximately 10 out of 12 
celiac cases did not complain of any 
abnormal uterine bleeding (83.3%). The 
menarche age in patients with CD on a 
GFD was decreased but was higher in the 
untreated CD patients; we concluded that 
the age at menarche in women with CD is 
regulated by a GFD. 
Discussion 
This study indicated that the risk of 
DUB is increasing in women with CD. The 
exact mechanism of DUB is uncertain but 
is thought to be caused by dysfunction of 
hypothalamic-pituitary-ovarian axis (9). 
Weight loss is another issue that has 
negative impact on reproduction. On the 
other hand, the spectrum of gluten related 
disorders is widening. This is because 
these common systemic disorders have 
multifactorial etiology with a multitude of 
symptoms and complications (10). 
 
Table 2. Association with dysfunctional uterine 
bleeding and clinical symptoms in celiac group 
Symptoms (%) DUB 
(n=12) 
Non-DUB 
(n=38) 
P-
value 
Diarrhea  4 (33.3) 7 (18.4) 0.28 
Bloating  6 (50) 18 (47.4) 0.87 
Heart Burn  4 (33.3) 7 (18.4) 0.27 
Weight Loss 8 (66.7) 12 (31.6) 0.03 
Neuse & 
Vomiting  
4 (33.3) 4 (10.5) 0.06 
Anemia 10 (83.3) 22 (57.9) 0.11 
Bone Disease 6 (50) 9 (23.7) 0.08 
 
Several studies have shown that celiac 
disease can impair women’s reproductive 
life eliciting delayed puberty, infertility, 
amenorrhea and early menopause. Some 
clinical and epidemiological studies have 
demonstrated that women with celiac 
disease are at a higher risk of miscarriage, 
low birth weight of the newborn (11-14). 
In particular, celiac women, have their 
menarche at an older age, compared to that 
of healthy controls, whereas the average 
age at menopause of celiac women has 
been observed to be younger than that of 
healthy women; in the same studies an 
increased frequency of cases of secondary 
amenorrhea has also been registered 
among celiac women (15). 
In the study by Ferguson et al. the 
reproductive life of 74 celiac patients 
including 54 patients on normal diet and 20 
under gluten free diet were studied. They 
found that delayed menarche and early 
menopause were more common in the 
untreated group than the controls (16). In 
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compatible with Ferguson et al. study, 
Molteni et al. (15) examined 54 celiac 
patients and 54 healthy women and 
detected that the mean age at menarche 
was significantly later in CD patients (15). 
In another study, the mean age of 
menarche in 59 girls with CD was 
significantly higher in untreated girls 
compared to those who were on a GFD 
(17). Delayed menarche and earlier 
menopause in CD that cause a decreased 
number of children may be interpreted as 
sub-fertility (18-20). 
Previous studies suggested that women 
with CD have higher risk of multiple 
abortions (5). An Italian case-control study 
on 62 celiac women and 186 healthy 
controls showed a higher percentage of 
menstrual cycle disorders in celiac women 
(21). In our study there was no association 
between CD and infertility or abortion 
which may be due to small sample size. 
But the results indicated that risk of DUB 
was higher for women with CD.  
The gluten itself, could explain the 
disturbances and malnutrition would 
worsen the disease in a consequent vicious 
cycle (22). So these reproductive disorders 
may be a consequence of the endocrine 
derangements caused by selective nutrient 
deficiencies (14).  
The occurrence of a significant 
correlation between CD and DUB suggests 
the possibility of considering CD as one of 
the potential causes of abnormal uterine 
bleeding. Dysfunctional uterine bleeding 
can be treated with medical therapy, a 
levonorgestrel releasing IUD and 
hysterectomy (23).  
Our results revealed that the gluten free 
diet could decrease the risk of DUB in CD 
women. Nowadays, the early diagnosis and 
treatment of CD is possible and not very 
costly. Therefore, celiac disease must be 
seriously considered in the screening and 
treatment of patients with reproductive 
disorders.  
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Increasing awareness and publication 
of recent data has left no doubt that 
Celiac Disease (CD), is affecting not 
only European but also the Middle 
Eastern countries with the same 
prevalence.  
As CD was considered to be very rare 
previously in Iran, based on this 
assumption; it was not generally 
considered as a possibility in the 
differential diagnosis of patients 
coming with nonspecific 
gastrointestinal symptoms. By the 
development of more epidemiological 
studies using sensitive and specific 
serological tests with biopsy 
verification established higher 
prevalence of CD (up to 1: 166 in 
healthy population) in recent decade in 
Iran.  
People of so-called ‘fertile crescent’ in 
South West Asia like Iran share a 
genetic background with European 
populations. It is therefore, not 
surprising to find a high incidence of 
CD in this region, where the HLA 
haplotype is present and large 
quantities of wheat are consumed. 
 
Important points extracted from this 
thesis: 
 According to presented studies in 
this thesis, the prevalence of CD in 
different ethnic groups in Iran was 
reported to be almost similar to the 
prevalence of CD in Western countries. 
Publication of our data has generated a 
significant interest between Iranian and 
Middle Eastern health professional in 
considering CD in their differential 
diagnosis and investigation the high 
risk group suspected for CD 
 The advise generated form 
extracted data have been formulated in 
Persian Language in Iranian Celiac 
website that is served as a valuable 
resource and information frequently 
used by patients and health 
professional. It has become a popular 
policy to follow up the cases where the 
diagnosis of gluten sensitivity or celiac 
disease is in doubt, in addition, 
observing the effect of either gluten 
withdrawal or gluten challenge in 
appropriate way is considered. 
 The Iranian health professional 
become more familiar with atypical 
presentation of CD and the behavior of 
this condition in this country. The 
policy of taking appropriate number of 
biopsies from appropriate sites and 
following a reasonable diagnostic 
pathway to detect the sufferers has 
become a practical tool in most of 
Iranian medical centers.  
 Some clinical behavior of CD is 
reflected in our studies indicating that 
atypical presentation, specially with 
dyspepsia, could be the main 
presentation of CD. However, this is 
also common presentation in non-
celiacs. 
 Using serological tests with a more 
realistic insight on their sensitivity and 
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specificities, appropriate use of other 
diagnostic tools like HLA typing in 
challenging cases has been promoted 
appropriately. 
 The results of our studies on 
patients at risk like in iron deficiency 
anemia, osteoporosis, infertility, 
recurrent miscarriages, liver enzyme 
abnormalities, seizures, chronic 
diarrhea, insulin-dependent diabetes 
mellitus, autoimmune thyroid disorders 
and malignancies have been widely 
published in Iranian media.  
 Clinicians are aware that CD is 
more prevalent among patients with 
atypical symptoms.  
 Similar to European our 
epidemiological data demonstrate that 
CD can occur at any age but in adults 
the peak incidence is in the forth 
decade. Females are more commonly 
affected than males, and of those 
patients presenting during their fertile 
years. 
 We produced some valuable data 
on HLA typing in Iranian celiac and 
non celiac. We observed that the 
frequency of DQ2 was higher in CD 
patients than controls. The prevalence 
of DQ8 in our CD population was 
higher than that reported in other 
populations.  
 Wheat is a major component of the 
Iranian diet and exposure to wheat 
proteins induces some degree of 
immune tolerance, leading to milder 
symptoms that may be misdiagnosed 
with other GI disorders. 
 
Finally 
The availability of serological tests for 
screening and diagnosis of CD has 
resulted in an increase rate of diagnosis 
of this disease in Middle East, specially 
in Iran where CD was traditionally 
considered to be very rare. CD is now 
reported to be as common in Iranian 
population, as in Western countries. 
This has important implications for 
clinicians, as well as for the authorities 
in Iran, who will need to address the 
supply of gluten-free diets to those 
diagnosed with CD. This certainly 
raises important issues for the health of 
Iranian population where the major 
staple diet is wheat. Since commercial 
gluten-free products are not readily 
available and significantly more 
expensive than their gluten-containing 
products in this area, this will represent 
a serious challenge for patients and 
health professionals.  
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Summary 
Celiac associated disorders and the 
questions around these associations seems 
to be one of the hottest topics in the world 
of patients with Celiac disease and the 
health professional who deal with this 
condition. This is because this common 
systemic disorder has a multifactorial 
etiology with a multitude of symptoms and 
complications inside and outside small 
bowel. Almost all those conditions as 
reported to have an association with 
coeliac disease are or must be HLA-
DQ2/DQ8 positive. That means that they 
all have a common characteristic sharing a 
similar genetic background. The 
environmental factors associated with a 
complex genetics are leading to 
destructions of the small intestinal villi 
resulting in malabsorption syndrome. The 
co-morbidity between celiac disease and 
other disorders has been clearly established 
and there have been many reports of 
numerous intestinal and extra intestinal 
coexistent disorders with CD. In this short 
systematic review the nature of these 
associations has been explored and 
classified according to their pathogenesis. 
Study on epidemiology, clinical behavior 
in Eastern countries and challenges in 
diagnosis and treatment of celiac disease 
are the outline of my research and training 
over the past few years. The study we 
performed so far includes 15 Original 
Article, 4 Review Articles, 5 Case Reports/ 
Letters and one Editorial. According to 
these studies coeliac disease (CD) is as 
common in Iran as in Western countries 
with similar association pattern with a 
prevalence of around 1% in Iranian 
population. Our preliminary study on 
genetic showed that the proportion of 
HLA-DQ2 in coeliac patients was higher 
than control and this finding is in 
agreement with other studies in Western 
populations. A short summery of the 
studies we published or under preparation 
is presented below. 
 
PART I 
Chapter I.1: INTRODUCTION and 
OUTLINES 
 
PART II 
EPIDEMIOLOGY 
 
Chapter II.1: In the past, celiac disease 
(CD) was believed to be a chronic 
enteropathy, almost exclusively affecting 
people of European origin. The availability 
of new, simple, very sensitive and specific 
serological tests (AGA, AEM and tTGA) 
has shown that CD is as common in 
Middle Eastern countries as in Europe, 
Australia and New Zealand where the 
major dietary staple is wheat. A high 
prevalence of CD has been found in Iran, 
in both general population and at-risk 
groups. In developing countries, 
serological testing in at risk groups is 
necessary for early identification of celiac 
patients. Clinical studies show that 
presentation with non-specific symptoms 
or a lack of symptoms is as common in the 
Middle East as in Europe. The 
implementation of GFD is a major 
challenge for both patients and clinicians in 
Iran, especially since commercial gluten-
free products are not available in this area. 
This review provides evidence and 
summarizes the epidemiological data on 
CD in Middle East and highlights different 
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clinical presentations and management of 
CD in Iran. 
Chapter II.2: Non-specific GI symptoms 
seem to be the typical presentation of 
atypical CD. This study had two 
objectives: first objective was to determine 
the prevalence of CD in patients with GI 
symptoms and the second objective was to 
characterize the typical manifestations of 
the atypical forms of CD. The results 
indicated that there is a high prevalence of 
CD antibodies among patients with GI 
symptoms (3.7%). Therefore, more 
awareness regarding the atypical 
presentation of CD could be the key step in 
identifying asymptomatic patients.  
Chapter II.3 and II.4: Among the most 
common neurology problems associated 
with CD are peripheral neuropathy, 
cerebellar ataxia, epilepsy, multiple 
sclerosis, psychiatric disorders and mental 
retard.  
Nutritional factors have been suspected in 
association with neurological defects but 
are rarely found and their correction does 
not seem to influence in the prognosis. 
Some reports show certain neurologic 
symptoms that respond to a GFD, 
especially if it is started in the first few 
months after their appearance. It is now 
evident that the link between CD and 
neurologic disorders results, in part, from 
common genetic background, most 
importantly, the HLA region on 
chromosome 6, and other markers. In 
addition to genetic predisposition, 
immunologic factors probably also play a 
role. 
Depression, intellectual disabilities, 
schizophrenia and other psychiatric 
symptoms have been reported as common 
complications of CD, occurring in about 
one third of patients. Common symptoms 
include apathy, excessive anxiety and 
irritability. All of them clearly improve 
after few months of adherence to a GFD. 
Chapter II.5: In this study CD was not 
associated with a high incidence of 
unfavorable outcomes. Overall, 1/66 
(1.5%) pregnant women had a confirmed 
CD. Despite pregnancy is acting as a 
triggering factor for manifestation of CD in 
susceptible individuals, it seems that CD 
severity is variable in different individual 
and not every untreated pregnant woman 
affected by CD is at high risk for reported 
complications. This may suggests that 
gluten free diet could be avoided in some 
of patients who had a normal pregnancy. 
Chapter II.6: In this multicenter study 931 
patients who underwent duodenal biopsy 
for celiac disease were studied at nine 
centers from west, south and east European 
and Middle Eastern countries. The results 
indicated that because the proportion of 
individuals undergoing duodenal biopsy 
who have ≥4 specimens increased recently, 
we should diffusing this guideline into 
clinical practice. This study shows that 
there is significant gap between evidence 
based medicine and the reality in clinical 
practice. Only a minority of individuals 
undergoing upper GI endoscopy had ≥4 
duodenal biopsies. Therefore, given the 
high incremental yield of submitting ≥4 
specimens, efforts to increase adherence to 
this standard are warranted.  
Chapter II.7: This is the first study 
conducted on the frequency of HLA typing 
in Iranian celiac disease patients compared 
to general population. We found that the 
frequency of DQ2 was higher in CD 
patients compared to controls. The 
prevalence of DQ8 in our CD population 
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was higher than the frequency reported in 
other populations. Our results underline the 
primary importance of HLA-DQ alleles in 
susceptibility to CD in the Iranian 
population. This can be used as a 
diagnostic modality, especially, in whom 
the diagnosis is uncertain. This paper is 
under submission. 
Chapter II.8: The metabolic changes in 
serum of celiac patients and control were 
explored using a metabonomics approach 
based on Proton nuclear magnetic 
resonance (1H NMR) spectroscopy. In 
order to find the important variables 
influencing the zinc level of the cases and 
control group, Classification and 
Regression Trees (CART) method was 
employed. Serum levels of zinc were 
measured using Atomic absorption 
method. To make a non-linear model 
between zinc and the 1HNMR matrix an 
artificial neural networks (ANN) model 
was employed. 
Our descriptors consisted of Lipid, Choline 
and Histidine. Based on the square of 
correlation coefficients (R2) for training, 
test and validation, there is good agreement 
between experimental and the theoretical 
zinc values. 
Chapter II.9: The experimental data 
consists of 56 blood serum samples, 
employing prometab software, NMR 
spectra data are reduced to 205 variables 
and then the orthogonal signal correction 
(OSC) effect on the celiac disease 
metabonomics as well as following the 
separation by Principle Component 
Analysis (PCA) was investigated. Partial 
least squares Discriminant Analysis (PLS-
DA) method was used for supervised 
study. PCA and PLS-DA models 
calculated following OSC showed 
enhanced separation between classes and 
tighter clustering within each class. 
Chapter II.10: In this paper, we have 
studied body mass index in celiac patients 
diagnosed in a population-based study, 
using a well-matched case-control analysis 
to assess the BMI in celiac patients. This 
study showed that up to 33% of CD 
patients were underweight. 
 
PART III 
ASSOCIATED DISORDERS 
Chapter III.1: Liver disease and CD share 
widespread risk factors. Different liver 
disorders such as autoimmune hepatitis, 
elevations of liver enzyme levels, primary 
biliary cirrhosis, nonspecific hepatitis, 
primary sclerosing cholangitis and 
nonalcoholic fatty liver disease have been 
reported in patients with CD. In this review 
we provide information regarding liver 
disorders that may be seen in association 
with celiac disease and the effect of 
treatment of CD on these disorders. 
Chapter III.2: It appears non-
responsiveness to HBV vaccine should 
lead to a routine assessment in patients 
with CD in those non-responsive to HBV 
vaccination. Non-responsiveness to 
vaccination might be a sign of a possible 
undiagnosed celiac disease or suggest the 
lack of compliance with gluten free diet.  
Chapter III.3: Microscopic enteritis (ME) 
is the stage of microscopic and sub-
microscopic changes (microenteropathy) 
associated with the symptoms of gluten 
sensitive enteropathy leading to 
micronutrient deficiencies. It is 
characterized by subtle mucosal 
abnormalities without prominent 
inflammation, villous affacement, erosions 
or ulcerations on conventional light 
 Celiac disease, Epidemiology, Genetic and Clinical Behavior in Iran 
182 English Summary 
microscopy. This review summarizes the 
patho-mechanism of Malabsorption in 
milder and severe enteropathy and shows 
that there is no correlation between the 
severity of Malabsorption and the degrees 
of mucosal changes. 
Chapter III.4: Coeliac disease and 
Toxoplasma gondii (TG) infection are 
associated with infertility and adverse 
pregnancy outcomes. The result of this 
study show that CD increases the risk of 
T.gondii infection as CD may facilitate 
distribution of the ingested TG oocysts 
beyond small bowel lesions during 
pregnancy and that this infection, but not 
CD, increases the serum levels of pro-
inflammatory cytokines such as IL8. CD 
was behind the increased risk of low birth 
weight and miscarriages irrespective of 
T.gondii infection. It is also possible that 
TG could theoretically increase sensitivity 
to gluten. This may precipitate the 
development of CD in susceptible 
individuals. This would be in keeping with 
studies that suggest that other enteric 
infections can predispose to the 
development of CD among susceptible 
individuals. 
Chapter III.5: Dyspepsia is a major health 
problem in Iranian population. It has been 
reported that the frequency of CD in 
people with dyspeptic complaints is 1.1-
3%, which is two to nine times higher than 
in the general population. Although a high 
prevalence of H pylori infection was found 
in this study, the relationship between Hp 
infection and CD was similar to that 
reported in other geographic areas. In this 
study we have shown that there are no 
differences between clinical presentation of 
coeliac disease and H. pylori. 
Chapter III.6: This is the first report of a 
case with unexplained nail deformity 
associated with CD. The result of this 
study show that celiac disease should be 
considered and ruled out in patients with 
persistent nail abnormalities who are not 
responding to the conventional treatment. 
Chapter III.7: Celiac disease is frequently 
associated with abnormalities of gastric 
histology and gastric function, including 
gastritis, peptic ulceration and atrophic 
gastritis. Although our knowledge of the 
pathogenesis of CD is rapidly expanding, 
the possible role of chronic Helicobacter 
pylori (HP) infection, known to be capable 
of inducing duodenal ulcers, needs further 
examination. In This study we examined 
the association of CD with chronic gastritis 
associated with Helicobacter Pylori (HP) 
infection. This manuscript introduced a 
way to simply the interpretation of gastric 
lesions classifying them in macroscopic 
and microscopic stages for clinical studies.  
Chapter III.8: Some discrepancies could 
stem from the heterogeneity of the studies. 
Regarding a potential pathogenic 
mechanism, since CD causes 
malabsorption of folic acid and other 
nutrients, this pathway has been proposed 
to explain the unfavourable outcomes of 
pregnancy. As serology scores a far higher 
sensitivity and specificity compared to 
histology for CD, our study suggests a 
higher prevalence of CD among 
unexplained infertile men and female. 
Regular screening for CD in men and 
females with unexplained infertility is 
recommended.  
Chapter III.9: It is important to recognize 
that there are a number of possible ways 
that infections might trigger autoimmunity, 
and many of these immunological 
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mechanisms have been proven in 
experimental systems. Some recent studies 
provide evidence that a rotavirus protein 
may be linked to celiac disease through a 
molecular mimicry mechanism and that the 
risk of developing celiac disease appears to 
increase in children in relation to the 
number of rotavirus infections.  This is not 
specific for as some infection may also be 
persistent and can mimic or trigger 
different autoimmune inflammatory 
disorders. This study shows that Rotavirus 
infection is common among Iranian 
patients with non-specific gastrointestinal 
symptoms. However, in contrast to studies 
in children, this study shows that active 
rotavirus infection was not statistically 
significantly different between individuals 
who were tTG antibody positive and those 
who were tTG antibody negative. 
Chapter III.10: Logit and probit models 
are special cases of general linear models 
to better treat the case of dichotomous and 
categorical variables. Although Probit is a 
variant of Logit modeling based on 
different data ssumptions, results of probit 
analysis are rarely reported in the original 
units. Logit is the more commonly used, 
based on the assumption of equal 
categories. Probit may be the more 
appropriate choice when the categories are 
assumed to reflect an underlying normal 
distribution of the dependent variable, even 
if there are just two categories. . Results 
from probit and logit models were similar 
to each others, indicated that probit 
analysis can be employed as a logit model 
to analyze the relationship between clinical 
and demographic factors and CD. 
PART IV 
EFFECT OF GLUTEN FREE DIET IN 
THE IMPROVEMENT OF CELIAC 
DISEASE 
Chapter IV.1: In the light of new 
advances and the discovery of entities such 
as non-coeliac gluten sensitivity, using 
subclinical instead of silent and atypical 
instead of potential / latent may simplify 
the understanding behind the clinical 
behaviour of CD. Accumulated evidence 
supports decreasing the treatment threshold 
for atypical CD and those with gluten 
sensitivity as the life quality of these cases 
will improve with GFD and the long-term 
health benefit of this strategy would 
perhaps be cost effective. 
Chapter IV.2: The prevalence of 
hypertransaminasemia (HT) in children is 
increased in CD. Studies show that patients 
with HT were younger than patients with 
normal aminotransferases. A significant 
percentage of adult patients with non-
alcoholic fatty liver disease (NAFLD) have 
no metabolic risk factors and may be 
related with the concomitant presence of 
CD. Mild liver abnormalities are common 
in adult patients with celiac disease and 
usually resolve with a GFD. The possible 
presence of celiac disease should be 
investigated in patients with severe liver 
disease. Dietary treatment may prevent 
progression to hepatic failure, even in 
cases in which liver transplantation is 
considered. Our study on 98 coeliac cases 
showed that CD may affect liver function 
and induce hypertransaminasemia in the 
absence of other possible causes of liver 
dysfunction. Moreover, GFD can improve 
liver function and decrease liver enzymes 
to normal values. 
Chapter IV.3: Celiac disease is an 
autoimmune disorder which can affect 
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women's reproductive life. Previous studies 
have suggested that women with 
undiagnosed CD to have 9-fold relative 
risk of multiple abortions and low birth 
weight babies compared to women with 
treated CD.  Dysfunctional uterine 
bleeding (DUB) is a common problem 
amongst women. It is defined as abnormal 
uterine bleeding in the absence of organic 
disease (excessively heavy, prolonged, or 
frequent intervals of bleeding), 
complications of pregnancy or systemic 
disease. The occurrence of a significant 
correlation between CD and DUB suggests 
the possibility of considering CD as one of 
the potential causes of abnormal uterine 
bleeding. Our results revealed that the 
gluten free diet could decrease the risk of 
DUB in CD women. 
Chapter IV.4: This is a case report of a 
male adult who presented with oral 
aphthous ulcerations, autoimmune hepatitis 
and mistaken with fatty liver disease. In 
this case, where the patient presented with 
high BMI and evidence of fatty liver 
disease, grade I, CD was suspected due to 
mild abnormal bloating, cryptogenic 
hypertransaminasemia, abnormal LFT and 
poor response to fatty liver treatment. This 
presentation type is not uncommon; 
diagnosis was confirmed by the presence 
of subtotal villous atrophy in the biospy 
specimen, by the positive specific antibody 
screening (AGA, tTG and EMA 
antibodies), by negative antibody screening 
and the normalisation of liver enzymes on 
a gluten-free diet. 
Chapter IV.5: A full blown CD 
presentation is rare. This case highlights 
classical presentation of CD with multiple 
deficiencies in modern life. In patients who 
suspected of having CD barium evaluation 
of the small bowel are seldom required. 
But by barium investigation of this patient 
we found abnormal roentgen findings 
included straightening of the valvulae 
conniventes, replacement of the normal 
delicate feathery mucosal pattern with 
either marked thickening or complete 
obliteration of the mucosal folds dilation of 
the small intestine. 
 
PART V 
DISCUSSION, SUMMERY, 
ACKNOWLEDGEMENT AND A 
BRIEF CV.  
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Aandoeningen geassocieerd met coeliakie 
evenals vragen die zich voordoen in dit 
verband lijken erg belangrijk te zijn voor 
de gezondheidsspecialisten die zich bezig 
houden met deze aspecten. Dit komt 
doordat algemene systemische 
aandoeningen een multifactoriële etiologie 
hebben, met een veelheid aan symptomen 
en complicaties binnen en buiten de dunne 
darm. Bijna alle gemelde aandoeningen die 
verband houden met coeliakie zijn of 
zouden HLA-DQ2/DQ8 positief moeten 
zijn. Dit betekent dat ze allemaal een 
gemeenschappelijk kenmerk hebben, 
namelijk dezelfde genetische achtergrond. 
Omgevingsfactoren geassocieerd met een 
immuno-genetisch complex leiden tot een 
enteropathie die als resultaat een 
malabsorptie syndroom zal hebben. Co-
morbiditeit tussen coeliakie en andere 
aandoeningen is duidelijk vastgesteld en er 
zijn  vele meldingen geweest van darm- en 
extra-intestinale aandoeningen, 
samengaand met coeliakie. In deze 
systematische studie werd de aard van deze 
verbandingen onderzocht en gerangschikt 
volgens hun pathogenese. 
      De studie over de epidemiologie, de 
verbanden met andere aandoeningen zoals 
het klinische gedrag, H.pylori, Rotaviros, 
Toxoplasma gonadii in Oosterse landen, 
evenals de uitdagingen in de diagnose en 
behandeling van coeliakie vertegenwoordigt 
het plan van mijn onderzoek en 
voorbereiding gedurende de afgelopen 4-5 
jaren. De studie die ik tot nu toe uitgevoerd 
heb, omvat 12 originele artikelen, 3 
beoordelingen, 2 brieven. Volgens deze 
studies is coeliakie net zo gewoon in Iran als 
in de Westerse landen, met een vergelijkbaar 
patroon van associaties met een prevalentie 
van ongeveer 1% onder de Iraanse bevolking. 
Onze voorafgaande studie met betrekking tot 
genetica toonde aan dat het aandeel van 
HLA-DQ2 bij coeliakie patiënten hoger was 
dan bij controle, en deze bevinding 
vertegenwoordigt een overeenkomst met 
andere studies onder Westerse 
bevolkingsgroepen. Hieronder volgt een 
korte samenvatting van deze studies die wij 
gepubliceerd hebben of welke in publicatie. 
 
DEEL I 
Hoofdstuk I.1. INLEIDING en 
SCHETSEN van Het Proefschrift 
 
DEEL II 
EPIDEMIOLOGIE 
Hoofdstuk II.1. In het verleden dacht 
men dat coeliakie een chronische 
enteropathie was die bijna uitsluitend 
mensen van Europese oorsprong trof. De 
beschikbaarheid van eenvoudige, zeer 
gevoelige en specifieke, nieuwe 
serologische testen (AEM, en tTGA) 
toonde aan dat coeliakie even gebruikelijk 
is in het Midden-Oosten landen als in  
Europa, Australië en Nieuw-Zeeland waar 
de basisvezels tarwe zijn. Een grote 
prevalentie van coeliakie werd 
geïdentificeerd in Iran, zowel onder de 
algemene bevolking als bij risicogroepen. 
In ontwikkelingslanden is serologisch 
testen van risicogroepen noodzakelijk voor 
de vroege identificatie van coeliakie 
patiënten. Klinische studies tonen aan dat 
de presentatie met niet-specifieke 
symptomen of geen symptomen even 
gewoon is in het Midden-Oosten als in 
Europa. De implementatie van GVD 
(glutenvrij dieet) is een grote uitdaging 
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voor zowel patiënten als voor artsen in 
Iran, vooral sinds commerciële glutenvrije 
producten niet meer beschikbaar zijn in dit 
gebied. Deze analyse levert het bewijs en 
verzamelt de epidemiologische gegevens 
over coeliakie in het Midden-Oosten en 
benadrukt de verschillende klinische 
verschijnselen en het beheer van coeliakie 
in Iran. 
Hoofdstuk II.2: Niet-specifieke GI 
symptomen schijnen de typische 
manifestatie van atypische coeliakie te zijn. 
Dit onderzoek had twee doelstellingen: het 
eerste doel was de prevalentie van 
coeliakie vast te stellen bij patiënten met 
gastro-intestinale symptomen en het 
tweede doel was de typische uitingen van 
atypische vormen van coeliakie te 
karakteriseren. De resultaten gaven aan dat 
er een hoge prevalentie van coeliakie-
antilichamen is bij patiënten met atypische 
GI symptomen (3,7%). Zo kan een groter 
bewustzijn betreffende atypische 
verschijnselen van coeliakie de 
belangrijkste stap zijn in het identificeren 
van deze patiënten met atypische 
manifestaties.  
Hoofdstuk II.3: Tussen de meest 
voorkomende neurologische problemen in 
verband met coeliakie zijn perifere 
neuropathie, cerebrale ataxie, epilepsie, 
multiple sclerose, psychiatrische 
stoornissen en mentale retardatie. 
Voedingsfactoren zijn verdacht  in verband 
met neurologische afwijkingen maar 
worden zelden geïdentificeerd en de 
correctie hiervan schijnt niet te worden 
beïnvloed in de prognose. Sommige 
rapporten tonen bepaalde neurologische 
symptomen aan die reageren op een 
glutenvrij dieet, vooral als deze wordt 
gestart binnen een paar maanden na hun 
verschijning. Nu is het duidelijk dat het 
verband tussen coeliakie en neurologische 
aandoeningen gedeeltelijk uit de 
gemeenschappelijke genetische 
achtergrond resulteert, vooral het HLA 
gebied op chromosoom 6 en andere 
merkers. Naast genetische aanleg, kunnen 
immunologische factoren misschien ook 
een rol spelen. 
Depressie, verstandelijke handicap, 
schizofrenie evenals andere psychiatrische 
symptomen zijn gemeld als zijnde 
gemeenschappelijke 
verbanden/complicaties van coeliakie die 
zich bij ongeveer een derde van de 
patiënten voordoen. Gemeenschappelijke 
symptomen zijn onder andere apathie, 
angst en overmatige prikkelbaarheid. 
Sommigen hiervan kunnen na een aantal 
maanden verbeteren na het volgen van een 
glutenvrij dieet. 
Hoofdstuk II.4: In deze multicenter 
studie werd een totaal van 931 patiënten 
geanalyseerd die zijn onderworpen aan een 
duodenale biopsie voor coeliakie in negen 
centra in de westerse, zuidelijke en 
oostelijke Europese landen, evenals landen 
in het Midden-Oosten. Deze studie toont 
aan dat er een groot verschil bestaat tussen 
de geneeskunde op basis van bewijzen en 
de realiteit van de klinische praktijk. 
Slechts een minderheid van gevallen die 
een GI endoscopie onderging, had 4 of 
meer dan 4 duodenale biopsiën. Dus, 
gezien de toenemende efficiëntie van de 
aangeboden monsters, zijn de inspanningen 
tot verhoging van de naleving van deze 
standaard gegarandeerd.  
Hoofdstuk II.5: Dit is de eerste studie 
verricht op de frequentie van HLA-
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typering bij Iraanse patiënten die aan 
coeliakie lijden, in vergelijking met de 
algemene bevolking. We vonden dat DQ2 
frequentie hoger was bij coeliakie 
patiënten in vergelijking met controles.  
De prevalentie van DQ8 in onze coeliakie 
bevolking was hoger dan de frequentie 
gemeld bij andere volken. Onze resultaten 
benadrukken het primaire belang van 
HLA-DQ allelen bij susceptibiliteit voor 
coeliakie bij de Iraanse bevolking. Dit kan 
gebruikt worden als een diagnosemethode, 
vooral bij personen bij wie de diagnose 
onzeker is. Dit document is in afwachting 
van de indiening. 
Hoofdstuk II.6: Het doel van deze 
multicenter studie was de etiologie van 
gastro-intestinale en niet-gastro-intestinale 
stoornissen te onderzoeken in het kader van 
een grote groep van symptomatische 
coeliakie patiënten uit Italië en Roemenië op 
Europees niveau en uit Iran in het Midden-
Oosten. De resultaten van deze studie 
toonden aan dat  bovenbuik aandoeningen 
zoals buikpijn en dyspepsie, de meest 
voorkomende primaire chronische ziekten 
waren bij Europese patiënten, terwijl bij 
Iraanse patiënten diarree en het opgeblazen 
gevoel werden beschouwd als uitingen van 
de klassieke coeliakie. 
Hoofdstuk II.7: Het doel van deze 
studie is de prevalentie van coeliakie te 
bespreken bij dyspeptische patiënten. 
Tussen november 2007 en oktober 2008, 
zijn er 407 patiënten onderzocht die 
willekeurig een bovenste gastro-intestinale 
endoscopie hebben ondergaan in het 
diagnostisch onderzoek voor dyspeptische 
symptomen. Duodenale histologie heeft 
Marsh-IIIc laesies aangetoond in 6,4% van 
de gevallen en de serologische testen 
bevestigden de aanwezigheid van coeliakie 
in 2,5% van hen. De resultaten van deze 
studie wijzen op een hoge prevalentie van 
coeliakie bij mensen met dyspeptische 
symptomen en als zodanig dient de 
dyspepsie te worden beschouwd als een 
basisreferentie voor coeliakie. 
Hoofdstuk II.8: In dit artikel 
bestudeerden we de lichaamsmassa-index 
bij coeliakie patiënten die gediagnosticeerd 
ware als gevolg van een 
bevolkingsgebaseerde studie, 
gebruikmakend van een gepaste case-
control analyse met het oog op de evaluatie 
van lichaamsmassa-index bij coeliakie 
patiënten. Deze studie heeft aangetoond dat 
33% van de coeliakie patiënten 
ondergewicht hadden. 
 
DEEL III 
GEASSOCIEERDE AANDOENINGEN 
Hoofdstuk III.1: Leverziekte en 
coeliakie delen wijdverspreide 
risicofactoren. Diverse leverstoornissen 
zoals auto-immune hepatitis, de toename 
van leverenzymen niveau, primaire biliaire 
cirrose, niet-gespecificeerde hepatitis, 
primaire sclerotische cholangitis en niet-
alcoholische leververvetting zijn gemeld 
bij patiënten met coeliakie. In deze analyse 
hebben we leveraandoeningen onderzocht 
die gemeld zijn als zijnde geassocieerd met 
coeliakie en het effect van coeliakie-
behandeling op deze aandoeningen. 
Hoofdstuk III.2: Zowel coeliakie als 
de infectie Toxoplasma gondii (TG) 
worden geassocieerd met onvruchtbaarheid 
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en ongunstige uitkomsten van de 
zwangerschap. De uitkomst van deze 
studie toont aan dat coeliakie het risico op 
T. gondii infectie verhoogt  omdat 
coeliakie de verspreiding van de 
ingenomen TG oocysten verder dan dunne 
darm-letsels tijdens de zwangerschap zou 
kunnen vergemakkelijken en dat deze 
infectie, en niet coeliakie, de 
serumconcentraties van pro-inflammatoire 
cytokines zoals IL8 verhoogt. Coeliakie 
bevond zich achter het verhoogde risico op 
een laag geboortegewicht of een miskraam, 
ongeacht de aan- of afwezigheid van 
T.gondii infectie. Het is ook mogelijk dat 
TG theoretisch de sensitiviteit voor gluten 
kan verhogen. Dit kan de ontwikkeling van 
coeliakie versnellen bij gevoelige 
personen. Dit zou in overeenstemming zijn 
met studies die suggereren dat andere 
enterische infecties de ontwikkeling van 
coeliakie kunnen versnellen bij gevoelige 
personen. 
Hoofdstuk III.3: Dyspepsie is een 
belangrijk gezondheidsprobleem onder de 
Iraanse bevolking. Er werd gemeld dat de 
frequentie van coeliakie bij mensen met 
dyspeptische ziekten 1 tot 1,3% is, hetgeen 3 
keer zoveel betekent dan bij de algemene 
bevolking. Hoewel een wijdverspreide H 
pylori-infectie (Helicobacter pylori) 
gevonden werd in deze studie, was de relatie 
tussen Hp-infectie en coeliakie onbeduidend 
in vergelijking met het gerapporteerde in 
andere geografische gebieden. In deze studie 
hebben we laten zien dat er geen verschillen 
zijn tussen de klinische manifestatie van 
coeliakie en H. pylori. 
Hoofdstuk III.4: Gezien coeliakie 
malabsorptie van foliumzuur en andere 
voedingsstoffen produceert, kan dat ook de 
ongunstige zwangerschapsuitkomsten 
verklaren. Sinds serologie een veel te hoge 
sensitiviteit en specificiteit scoort in 
vergelijking met milde histologie van 
coeliakie, suggereert onze studie een 
bredere prevalentie van coeliakie bij 
mannen en vrouwen met onverklaarbare 
onvruchtbaarheid. Het wordt aanbevolen 
om de mannen en vrouwen met 
onverklaarbare onvruchtbaarheid 
regelmatig te onderzoeken op coeliakie.  
Hoofdstuk III.5: Het is belangrijk te 
erkennen dat er een aantal mogelijke 
methoden zijn waardoor infecties auto-
immuniteit kunnen uitlokken, en veel van 
deze immunologische mechanismen 
werden bewezen in experimentele studies. 
Enkele recente studies tonen aan dat een 
rotavirus eiwit kan worden gekoppeld aan 
coeliakie door middel van een moleculair 
mechanisme van imitatie en het risico op 
het ontwikkelen van coeliakie lijkt te 
verhogen onder kinderen in verband met 
het aantal rotavirus infecties. Dit is niet 
specifiek, omdat sommige infecties tevens 
persistent kunnen zijn en diverse auto-
inflammatoire aandoeningen kunnen 
imiteren of uitlokken. Deze studie toont 
aan dat rotavirus-infectie veel voorkomt bij 
Iraanse patiënten met niet-specifieke 
gastro-intestinale symptomen. Echter, in 
tegenstelling tot studies bij kinderen, toont 
deze studie aan dat actieve infectie met het 
rotavirus statistisch niet significant 
verschillend was tussen degenen die 
positieve tTG antilichamen hadden en 
degenen met negatieve tTG antilichamen. 
Hoofdstuk III.6: Logit- en 
probitmodellen zijn speciale gevallen van 
algemene lineaire modellen om het geval 
van dichotome en categorische variabelen 
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optimaal te behandelen. Hoewel Probit een 
variant is op Logit model op basis van 
verschillende gegevenssimulatie, worden 
probit analyseresultaten zelden gemeld in 
de oorspronkelijke eenheden. Logit wordt 
vaker gebruikt, gebaseerd op de aanname 
van gelijke categorieën. Probit kan een 
betere keuze zijn wanneer de categorieën 
verondersteld worden een normale 
basisverdeling van de afhankelijke 
variabele te reflecteren, zelfs indien er 
slechts twee categorieën zijn. De resultaten 
uit Probit en logit modellen waren 
vergelijkbaar met elkaar, aangevend dat de 
probit-analyse kan worden toegepast als 
een logit model voor het analyseren van de 
relatie tussen demografische en klinische 
factoren enerzijds en coeliakie anderzijds. 
DEEL IV 
HET EFFECT VAN HET 
GLUTENVRIJE  DIEET 
Hoofdstuk IV.1: In het licht van de 
nieuwe vooruitgang en van de ontdekking 
van entiteiten zoals niet-coeliakie gluten 
sensitiviteit, gebruikmakend van de term 
subklinisch in plaats van stil en atypisch in 
plaats van potentieel/latent, kan het inzicht 
achter het klinische gedrag van coeliakie 
vereenvoudigd worden. De verzamelde 
bewijzen ondersteunen de verlaging van 
behandelingsdrempel voor atypische 
coeliakie en die met gluten sensitiviteit 
dienen aangegeven te worden omdat de 
levenskwaliteit van deze gevallen zal 
verbeteren tegelijk met GVD en de lange 
termijn voordelen van deze strategie 
zouden het meest waarschijnlijk de 
rentabiliteit zijn, in wat betreft de kosten. 
Hoofdstuk IV.2: De prevalentie van 
hypertransaminasemie (HT) bij kinderen is 
verhoogd in coeliakie. Studies tonen aan dat 
patiënten met HT jonger waren dan die met 
normale aminotransferasen. Een aanzienlijk 
percentage van de volwassen patiënten met 
niet-alcoholische leververvetting (NAFLD) 
heeft geen metabole risicofactoren en kan 
worden gerelateerd aan de gelijktijdige 
aanwezigheid van coeliakie. Onze studie op 
98 coeliakiegevallen heeft aangetoond dat 
coeliakie de leverfunctie kan beïnvloeden en 
hypertransaminasemie induceren in de 
afwezigheid van andere mogelijke oorzaken 
van leverfunctiestoornissen. Bovendien kan 
GFD de leverfunctie verbeteren en kan 
leverenzymen naar normale waarden 
brengen. 
Hoofdstuk IV.3: Disfunctioneel 
bloeding van de uterus (DUB) is een 
veelvoorkomend probleem bij vrouwen. Het 
wordt gedefinieerd als abnormale 
bloedverlies uit de baarmoeder in de 
afwezigheid van een organische ziekte 
(uiterst moeilijke, langdurige of frequente 
periodes van bloeding), complicaties van de 
zwangerschap of systemische ziekte. Het 
optreden van een significante correlatie 
tussen coeliakie en DUB suggereert de 
mogelijkheid om coeliakie in aanmerking te 
nemen als een van de mogelijke oorzaken 
van abnormaal uterus bloedverlies. Onze 
resultaten laten zien dat een glutenvrij dieet 
het risico op disfunctionele 
baarmoederbloeding kan verminderen bij 
vrouwen die aan coeliakie lijden. 
DEEL V 
DISCUSSIE, SAMENVATTING, 
ERKENNING en een korte CV.  
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 ﺧﻼﺻﻪ
اﺧﺘﻼﻻت ﻣﺮﺗﺒﻂ ﺑﺎ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك و ﺳﺌﻮاﻻت 
ﭘﻴﺮاﻣﻮن اﻳﻦ ﺑﻴﻤﺎري ﺑﺮاي ﻣﺘﺨﺼﺼﺎن ﺳﻼﻣﺘﻲ ﻛﻪ 
ﻛﻨﻨﺪ ﺑﺴﻴﺎر ﺑﺎ اﻫﻤﻴﺖ ﺑﻪ اﻳﻦ وﺿﻌﻴﺖ رﺳﻴﺪﮔﻲ ﻣﻲ
ﻋﻠﺖ آن اﻳﻦ اﺳﺖ ﻛﻪ اﻳﻦ اﺧﺘﻼل . اﺳﺖ
ﻣﺨﺘﻠﻔﻲ دارد ﻛﻪ ﺑﺎ ﻋﻼﻳﻢ و ﺳﻴﺴﺘﻤﻴﻚ ﺷﺎﻳﻊ ﻋﻠﻞ 
 .اي ﻫﻤﺮاه اﺳﺖاي و ﺧﺎرج رودهﻋﻮارض روده
ﺗﻘﺮﻳﺒﺎً ﺗﻤﺎم ﻛﺴﺎﻧﻲ ﻛﻪ ﺷﺮاﻳﻂ ﻣﺸﺎﺑﻬﻲ در ارﺗﺒﺎط 
ﺑﺎ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در آﻧﻬﺎ ﮔﺰارش ﺷﺪه ﻳﺎ 
ﻣﺜﺒﺖ ﻫﺴﺘﻨﺪ ﻳﺎ در آﻳﻨﺪه ﺧﻮاﻫﻨﺪ  8/2QDALH
اﻳﻦ ﺑﺪان ﻣﻌﻨﻲ اﺳﺖ ﻛﻪ ﻫﻤﻪ اﻳﻦ ﺑﻴﻤﺎران . ﺑﻮد
ﻋﻮاﻣﻞ . ﻫﺴﺘﻨﺪداراي زﻣﻴﻨﻪ ژﻧﺘﻴﻜﻲ ﻣﺸﺘﺮﻛﻲ 
ژﻧﺘﻴﻚ در  –ﻣﺤﻴﻄﻲ ﻣﺮﺗﺒﻂ ﺑﺎ ﻛﻤﭙﻠﻜﺲ اﻳﻤﻨﻲ
ﻧﻬﺎﻳﺖ ﻣﻨﺠﺮ ﺑﻪ اﻧﺘﺮوﭘﺎﺗﻲ ﻣﻨﻔﻚ ﺷﺪه از ﺳﻨﺪرم 
 .ﺳﻮء ﺟﺬب ﺧﻮاﻫﺪ ﺷﺪ
ﻋﻮارض ﻣﺸﺘﺮك ﺑﻴﻦ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك و دﻳﮕﺮ 
اﺧﺘﻼﻻت ﺑﻪ ﺧﻮﺑﻲ ﺛﺎﺑﺖ ﺷﺪه اﺳﺖ و ﮔﺰارﺷﺎت 
اي و ﺧﺎرج ﻣﺨﺘﻠﻔﻲ از اﺧﺘﻼﻻت ﻫﻤﺰﻣﺎن روده
  . دﺳﺖ اﺳﺖ اي ﺑﺎ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك درروده
در اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﻣﺮوري ﺳﻴﺴﺘﻤﺎﺗﻴﻚ ﻣﺎﻫﻴﺖ اﻳﻦ 
ارﺗﺒﺎﻃﺎت ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ ﭘﺎﺗﻮژﻧﺰ ﺑﻴﻤﺎري ﺑﺮرﺳﻲ و 
ﺑﺮرﺳﻲ اﭘﻴﺪﻣﻴﻮﻟﻮژي، ارﺗﺒﺎط . ﺑﻨﺪي ﺷﺪه اﺳﺖﻃﺒﻘﻪ
ﻫﻠﻴﻜﻮﺑﺎﻛﺘﺮﭘﻴﻠﻮري، ﺑﺎ دﻳﮕﺮ ﺑﻴﻤﺎرﻫﺎ ﻣﺎﻧﻨﺪ 
روﺗﺎوﻳﺮوس، ﺗﻮﻛﺴﻮﭘﻼﺳﻤﺎ ﮔﻮﻧﺪي، ﺑﺮﺧﻮردﻫﺎي 
 ﻫﺎيﻛﻠﻴﻨﻴﻜﻲ در ﻛﺸﻮرﻫﺎي اروﭘﺎﻳﻲ و ﭼﺎﻟﺶ
ﺗﺎ  4ﺗﺸﺨﻴﺼﻲ و درﻣﺎﻧﻲ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك ﻛﻪ ﺣﺎﺻﻞ 
ﺳﺎل ﻣﻄﺎﻟﻌﺎت ﻣﺎ ﺗﺎﻛﻨﻮن ﺑﻮده، ﻫﺪف اﺻﻠﻲ ﻣﻦ در  5
ﻣﻄﺎﻟﻌﺎت اﻧﺠﺎم ﺷﺪه . ﻧﺎﻣﻪ ﺑﻮده اﺳﺖاﻧﺠﺎم اﻳﻦ ﭘﺎﻳﺎن
 2ﻣﻘﺎﻟﻪ ﻣﺮوري،  3ﻣﻘﺎﻟﻪ ﭘﮋوﻫﺸﻲ،  21ﻣﺎ ﺷﺎﻣﻞ 
ﺑﺮ ﭘﺎﻳﻪ ﻣﻄﺎﻟﻌﺎت اﻧﺠﺎم . ﺑﻮده اﺳﺖ ﺑﻪ ﺳﺮدﺑﻴﺮ ﻣﻘﺎﻟﻪ
ﻳﺮان داراي اﻟﮕﻮي ﺷﺪه، ﺷﻴﻮع ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در ا
ﻣﺸﺎﺑﻪ ﻛﺸﻮرﻫﺎي ﻏﺮﺑﻲ ﺑﺎ ﺷﻴﻮﻋﻲ در ﺣﺪود ﻳﻚ 
   .درﺻﺪ اﺳﺖ
ﻣﻄﺎﻟﻌﺎت اوﻟﻴﻪ ﻣﺎ در ﺑﺤﺚ ژﻧﺘﻴﻚ ﻧﺸﺎن داد ﻛﻪ 
در ﺑﻴﻤﺎران ﻣﺒﺘﻼ ﺑﻪ ﺳﻴﻠﻴﺎك  2QDALHﻧﺴﺒﺖ 
ﻫﺎ ﻣﺸﺎﺑﻪ ﺑﺎﻻﺗﺮ از ﮔﺮوه ﺷﺎﻫﺪ اﺳﺖ و اﻳﻦ ﻳﺎﻓﺘﻪ
ﻧﺘﺎﻳﺞ ﻣﻄﺎﻟﻌﺎت اﻧﺠﺎم ﺷﺪه در ﻛﺸﻮرﻫﺎي ﻏﺮﺑﻲ 
ﻣﻄﺎﻟﻌﺎت ﻣﻨﺘﺸﺮ ﺷﺪه و اي ﻛﻮﺗﺎه از ﺧﻼﺻﻪ. اﺳﺖ
  :در ذﻳﻞ اراﺋﻪ ﺷﺪه اﺳﺖ در ﺣﺎل اﻧﺘﺸﺎرﻳﺎ 
 
  ﺑﺨﺶ اول
 ﻧﺎﻣﻪﻣﻘﺪﻣﻪ و اﻫﺪاف ﭘﺎﻳﺎن :1.Iﻓﺼﻞ 
  :ﺑﺨﺶ دوم
  اﭘﻴﺪﻣﻴﻮﻟﻮژي
در ﮔﺬﺷﺘﻪ اﻋﺘﻘﺎد ﺑﺮ اﻳﻦ ﺑﻮد ﻛﻪ : 1.IIﻓﺼﻞ 
ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك ﻳﻚ اﻧﺘﺮوﭘﺎﺗﻲ ﻣﺰﻣﻦ اﺳﺖ ﻛﻪ ﺗﻘﺮﻳﺒﺎً 
 در دﺳﺘﺮس. ﺑﻄﻮر اﻧﺤﺼﺎري در ﻣﺮدم اروﭘﺎ وﺟﻮد دارد
ﻫﺎي ﺳﺎده، ﺑﺴﻴﺎر ﺣﺴﺎس و اﺧﺘﺼﺎﺻﻲ ﺑﻮدن آزﻣﺎﻳﺶ
ﻧﺸﺎن داد ﻛﻪ ( GTtو  AME  ،AGA)ﺳﺮوﻟﻮژﻳﻜﻲ 
ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك ﻫﻤﺎﻧﻨﺪ ﻛﺸﻮرﻫﺎي اروﭘﺎﻳﻲ، اﺳﺘﺮاﻟﻴﺎ و 
ﻧﻴﻮزﻟﻨﺪ ﻛﻪ ﻋﻤﺪه رژﻳﻢ ﻏﺬاﻳﻲ آﻧﻬﺎ ﮔﻨﺪم اﺳﺖ در 
ﻛﺸﻮرﻫﺎي ﺧﺎورﻣﻴﺎﻧﻪ ﻧﻴﺰ ﺷﻴﻮع دارد و ﺷﻴﻮع ﺑﺎﻻي 
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ﻫﺎي در ﮔﺮوهاﻳﻦ ﺑﻴﻤﺎري در ﻫﺮ دو ﺟﻤﻌﻴﺖ ﻧﺮﻣﺎل و 
  .ﻣﻌﺮض ﺧﻄﺮ ﺑﺎﻻ دﻳﺪه ﺷﺪه اﺳﺖ
ﻫﺎي در ﻛﺸﻮرﻫﺎي در ﺣﺎل ﺗﻮﺳﻌﻪ، آزﻣﻮن
ﺳﺮوﻟﻮژﻳﻜﻲ در ﮔﺮوه ﺧﻄﺮ ﺑﺮاي ﺷﻨﺎﺳﺎﻳﻲ زود ﻫﻨﮕﺎم 
ﻣﻄﺎﻟﻌﺎت ﺑﺎﻟﻴﻨﻲ . ﺑﻴﻤﺎران ﻣﺒﺘﻼ ﺑﻪ ﺳﻴﻠﻴﺎك ﻻزم اﺳﺖ
دﻫﺪ ﻛﻪ ﺗﻈﺎﻫﺮات ﺑﺎ ﻋﻼﻳﻢ ﻏﻴﺮاﺧﺘﺼﺎﺻﻲ و ﻧﺸﺎن ﻣﻲ
اي ﻳﺎ ﻋﺪم وﺟﻮد ﻋﻼﻳﻢ در ﻛﺸﻮرﻫﺎي ﺧﺎورﻣﻴﺎﻧﻪ دار
اﻧﺠﺎم و ﭘﻴﮕﻴﺮي . ﺷﻴﻮع ﺑﺮاﺑﺮ ﻛﺸﻮرﻫﺎي ﻏﺮﺑﻲ اﺳﺖ
ﺗﺮﻳﻦ ﭼﺎﻟﺶ ﺑﻴﻤﺎران و رژﻳﻢ ﻏﺬاﻳﻲ ﺑﺪون ﮔﻠﻮﺗﻦ ﻣﻬﻢ
ﺑﺨﺼﻮص از آﻧﺠﺎﻳﻲ ﻛﻪ . ﭘﺰﺷﻜﺎن اﻳﺮاﻧﻲ اﺳﺖ
ﻣﺤﺼﻮﻻت ﻓﺎﻗﺪ ﮔﻠﻮﺗﻦ ﺗﺠﺎري در اﻳﻦ زﻣﻴﻨﻪ در 
اﻳﻦ ﺑﺮرﺳﻲ ﺷﻮاﻫﺪ و ﺧﻼﺻﻪ . دﺳﺘﺮس ﻧﻴﺴﺖ
اﻃﻼﻋﺎت اﭘﻴﺪﻣﻴﻮﻟﻮژﻳﻚ ﻣﻨﺘﺸﺮ ﺷﺪه در زﻣﻴﻨﻪ ﺑﻴﻤﺎري 
ﻴﻠﻴﺎك را در ﺧﺎورﻣﻴﺎﻧﻪ و ﻫﻤﭽﻨﻴﻦ ﻋﻼﻳﻢ ﻣﺨﺘﻠﻒ ﺳ
ﺑﺎﻟﻴﻨﻲ ﺑﺎرز و ﻣﺪﻳﺮﻳﺖ اﻳﻦ ﺑﻴﻤﺎري در اﻳﺮان را ﻧﺸﺎن 
  .دﻫﺪﻣﻲ
رﺳﺪ ﻋﻼﻳﻢ ﻏﻴﺮاﺧﺘﺼﺎﺻﻲ ﺑﻪ ﻧﻈﺮ ﻣﻲ: 2.IIﻓﺼﻞ 
ﮔﻮارﺷﻲ ﻧﺸﺎن دﻫﻨﺪه ﻋﻼﻳﻢ ﺑﺎرز ﻏﻴﺮﭘﭙﺘﻴﻚ ﺑﻴﻤﺎري 
ﻫﺪف اول : اﻳﻦ ﻣﻄﺎﻟﻌﻪ دو ﻫﺪف داﺷﺖ. ﺳﻴﻠﻴﺎك ﺑﺎﺷﺪ
در ﺑﻴﻤﺎران ﻣﺒﺘﻼ ﺑﻪ ﺗﻌﻴﻴﻦ ﺷﻴﻮع ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك 
ﻋﻼﻳﻢ ﮔﻮارﺷﻲ و ﻫﺪف دوم اﻓﺘﺮاق ﻋﻼﻳﻢ ﭘﭙﺘﻴﻚ از 
ﻧﺘﺎﻳﺞ ﻣﻄﺎﻟﻌﻪ ﻧﺸﺎن . ﻏﻴﺮ ﭘﭙﺘﻴﻚ ﺑﻴﻤﺎر ﺳﻴﻠﻴﺎك اﺳﺖ
ﺑﺎدي ﻣﺮﺗﺒﻂ ﻳﺎ ﺳﻴﻠﻴﺎك در دﻫﻨﺪ ﺷﻴﻮع ﺑﺎﻻي آﻧﺘﻲ
ﺑﻨﺎﺑﺮاﻳﻦ %( 3/7)ﺑﻴﻤﺎران ﺑﺎ ﻋﻼﻳﻢ ﻏﻴﺮﭘﭙﺘﻴﻚ ﺑﻮد 
آﮔﺎﻫﻲ ﺑﻴﺸﺘﺮ در راﺑﻄﻪ ﺗﻈﺎﻫﺮات ﻏﻴﺮﻣﻌﻤﻮل ﺑﻴﻤﺎري 
ﺗﻮاﻧﺪ ﻛﻠﻴﺪ ﺷﻨﺎﺳﺎﻳﻲ اﻳﻦ ﺑﻴﻤﺎران ﺑﺎ ﺳﻴﻠﻴﺎك ﻣﻲ
  .ﺗﻈﺎﻫﺮات ﻏﻴﺮﻣﻌﻤﻮل ﺑﺎﺷﺪ
ﺗﺮﻳﻦ ﻣﺸﻜﻼت ﻣﻐﺰ  و اﻋﺼﺎب از راﻳﺞ: 3.IIﻓﺼﻞ 
ﺗﻮان ﻛﻪ ﺑﺎ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در ارﺗﺒﺎط ﻫﺴﺘﻨﺪ ﻣﻲ
ﻧﻮروﭘﺎﺗﻲ ﻣﺤﻴﻄﻲ، آﺗﺎﻛﺴﻲ ﻣﺨﭽﻪ، ﺻﺮع، ﻣﺎﻟﺘﻴﭙﻞ 
ﻣﺎﻧﺪﮔﻲ ذﻫﻨﻲ را اﺳﻜﺮوزﻳﺰ، اﺧﺘﻼﻻت رواﻧﻲ و ﻋﻘﺐ
اي و ﺑﻴﻦ ﺑﻴﻦ ﻋﻮاﻣﻞ ﺗﻐﺬﻳﻪارﺗﺒﺎط ﻣﺸﻜﻮﻛﻲ . ﻧﺎم ﺑﺮد
رﺳﺪ ﻧﻘﺎﻳﺺ ﻧﻮروﻟﻮژﻳﻜﻲ دﻳﺪه ﺷﺪه ﻛﻪ ﺑﻪ ﻧﻈﺮ ﻧﻤﻲ
آﮔﻬﻲ ﺑﻴﻤﺎري را ﺗﺤﺖ ﺗﺄﺛﻴﺮ ﺑﻬﺒﻮد اﻳﻦ وﺿﻊ ﭘﻴﺶ
    .ﻗﺮار دﻫﺪ
دﻫﺪ ﺑﺮﺧﻲ ﻋﻼﻳﻢ ﻋﺼﺒﻲ ﻫﺎ ﻧﺸﺎن ﻣﻲﺑﺮﺧﻲ ﮔﺰارش
ﻫﺎي اوﻟﻴﻪ ﻇﻬﻮر ﺑﺎﺷﻨﺪ ﺑﺎ ﺷﺮوع ﺑﺨﺼﻮص اﮔﺮ در ﻣﺎه
اﻣﺮوزه . ﻳﺎﺑﻨﺪرژﻳﻢ ﻏﺬاﻳﻲ ﺑﺪون ﮔﻠﻮﺗﻦ ﺑﻬﺒﻮد ﻣﻲ
ﻧﺸﺎن داده ﺷﺪه ﻛﻪ راﺑﻄﻪ ﺑﻴﻦ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك و 
ﻧﺘﺎﻳﺞ اﺧﺘﻼﻻت ﻋﺼﺒﻲ ﻣﺮﺑﻮط ﺑﻪ زﻣﻴﻨﻪ ژﻧﺘﻴﻜﻲ 
ﺑﺮ روي  ALHﺗﺮ از ﻫﻤﻪ ژن ﻣﺸﺘﺮك و ﻣﻬﻢ
ﻋﻼوه ﺑﺮ زﻣﻴﻨﻪ . ﮔﺮ ﻫﺎﺳﺖو دﻳﮕﺮ ﻧﺸﺎن 6ﻛﺮوﻣﻮزوم 
ژﻧﺘﻴﻜﻲ، ﻋﻮاﻣﻞ اﻳﻤﻨﻮﻟﻮژي ﻧﻴﺰ اﺣﺘﻤﺎﻻً در اﻳﻦ راﺑﻄﻪ 
ﻮﻟﻴﺖ اﻓﺴﺮدﮔﻲ، ﻣﻌﻠ. را داراي ﻧﻘﺸﻲ ﻣﺸﺨﺺ ﻫﺴﺘﻨﺪ
ﻓﻜﺮي، اﺳﻜﻴﺰوﻓﺮﻧﻲ و ﺳﺎﻳﺮ ﻋﻼﻳﻢ رواﻧﻲ ﺑﻪ ﻋﻨﻮان 
ﻋﻮارض و ﻋﻼﻳﻢ ﻣﺸﺘﺮك ﺑﺎ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك ﮔﺰارش 
- اﻧﺪ ﻛﻪ در ﺣﺪود ﻳﻚ ﺳﻮم از ﺑﻴﻤﺎران اﺗﻔﺎق ﻣﻲﺷﺪه
ﺗﻔﺎوﺗﻲ، ﻋﻼﻳﻢ راﻳﺞ اﻳﻦ ﺑﻴﻤﺎري ﺷﺎﻣﻞ ﺑﻲ. اﻓﺘﺪ
ﭘﺬﻳﺮي ﺑﻴﺶ از ﺣﺪ اﺳﺖ ﻛﻪ اﺿﻄﺮاب و ﺗﺤﺮﻳﻚ
رﻋﺎﻳﺖ  ﺑﺮﺧﻲ از آﻧﻬﺎ ﻣﻤﻜﻦ اﺳﺖ ﭘﺲ از ﭼﻨﺪ ﻣﺎه
  . رژﻳﻢ ﻏﺬاﻳﻲ ﻓﺎﻗﺪ ﮔﻠﻮﺗﻦ ﺑﻬﺒﻮد ﻳﺎﺑﻨﺪ
ﺑﻴﻤﺎر  139در اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﭼﻨﺪ ﻣﺮﻛﺰي : 4.IIﻓﺼﻞ 
ﻛﻪ ﺑﻴﻮﭘﺴﻲ دﺋﻮدﻧﻮم ﺑﺮاي  ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك اﻧﺠﺎم 
ﻣﺮﻛﺰ واﻗﻊ در ﻏﺮب، ﺟﻨﻮب و ﺷﺮق  9داده ﺑﻮدﻧﺪ از 
اروﭘﺎ و ﻛﺸﻮرﻫﺎي ﺧﺎورﻣﻴﺎﻧﻪ ﻣﻮرد ﻣﻄﺎﻟﻌﻪ ﻗﺮار 
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اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﻧﺸﺎن داد ﻛﻪ ﺷﻜﺎف ﻗﺎﺑﻞ . ﮔﺮﻓﺘﻨﺪ
ﺗﻮﺟﻬﻲ ﺑﻴﻦ ﭘﺰﺷﻜﻲ ﻣﺒﺘﻨﻲ ﺑﺮ ﺷﻮاﻫﺪ و واﻗﻌﻴﺖ در 
ﺗﻨﻬﺎ در اﻗﻠﻴﺘﻲ از اﻓﺮاد . ﻋﻤﻠﻜﺮد ﺑﺎﻟﻴﻨﻲ وﺟﻮد دارد
ﺗﺤﺖ آﻧﺪوﺳﻜﻮﭘﻲ دﺳﺘﮕﺎه ﮔﻮارش ﻓﻮﻗﺎﻧﻲ راﻫﻨﻤﺎﻫﺎي 
ﺑﻴﻮﭘﺴﻲ از  4ﭘﻴﺸﻨﻬﺎد ﺷﺪه ﺟﻬﺖ اﺧﺬ ﺑﻴﺸﺘﺮ از 
ﺑﺎ ﺗﻮﺟﻪ ﺑﻪ ﺑﻨﺎﺑﺮاﻳﻦ . دوازدﻫﻪ را رﻋﺎﻳﺖ ﻛﺮده ﺑﻮدﻧﺪ
ﻧﻤﻮﻧﻪ  4ﻧﺘﺎﻳﺞ ﻓﻮق اﻓﺰاﻳﺶ ارﺳﺎل ﺑﻴﺸﺘﺮ ﻳﺎ ﻣﺴﺎوي 
  . ﺑﻴﻮﭘﺴﻲ ﻻزم و ﺿﺮوري اﺳﺖ
در اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﺑﺮاي اوﻟﻴﻦ ﺑﺎر در : 5.IIﻓﺼﻞ 
در ﺑﻴﻤﺎران ﻣﺒﺘﻼ ﺑﻪ  ALHاﻳﺮان ﻓﺮاواﻧﻲ ﺗﺎﻳﭗ 
. ﺳﻴﻠﻴﺎك در ﻣﻘﺎﻳﺴﻪ ﺑﺎ ﺟﻤﻌﻴﺖ ﻋﻤﻮﻣﻲ ﺑﺮرﺳﻲ ﺷﺪ
ﺷﻴﻮع ﺑﺎﻻﺗﺮي در  2QDﻧﺘﺎﻳﺞ ﻣﻄﺎﻟﻌﻪ ﻧﺸﺎن داد ﻛﻪ 
ﻴﺎن ﺑﻴﻤﺎران ﺳﻴﻠﻴﺎﻛﻲ در ﻣﻘﺎﻳﺴﻪ ﺑﺎ ﺟﻤﻌﻴﺖ ﻧﺮﻣﺎل ﻣ
در ﻣﻴﺎن ﺑﻴﻤﺎران ﺳﻴﻠﻴﺎﻛﻲ ﻣﻮرد  8QDﺷﻴﻮع . داﺷﺖ
ﻫﺎي ﻣﻄﺎﻟﻌﻪ ﺑﺎﻻﺗﺮ از ﻓﺮاواﻧﻲ ﮔﺰارش ﺷﺪه در ﺟﻤﻌﻴﺖ
 ALHﻫﺎي ﻧﺘﺎﻳﺞ ﻣﺎ ﺑﺮ اﻫﻤﻴﺖ ﺑﺮرﺳﻲ آﻟﻞ. دﻳﮕﺮ ﺑﻮد
در اﻓﺮاد ﻣﻀﻨﻮن ﺑﻪ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در ﺟﻤﻌﻴﺖ 
ﻮاﻧﺪ ﺑﻪ ﻋﻨﻮان ﻳﻚ ﺗاﻳﻦ ﻧﻜﺘﻪ ﻣﻲ. اﻳﺮاﻧﻲ ﺗﺄﻛﻴﺪ دارد
روش ﺗﺸﺨﻴﺼﻲ ﺑﺨﺼﻮص در اﻓﺮادي ﻛﻪ در آﻧﻬﺎ 
 . ﺗﺸﺨﻴﺺ ﻧﺎﻣﺸﺨﺺ اﺳﺖ ﻣﻮرد اﺳﺘﻔﺎده ﻗﺮار ﮔﻴﺮد
ﻫﺪف اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﭼﻨﺪ ﻣﺮﻛﺰي ﺑﺮرﺳﻲ : 6.IIﻓﺼﻞ 
ﺷﻨﺎﺳﻲ اﺧﺘﻼﻻت ﮔﻮارﺷﻲ و ﻏﻴﺮﮔﻮارﺷﻲ در ﻋﻠﺖ
ﺑﻴﻤﺎران داراي ﻋﻼﻳﻢ ﮔﻮارﺷﻲ  trohoCﺟﻤﻌﻴﺖ 
ز اروﭘﺎ و اﻳﺮان ﻣﺒﺘﻼ ﺑﻪ ﺳﻴﻠﻴﺎك در اﻳﺘﺎﻟﻴﺎ و روﻣﺎﻧﻲ ا
ﻧﺘﺎﻳﺞ اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﻧﺸﺎن داد . از ﺧﺎورﻣﻴﺎﻧﻪ ﺑﻮد
اﺧﺘﻼﻻت ﮔﻮارﺷﻲ ﺷﻜﻤﻲ ﺑﺎﻻروﻧﺪه ﻣﺎﻧﻨﺪ درد ﺷﻜﻢ 
ﺗﺮﻳﻦ ﺷﻜﺎﻳﺖ ﺑﻴﻤﺎران اروﭘﺎﻳﻲ ﺑﻮد و ﺳﻮءﻫﺎﺿﻤﻪ ﺷﺎﻳﻊ
در ﺣﺎﻟﻲ ﻛﻪ ﺑﺮاي ﺑﻴﻤﺎران اﻳﺮاﻧﻲ اﺳﻬﺎل و ﻧﻔﺦ ﺑﻪ 
  .ﻋﻨﻮان ﻋﻼﻳﻢ ﻛﻼﺳﻴﻚ ﺷﺎﻳﻊ دﻳﺪه ﺷﺪﻧﺪ
اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﺑﺮرﺳﻲ ﻫﺪف از اﻧﺠﺎم : 7.IIﻓﺼﻞ 
ﺷﻴﻮع ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در ﺑﻴﻤﺎران ﻣﺒﺘﻼ ﺑﻪ 
ﺗﻌﺪاد  7002- 8002ﺳﻮءﻫﺎﺿﻤﻪ اﺳﺖ ﺑﻴﻦ ﺳﺎﻟﻬﺎي 
ﺑﻴﻤﺎر ﻛﻪ ﺗﺤﺖ اﻧﺠﺎم آﻧﺪوﺳﻜﻮﭘﻲ ﺗﺸﺨﻴﺼﻲ  704
دﺳﺘﮕﺎه ﮔﻮارش ﻗﺮار ﮔﺮﻓﺘﻪ ﺑﻮدﻧﺪ ﺑﻪ ﺻﻮرت ﺗﺼﺎدﻓﻲ 
ﺷﻨﺎﺳﻲ دﺋﻮدﻧﻮم ﺿﺎﻳﻌﺎت ﺑﺎﻓﺖ. وارد ﻣﻄﺎﻟﻌﻪ ﺷﺪﻧﺪ
درﺻﺪ ﻣﻮارد  6/4را در  cIII hsraMﺗﺎ  I hsraM
ﻧﺸﺎن داد ﻛﻪ ﺑﺎ اﻧﺠﺎم ﻏﺮﺑﺎﻟﮕﺮي ﺳﺮوﻟﻮژي ﺑﻴﻤﺎري 
ﻧﺘﺎﻳﺞ اﻳﻦ . درﺻﺪ آﻧﻬﺎ ﺗﺄﻳﻴﺪ ﮔﺮدﻳﺪ 2/5ﺳﻴﻠﻴﺎك در 
دﻫﻨﺪه ﺷﻴﻮع ﺑﺎﻻي ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در ﺗﺤﻘﻴﻖ ﻧﺸﺎن 
در . ﻣﻴﺎن ﻣﺒﺘﻼﻳﺎن ﺳﻮءﻫﺎﺿﻤﻪ داراي ﻋﻼﻣﺖ اﺳﺖ
ﻧﺘﻴﺠﻪ ﺳﻮءﻫﺎﺿﻤﻪ ﺑﺎﻳﺴﺘﻲ ﺑﻪ ﻋﻨﻮان ﻋﻼﻣﺖ اﺻﻠﻲ 
  .ﺑﺎﺷﺪﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك ﻣﺪ ﻧﻈﺮ 
ﺑﻴﻤﺎران  IMBدر اﻳﻦ ﻣﻄﺎﻟﻌﻪ : 8.IIﻓﺼﻞ 
ﺳﻴﻠﻴﺎﻛﻲ ﺗﺸﺨﻴﺺ داده ﺷﺪه در ﻣﻄﺎﻟﻌﻪ ﺑﺮ ﭘﺎﻳﻪ 
. ﺟﻤﻌﻴﺖ در ﻣﻘﺎﻳﺴﻪ ﮔﺮوه ﻛﻨﺘﺮل ﻫﻤﺴﺎن ﺑﺮرﺳﻲ ﺷﺪ
درﺻﺪ  33ﻧﺘﺎﻳﺞ اﻳﻦ ﻣﻄﺎﻟﻌﻪ اﻓﺰاﻳﺶ وزن را در ﺣﺪود 
 .از ﺑﻴﻤﺎران ﺳﻴﻠﻴﺎﻛﻲ ﻧﺸﺎن داد
  ﺑﺨﺶ ﺳﻮم
 اﺧﺘﻼﻻت ﻣﺮﺗﺒﻂ
ﺑﻴﻤﺎري ﻫﺎي ﻛﺒﺪي و ﺑﻴﻤﺎري: 1.IIIﻓﺼﻞ 
ي ﺳﻴﻠﻴﺎك داراي ﻓﺎﻛﺘﻮرﻫﺎي ﺧﻄﺮ ﻣﺸﺘﺮك و ﮔﺴﺘﺮده
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اﺧﺘﻼﻻت ﻛﺒﺪي ﻣﺘﻨﻮﻋﻲ ﻣﺎﻧﻨﺪ ﻫﭙﺎﺗﻴﺖ . ﻫﺴﺘﻨﺪ
ﻫﺎي ﻛﺒﺪي، ﺳﻴﺮوز اﺗﻮاﻳﻤﻴﻮن، اﻓﺰاﻳﺶ ﺳﻄﺢ آﻧﺰﻳﻢ
اوﻟﻴﻪ ﺻﻔﺮاوي، ﻫﭙﺎﺗﻴﺖ ﻏﻴﺮاﺧﺘﺼﺎﺻﻲ، اﺳﻜﻠﺮوز 
ﻛﻮﻻﻧﮋﻳﺖ اوﻟﻴﻪ و ﻛﺒﺪ ﭼﺮب ﻏﻴﺮاﻟﻜﻠﻲ در ﺑﻴﻤﺎران 
اﻳﻦ ﻣﻄﺎﻟﻌﻪ در . ﻣﺒﺘﻼ ﺑﻪ ﺳﻴﻠﻴﺎك ﮔﺰارش ﺷﺪه اﺳﺖ
ﻣﺮوري ﻣﺎ ﻛﻠﻴﻪ اﺧﺘﻼﻻت ﻛﺒﺪي ﻛﻪ ﺑﺎ ﺑﻴﻤﺎري 
ﺳﻴﻠﻴﺎك در ارﺗﺒﺎط ﻫﺴﺘﻨﺪ را ﺑﺮرﺳﻲ و ﺗﺄﺛﻴﺮ درﻣﺎن 
ﻫﺎ را ﺑﻪ ﺑﺤﺚ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در ﺑﻬﺒﻮد اﻳﻦ ﺑﻴﻤﺎري
 . ﮔﺬارﻳﻢﻣﻲ
ﻫﺮ دو ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك و ﻋﻔﻮﻧﺖ : 2.IIIﻓﺼﻞ 
ﺗﻮﻛﺴﻮﭘﻼﺳﻤﺎﮔﻮﻧﺪي ﺑﺎ ﻧﺎزاﻳﻲ و ﻋﻮارض ﺟﺎﻧﺒﻲ 
ﻧﺘﺎﻳﺞ اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﻧﺸﺎن داد . ﺑﺎرداري ﻫﻤﺮاه ﻫﺴﺘﻨﺪ
ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك ﺧﻄﺮ اﺑﺘﻼ ﺑﻪ ﻋﻔﻮﻧﺖ ﺗﻮﻛﺴﻮﭘﻼﺳﻤﺎ 
را اﻓﺰاﻳﺶ داده و ﻫﻤﭽﻨﻴﻦ در ﻃﻲ ﺣﺎﻣﻠﮕﻲ 
    ﻫﺎي ﻫﻀﻢ ﺷﺪه ﺗﻮﻛﺴﻮﭘﻼﺳﻤﺎ را روي اووﺳﻴﺖ
از . ﮔﺴﺘﺮاﻧﺪﻫﺎي روده ﻛﻮﭼﻚ ﺑﻄﻮر وﺳﻴﻌﻲ ﻣﻲزﺧﻢ
ﻃﺮﻓﻲ ﻋﻔﻮﻧﺖ ﺗﻮﻛﺴﻴﻮﭘﻼﺳﻤﺎ ﺑﺪون ﺗﻮﺟﻪ ﺑﻪ ﺑﻴﻤﺎري 
- ﻫﺎي ﭘﻴﺶاﻓﺰاﻳﺶ ﻣﻘﺪار ﺳﺎﻳﺘﻮﻛﺎﻳﻦﺳﻴﻠﻴﺎك ﺑﺎﻋﺚ 
ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك ﺳﺒﺐ . ﺷﻮدﻣﻲ 8LIاﻟﺘﻬﺎﺑﻲ ﻣﺎﻧﻨﺪ 
اﻓﺰاﻳﺶ ﺧﻄﺮ ﺗﻮﻟﺪ ﻧﻮزادان ﺑﺎ وزن ﻛﻢ ﻫﻨﮕﺎم ﺗﻮﻟﺪ و 
ﺳﻘﻂ ﺟﻨﻴﻦ ﺑﺪون درﻧﻈﺮ ﮔﺮﻓﺘﻦ ﻋﻔﻮﻧﺖ 
 .ﺗﻮﻛﺴﻮﭘﻼﺳﻤﺎﮔﻮﻧﺪي اﺳﺖ
ﻫﻤﭽﻨﻴﻦ ﻣﻤﻜﻦ اﺳﺖ ﺗﻮﻛﺴﻮﭘﻼﺳﻤﺎ ﮔﻮﻧﺪي ﺑﻄﻮر 
ﻧﻈﺮي ﺑﺎﻋﺚ اﻓﺰاﻳﺶ ﺣﺴﺎﺳﻴﺖ ﺑﻪ ﮔﻠﻮﺗﻦ ﮔﺮدد و 
ﻳﻦ ﻣﻤﻜﻦ اﺳﺖ ﺑﺎﻋﺚ ﮔﺴﺘﺮش ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در ا
اﻳﻦ اﻣﺮ در راﺳﺘﺎي ﻣﻄﺎﻟﻌﺎﺗﻲ . اﻓﺮاد ﺣﺴﺎس ﮔﺮدد
اي ﻫﺎي رودهدﻫﺪ دﻳﮕﺮ ﻋﻔﻮﻧﺖاﺳﺖ ﻛﻪ ﻧﺸﺎن ﻣﻲ
ﺗﻮاﻧﻨﺪ ﺑﻪ ﺗﻮﺳﻌﻪ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در اﻓﺮاد ﻣﺴﺘﻌﺪ ﻣﻲ
  . و ﺣﺴﺎس ﻛﻤﻚ ﻛﻨﺪ
ﺗﺮﻳﻦ ﻋﻠﻞ ﺳﻮءﻫﺎﺿﻤﻪ از ﻣﻬﻢ: 3.IIIﻓﺼﻞ 
ﺷﻴﻮع . اﺳﺖﻣﺸﻜﻼت ﺳﻼﻣﺖ در ﺟﻤﻌﻴﺖ اﻳﺮاﻧﻲ 
ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در ﺟﻤﻌﻴﺖ ﻣﺒﺘﻼ ﺑﻪ ﺳﻮءﻫﺎﺿﻤﻪ 
 3درﺻﺪ ﮔﺰارش ﺷﺪه ﻛﻪ اﻳﻦ ﻣﻴﺰان  3ﺗﺎ  1/1ﺑﻴﻦ 
اﮔﺮ . ﺑﺮاﺑﺮ ﺷﻴﻮع اﻳﻦ ﺑﻴﻤﺎري در ﺟﻤﻌﻴﺖ ﻧﺮﻣﺎل اﺳﺖ
ﻫﻠﻴﻜﻮﺑﺎﻛﺘﺮﭘﻴﻠﻮري در  ﭼﻪ ﺷﻴﻮع ﺑﺎﻻي از ﻋﻔﻮﻧﺖ
ﻣﻄﺎﻟﻌﻪ ﺣﺎﺿﺮ ﮔﺰارش ﺷﺪ اﻣﺎ ﻫﻤﺎﻧﻨﺪ دﻳﮕﺮ ﻣﻄﺎﻟﻌﺎت 
ﻮﻧﺖ و ﺑﻴﻤﺎري داري ﺑﻴﻦ اﻳﻦ ﻋﻔارﺗﺒﺎط ﻣﻌﻨﻲ
در اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﻫﻤﭽﻨﻴﻦ . ﺳﻴﻠﻴﺎك ﻳﺎﻓﺖ ﻧﺸﺪ
اﺧﺘﻼف ﺑﻴﻦ ﻋﻼﻳﻢ ﺑﺎﻟﻴﻨﻲ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك و 
  . ﻫﻠﻴﻜﻮﺑﺎﻛﺘﺮﭘﻴﻠﻮري دﻳﺪه ﻧﺸﺪ
از آﻧﺠﺎﻳﻲ ﻛﻪ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك : 4.IIIﻓﺼﻞ 
ﺑﺎﻋﺚ ﺳﻮءﺟﺬب اﺳﻴﺪﻓﻮﻟﻴﻚ و ﺳﺎﻳﺮ ﻣﻮاد ﻣﻐﺬي 
ﮔﺮدد، ﻣﻤﻜﻦ اﺳﺖ ﻧﺘﺎﻳﺞ ﻧﺎﻣﻄﻠﻮﺑﻲ ﺑﺎرداري را ﻣﻲ
ﺳﺮوﻟﻮژي ز ﻃﺮﻓﻲ ﭼﻮن ﻧﺘﺎﻳﺞ ا. ﻧﻴﺰ ﺗﻮﺿﻴﺢ دﻫﺪ
- ﺣﺴﺎﺳﻴﺖ و اﺧﺘﺼﺎﺻﻴﺖ ﺑﺎﻻﺗﺮي در ﻣﻘﺎﻳﺴﻪ ﺑﺎ ﺑﺎﻓﺖ
ﺷﻨﺎﺳﻲ ﺧﻔﻴﻒ در ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك دارد، ﻣﻄﺎﻟﻌﻪ ﻣﺎ ﺷﻴﻮع 
ﺑﺎﻻي اﻳﻦ ﺑﻴﻤﺎري را در ﻣﻴﺎن ﻣﺮدان و زﻧﺎن ﻧﺎﺑﺎرور ﺑﺎ 
ﻏﺮﺑﺎﻟﮕﺮي ﻣﻨﻈﻢ ﺑﻴﻤﺎري . دﻫﺪﻋﻠﺖ ﻧﺎﺷﻨﺎﺧﺘﻪ ﻧﺸﺎن ﻣﻲ
ي ﺑﺎ ﻋﻠﺖ ﺳﻴﻠﻴﺎك در ﻣﺮدان و زﻧﺎن ﻣﺒﺘﻼ ﺑﻪ ﻧﺎﺑﺎرور
  .ﮔﺮددﻧﺎﺷﻨﺎﺧﺘﻪ ﺗﻮﺻﻴﻪ ﻣﻲ
ﺑﺮﺧﻲ از ﻣﻄﺎﻟﻌﺎت اﺧﻴﺮ ﺷﻮاﻫﺪي : 5.IIIﻓﺼﻞ 
دﻫﺪ ﭘﺮوﺗﺌﻴﻦ روﺗﺎوﻳﺮوس ﻛﻨﺪ ﻛﻪ ﻧﺸﺎن ﻣﻲاراﺋﻪ ﻣﻲ
از ﻃﺮﻳﻖ ﻳﻚ ﻣﻜﺎﻧﻴﺴﻢ ﺗﻘﻠﻴﺪ ﻣﻮﻟﻜﻮﻟﻲ ﺑﺎ ﺑﻴﻤﺎري 
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رﺳﺪ ﻛﻪ ﺧﻄﺮ ﺳﻴﻠﻴﺎك ارﺗﺒﺎط داﺷﺘﻪ و ﺑﻪ ﻧﻈﺮ ﻣﻲ
اﺑﺘﻼ ﺑﻪ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در ﻛﻮدﻛﺎن ﺑﺎ اﻓﺰاﻳﺶ 
اﻟﺒﺘﻪ اﻳﻦ ﻣﻄﻠﺐ . روﺗﺎوﻳﺮوس ﻣﺮﺗﺒﻂ ﺑﺎﺷﺪﻋﻔﻮﻧﺖ 
ﻫﺎ ﺧﺎص اﻳﻦ ﻋﻔﻮﻧﺖ ﻧﻴﺴﺖ زﻳﺮا ﺑﺮﺧﻲ از ﻋﻔﻮﻧﺖ
ﺗﻮاﻧﻨﺪ ﺑﺎ ﺣﻀﻮر ﺧﻮد و ﺗﻘﻠﻴﺪ ﻣﻮﻟﻜﻮﻟﻲ ﺑﺎﻋﺚ ﻣﻲ
ﻣﻄﺎﻟﻌﻪ . اﺧﺘﻼﻻت اﻟﺘﻬﺎﺑﻲ ﺧﻮداﻳﻤﻨﻲ ﻣﺘﻨﻮﻋﻲ ﮔﺮدﻧﺪ
ﺗﺮﻳﻦ ﻣﺎ ﻧﺸﺎن داد ﻛﻪ ﻋﻔﻮﻧﺖ روﺗﺎوﻳﺮوس از ﺷﺎﻳﻊ
ﻫﺎي ﮔﻮارﺷﻲ ﻏﻴﺮاﺧﺘﺼﺎﺻﻲ در ﺑﻴﻤﺎران ﻋﻼﻣﺖ
ﻲ اﺳﺖ ﻫﺮ ﭼﻨﺪ در ﻣﻘﺎﻳﺴﻪ ﺑﺎ ﻣﻄﺎﻟﻌﺎت اﻧﺠﺎم اﻳﺮاﻧ
ﺷﺪه در ﻛﻮدﻛﺎن، ﺑﺮرﺳﻲ ﺣﺎﺿﺮ ﻧﺸﺎن داد ﻋﻔﻮﻧﺖ 
داري در ﻣﻴﺎن اﻓﺮاد ﻓﻌﺎل روﺗﺎوﻳﺮوس ﺗﻔﺎوت ﻣﻌﻨﻲ
  .ﻣﺜﺒﺖ و ﻣﻨﻔﻲ ﻧﺪارد GTIﺑﺎدي آﻧﺘﻲ
ﻫﺎي ﻣﺪل tiborPو  tigoL: 6.IIIﻓﺼﻞ 
ﻫﺎي ﻋﻤﻮﻣﻲ ﺧﻄﻲ ﻫﺴﺘﻨﺪ ﻛﻪ ﻣﻮارد ﻣﺨﺼﻮص ﻣﺪل
ﺑﻬﺘﺮ ﺷﻨﺎﺳﺎﻳﻲ ﺷﻮﻧﺪ  ﻣﺘﻐﻴﺮﻫﺎي دو ﺑﺨﺸﻲ و ﻣﻄﻠﻖ
 tigoLﻣﺘﻔﺎوت از ﻣﺪل  tiborPاﮔﺮ ﭼﻪ ﻣﺪل 
ﺑﺮﭘﺎﻳﻪ ﻧﻤﻮﻧﻪ ﺳﺎزي اﺳﺖ اﻣﺎ ﻧﺘﺎﻳﺞ ﺣﺎﺻﻞ از ﺗﺤﻠﻴﻞ 
ﺑﻨﺪرت در واﺣﺪ ﻫﺎي اﺻﻠﻲ ﮔﺰارش  tiborPﻣﺪل 
ﻫﺎي ﻳﻜﺴﺎن ﻣﺪل ﺑﺮﭘﺎﻳﻪ ﻓﺮض ﻃﺒﻘﻪ. ﺷﺪه اﺳﺖ
ﻣﺪل . ﻣﻌﻤﻮﻻً ﺑﻴﺸﺘﺮ ﺑﻪ ﻛﺎر ﺑﺮده ﺷﺪه اﺳﺖ tigoL
ﻫﺎ ﺑﻨﺪيﻣﻤﻜﻦ اﺳﺖ ﻫﻨﮕﺎﻣﻲ ﻛﻪ ﻃﺒﻘﻪ tiborP
ﻣﻨﻌﻜﺲ ﻛﻨﻨﺪه ﺗﻮزﻳﻊ ﻳﻚ ﻣﺘﻐﻴﺮ واﺑﺴﺘﻪ ﺣﺘﻲ اﮔﺮ 
ﻓﻘﻂ دو دﺳﺘﻪ ﻣﻨﺎﺳﺒﺘﺮﻳﻦ اﻧﺘﺨﺎب ﺑﺎﺷﺪ اﺳﺘﻔﺎده 
ﺑﻪ  tigoLو  tiborPﻫﺎي ﻧﺘﺎﻳﺞ ﻣﺪل. ﮔﺮدد
ﻳﻜﺪﻳﮕﺮ ﺷﺒﺎﻫﺖ داﺷﺖ و ﻧﺸﺎن داد ﻛﻪ آﻧﺎﻟﻴﺰ ﻣﺪل 
ﺗﻮاﻧﺪ ﺑﻪ ﻋﻨﻮان ﺟﺎﻳﮕﺰﻳﻦ ﻣﻨﺎﺳﺒﻲ ﺑﺮاي ﻣﻲ tiborP
آﻧﺎﻟﻴﺰ ارﺗﺒﺎط ﺑﻴﻦ ﻓﺎﻛﺘﺮوﻫﺎي  ﺟﻬﺖ tigoLﻣﺪل 
 .ﺑﺎﺷﺪ ﺑﺎﻟﻴﻨﻲ و دﻣﻮﮔﺮاﻓﻴﻚ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك
 ﺑﺨﺶ ﭼﻬﺎرم
  ﺗﺄﺛﻴﺮ رژﻳﻢ ﻏﺬاي ﺑﺪون ﮔﻠﻮﺗﻦ
ﻫﺎي ﺟﺪﻳﺪ و ﻛﺸﻒ در ﭘﺮﺗﻮ ﭘﻴﺸﺮﻓﺖ: 1.VIﻓﺼﻞ 
ﺣﺴﺎﺳﺒﺖ ﺑﻪ ﮔﻠﻮﺗﻦ ﻏﻴﺮﺳﻴﻠﻴﺎﻛﻲ و ﻋﻨﺎوﻳﻦ ﻣﺎﻧﻨﺪ 
ﺑﻪ ﺟﺎي ﺧﺎﻣﻮش و  lacinilcbuSاﺳﺘﻔﺎده از ﻋﺒﺎرت 
ﺗﻮاﻧﺪ درك ﺑﻪ ﺟﺎي ﺑﺎﻟﻘﻮه و ﻧﻬﻔﺘﻪ ﻣﻲ lacipytA
. ﺗﺮ ﻛﻨﺪرﻓﺘﺎرﻫﺎي ﺑﺎﻟﻴﻨﻲ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك را ﺳﺎده
ﺷﻮاﻫﺪ ﻓﺮاواﻧﻲ ﻛﺎﻫﺶ رﻓﺘﺎر آﺳﺘﺎﻧﻪ درﻣﺎن ﺑﻴﻤﺎران 
و اﻓﺮاد ﺣﺴﺎس ﺑﻪ ﮔﻠﻮﺗﻦ را  lacipytAﺳﻴﻠﻴﺎﻛﻲ 
ﻛﻴﻔﻴﺖ زﻧﺪﮔﻲ اﻳﻦ اﻓﺮاد ﺑﺎ رﻋﺎﻳﺖ رژﻳﻢ . دﻫﺪﻧﺸﺎن ﻣﻲ
ﺳﺘﺮاﺗﮋي ﻏﺬاﻳﻲ ﺑﺪون ﮔﻠﻮﺗﻦ ﺑﻬﺒﻮد ﺧﻮاﻫﺪ ﻳﺎﻓﺖ و ا
ﻫﺎ ﻫﺰﻳﻨﻪ  ﺳﻼﻣﺖ اﻳﻦ اﻓﺮاد در دراز ﻣﺪت در ﻛﺎﻫﺶ 
  .ﻣﺆﺛﺮ ﺧﻮاﻫﺪ ﺑﻮد
ﻫﺎي ﻛﺒﺪي در ﺷﻴﻮع اﻓﺰاﻳﺶ آﻧﺰﻳﻢ: 2.VIﻓﺼﻞ 
ﻣﻄﺎﻟﻌﺎت ﻣﺨﺘﻠﻒ . ﻛﻮدﻛﺎن ﻣﺒﺘﻼ ﺑﻪ ﺳﻴﻠﻴﺎك ﺑﺎﻻ اﺳﺖ
دﻫﺪﻛﻪ ﺑﻴﻤﺎران ﻣﺒﺘﻼ ﺑﻪ ﻧﺸﺎن ﻣﻲ
ﺟﻮاﻧﺘﺮ از  aimesanimasmartrepyH
. ﺎ ﻫﺴﺘﻨﺪﺑﻴﻤﺎران ﺑﺎ ﺳﻄﺢ ﻧﺮﻣﺎل آﻣﻴﻨﻮﺗﺮاﻧﺴﻔﺮازﻫ
درﺻﺪ ﺑﺎﻻي از ﺑﻴﻤﺎران ﻣﺒﺘﻼ ﺑﻪ ﺑﻴﻤﺎري ﻛﺒﺪ ﭼﺮب 
ﻏﻴﺮاﻟﻜﻠﻲ ﻓﺎﻗﺪ ﻓﺎﻛﺘﻮرﻫﺎي ﺧﻄﺮ ﻣﺘﺎﺑﻮﻟﻴﻚ ﻫﺴﺘﻨﺪ ﻛﻪ 
ﻋﻠﺖ اﻳﻦ ﺑﻴﻤﺎري را ﺑﺎﻳﺴﺘﻲ در اﺑﺘﻼ ﺑﻪ ﺑﻴﻤﺎري 
ﺑﻴﻤﺎر ﻣﺒﺘﻼ  89ﻣﻄﺎﻟﻌﻪ ﻣﺎ روي . ﺳﻴﻠﻴﺎك ﺟﺴﺘﺠﻮ ﻛﺮد
ﺗﻮاﻧﺪ ﺑﻪ ﺳﻴﻠﻴﺎك ﻧﺸﺎن داد ﻛﻪ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك ﻣﻲ
ﻴﺮ ﮔﺬاﺷﺘﻪ و در ﺻﻮرت ﻋﺪم روي ﻋﻤﻠﻜﺮد ﻛﺒﺪي ﺗﺄﺛ
وﺟﻮد ﻋﻠﺖ ﺧﺎﺻﻲ ﺑﺮاي ﻣﻄﺎﻟﻌﻪ ﻋﻤﻠﻜﺮد ﺑﺪ ﻛﺒﺪ 
 .اﻓﺰاﻳﺶ ﺗﺮاﻧﺲ آﻣﻴﻨﺎز را اﻟﻘﺎ ﻧﻤﺎﻳﺪ
   ژﻧﺘﻴﻚ و وﻳﮋﮔﻲ ﻫﺎي ﻛﻠﻴﻨﻴﻜﻲ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك در اﻳﺮان ،اﭘﻴﺪﻣﻴﻮﻟﻮژي
 002   ﻓﺎرﺳﻲ ﺧﻼﺻﻪ
ﺗﻮاﻧﺪ ﻋﻤﻠﻜﺮد ﻫﺮ ﭼﻨﺪ رژﻳﻢ ﻏﺬاي ﺑﺪون ﮔﻠﻮﺗﻦ ﻣﻲ
ﻫﺎي ﻛﺒﺪي را ﻛﺒﺪ و ﻫﻤﭽﻨﻴﻦ ﺑﺎزﮔﺮداﻧﺪن ﺳﻄﺢ آﻧﺰﻳﻢ
  .ﺑﻪ ﺳﻄﺢ ﻧﺮﻣﺎل ﺑﻬﺒﻮد ﺑﺨﺸﺪ
ﺧﻮﻧﺮﻳﺰي رﺣﻤﻲ ﺑﺪون ﻋﻠﺖ : 3.VIﻓﺼﻞ 
ﺗﺮﻳﻦ ﻣﺸﻜﻼت در ﻣﻴﺎن ﻳﻜﻲ از ﻣﻌﻤﻮل )BUD(
اﻳﻦ ﻋﻼﻣﺖ ﺑﻪ ﺻﻮرت ﺧﻮﻧﺮﻳﺰي رﺣﻤﻲ . زﻧﺎن اﺳﺖ
ﻏﻴﺮﻃﺒﻴﻌﻲ در ﻏﻴﺎب ﺑﻴﻤﺎري ارﮔﺎﻧﻴﻚ، ﻋﻮارض 
. ﺷﻮدﻫﺎي ﺳﻴﺴﺘﻤﻴﻚ ﺛﺎﺑﺖ ﻣﻲﺑﺎرداري و ﻳﺎ ﺑﻴﻤﺎري
 BUDدار ﺑﻴﻦ ﺑﻴﻤﺎري ﺳﻴﻠﻴﺎك و ارﺗﺒﺎط ﻣﻌﻨﻲ
اﺣﺘﻤﺎل ﺑﺮرﺳﻲ اﻳﻦ ﺑﻴﻤﺎري را ﺑﻪ ﻋﻨﻮان ﻳﻜﻲ از 
ﻧﺘﺎﻳﺞ ﻣﻄﺎﻟﻌﻪ . ﻛﻨﺪﺑﻴﺎن ﻣﻲ BUDﺪه ﻋﻮاﻣﻞ اﻳﺠﺎدﻛﻨﻨ
ﺗﻮاﻧﺪ در ﻣﺎ ﻧﺸﺎن داد ﻛﻪ رژﻳﻢ ﻏﺬاﻳﻲ ﺑﺪون ﮔﻠﻮﺗﻦ ﻣﻲ
در ﺑﻴﻤﺎران ﻣﺒﺘﻼ ﺑﻪ ﺳﻴﻠﻴﺎك  BUDﻛﺎﻫﺶ رﻳﺴﻚ 
  . ﻣﺆﺛﺮ ﺑﺎﺷﺪ
 ﺑﺨﺶ ﭘﻨﺠﻢ
ﺧﻼﺻﻪ، ﺗﻘﺪﻳﺮ و ﺗﺸﻜﺮ و رزوﻣﻪ ﻛﻮﺗﺎه و ﺑﺤﺚ، 
 ﺨﺘﺼﺮﻣ
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